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QUILL ON SCALPEL
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T h e Operating-Room Nurse —
a Small-Business Manager
Evelyn Dessureault, RN; Nelson Mitchell, MD, CM, FRCSC
Department o f Surgery, Royal Victoria Hospital, Montreal, Que.

rying times need new solutions.
Governments seek to contain
health care costs, and hospital bud
gets shrink. Patient services and
surgeons’ incomes face a sure and
steady erosion. The surgeon looks
for help, and it is there in the
operating room . . . the nursemanager. The concept of nursemanager at the operating-room
level has received little attention in
present-day management systems.
Labour accounts for three-quarters
of the cost of running hospitals, yet
in the operating room implants and
supplies consume two-thirds of the
budget. This area should be a tar
get for cost reduction.
The objective is to reduce costs
without compromising care. Effec
tive management should increase
patient volume and reduce unit
costs.
The operating-room head nurse
is in the best position to observe the
“chemistry” that develops within
the team. The nurse can promote
labour efficiencies by assigning staff
to specific surgeries and surgeons,
rather than by following rigid staff
ing rules. The nurse could even
alter work hours to accommodate
the workload peculiar to the disci
pline. By definition, efficiency is
cost effective and would reduce
overall expense.
The operating-room head nurse

T

must have a budget with which to
manage the unit and must exercise
control over inventory and purchas
ing. The success of cost reduction
is often reflected in good inventory
control. We recently obtained a
$38 000 credit by redesigning the
consignment list from one of our
suppliers. We brought our present
needs up to date and received credit
for obsolete equipment. As equip
ment needs change it is vital to
monitor inventory constantly. When
a different supplier is considered,
the effect on inventory must be
assessed. The potential return of
unused inventory or loss of original
investment must be taken into ac
count when calculating new costs.
Who better than the nurse-mana
ger to do this?
Purchasing control is another
key element in operating-room
management. Day-to-day purchase
of supplies is clearly the responsibil
ity of the nurse-manager, based on
input from the surgeons. On major
purchases, such as a change in
implants or equipment, the nurse
should preside over the decision
making process and advise sur
geons on the relative merits of the
purchase in relation to overall
costs, operating-room efficiencies
and their own practice. When dis
putes arise the nurse should be able
to arbitrate.

Costly errors are often made be
cause managers, far removed from
the daily activity of the specialty,
make the purchases. The purchase
of materials and equipment must
reflect both cost and simplicity of
use and ease of maintenance. Often
items purchased at a low price, but
without consultation, remain un
used because they are of poor quali
ty and demand complicated mainte
nance.
The head nurse, through daily
contact with surgeons and suppli
ers, can negotiate better prices and
contracts. The nurse is an effective
buffer between the surgical team
and the sales representatives. Ad
vantage should be made of existing
competitive markets. Our head
nurse communicates directly with
sales representatives and has re
ceived significant price reductions.
Maintenance of the operating
room and its equipment is an ongo
ing task. By dealing directly with
the various service departments
within the hospital, problems can be
resolved without having to pass
through several layers of manage
ment. We have considerably re
duced response time for repairs by
this method.
It is important to relate the work
ing environment to cost efficiency.
If a team concept is established,
each member feels responsible for
CJS, VOL. 35, NO. 2, APRIL 1992
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the productivity of the operating
room. Attainable goals can be set
and achieved by the “team.”
What, then, should be the au
thority and accountability of the
operating-room head nurse? Au
thority must not be absolute, but
should include enough flexibility to
influence staffing and training of

personnel. The nurse should be
accountable for overall budget con
trol in the operating room, but only
within the context of identifying
and generating cost savings. The
ability to retain these savings in the
unit is axiomatic to the success of
the enterprise. If the institution
permits the nurse to manage the

resources to generate cost savings
then these must be passed on to the
budget used by the “team.”
Finally the nurse must have ac
cess to the best reporting system
that senior management can pro
vide and be given access to the
hardware and software necessary
for its use.B

tion for thoracic outlet syndrome, using
a counterbalanced sky-hook fixed to the
operating room ceiling to allow rapid
and easy positioning and repositioning
of the arm. The issue of supraclavicular
neurolysis should also be addressed in
this chapter.
Chapter 15 should elaborate the in
formation on the Clagett window and
Eleasser flap techniques and thoraco
plasty for space problems after lung
resection.
In section IV, on surgery of the
trachea, the addition of material on jet
ventilation techniques, especially for
sleeve and carinal resections, is recom
mended. The chapter also needs further
discussion of the different types of
incisions for resection of upper tracheal
tumours and the different lengthening
procedures to include hilar, infrahyoid
and suprahyoid release.
Section V covers surgery of the
lungs and pleural space. In chapter 22,
a description of the technique of transaxillary incision and apical pleurectomy
for spontaneous pneumothorax, as pop
ularized by DeLaurier, would be help
ful. Chapter 23 on bullous disease
should contain information on the use
of stapling and lung-shaving proce
dures. Similarly, in chapter 28, the
transaxillary approach to right upper
lobectomy and the use of staplers in
fashioning right, middle-right, lowerlobe pexy after right upper lobectomy
might also be added.

In regard to section VI on mediasti
nal surgery, in chapter 41 addition of
the current TNM staging classification
would enhance the understanding of
the need for preoperative staging at
mediastinoscopy. In chapter 43, a possi
ble addition could be the description of
the Toronto-type cervical thymectomy
approach to patients with myasthenia
gravis.
In section VII, on esophageal sur
gery, a description of the indications
for, and techniques of, diverticulopexy
would be a useful addition to the mate
rial on excision of the pharyngeal
pouch. In the section on other methods
of esophageal reconstruction, a descrip
tion of the transhiatal pull-through eso
phagectomy with gastroesophageal re
construction through the neck should
be added.
In summary, these criticisms should
not detract from the overall superb
organization and simplified practical il
lustrations in this very useful primer
and operative manual of general thorac
ic surgery.

BOOK REVIEWS
CRITIQUES DE LIVRES

THORACIC SURGICAL TECH
NIQUES. F.C. Wells and B.B. Milstein.
280 pp. Illust. Bailliere Tindall
Ltd. / W.B. Saunders Company, Lon
don; HBJ-Holt-Saunders Distribution
Services, Toronto. 1990. $201.50.
ISBN 0 -7 0 2 0 -1 2 3 9 -4

This book is a good reference for
rationales for thoracic surgical proce
dures and illustrations of thoracic surgi
cal techniques. It is divided into seven
sections.
All four chapters in section I, on
investigative and minor thoracic surgi
cal procedures, are well written and
detailed.
Section II on the anatomy of the
chest wall and thoracic incisions could
be improved by the addition of a chap
ter on embryology of the diaphragm,
correlating developmental stages to the
different defects encountered. This sec
tion could also be strengthened by a
summary of the different approaches
that spare the phrenic nerve.
In section III, on chest-wall proce
dures, a different approach to the resec
tion of chest-wall tumours is recom
mended. The reviewer performs a com
plete resection of the involved ribs, as
well as one above and one below be
cause of the risk of transmarrow
spread.
In chapter 14, Melems describes his
extensive experience with first-rib resec
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continued on page 212

CORRESPONDENCE
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High-Pressure Injection
Injuries of the Hand
To the editors. Dr. Peters is to be
complimented for bringing to our
attention once again the importance
of extensive debridement in
high-pressure injection injuries of
the hand (Can J Surg 1991; 34:
511-513). All hand surgeons can
attest to the difficulties encountered
in managing these injuries, particu
larly when the offending agent is
paint, hydraulic fluid or grease.
Fortunately, such injuries are rare,
and this probably accounts for the
fact that most articles in the litera
ture do not report large series.
Dr. Peters made no reference to
the use of systemic corticosteroid
therapy. Following publication of
the article by Phelps, Hastings and
Boswick1 in 1976, we have used
systemic corticosteriods on several
occasions. Our experience has been
similar to that described in Phelps’s
article, and we still believe that
corticosteroids have a place in the
management of these very difficult
injuries, particularly when the of
fending agent has chemically irritat
ing characteristics.
G. Allan Taylor, MD
Ste. 304
1081 Carling Ave.
Ottawa, ON
K1Y 4G2

ings and Boswick1 indicated that
high-dose systemic corticosteroids
may have a beneficial role in certain
high-pressure injection injuries, al
though the paper was somewhat
anecdotal and involved only two
patients.
Like others we believe that highdose systemic corticosteroids may
help to reverse the local mechanical
tissue destruction and deleterious
tissue responses to the injectant
with this type of injury. However,
we do remain concerned that these
levels of steroids may facilitate an
even higher incidence of secondary
bacterial infection.
Of course, the final answer re
garding this form of steroids still
awaits a controlled study, wherein,
perhaps with an appropriate animal
model, the advantages and disad
vantages can be carefully assessed,
after an identical injection injury in
a large number of animals.
W.J. Peters, MD, FRCSC
Ste. 224, 2nd Floor
Turner Wing
The Wellesley Hospital
160 Wellesley St. E
Toronto, ON
M4Y 1J3

with ischemic heart disease. Papilla
ry grade II transitional cell carcino
ma formed the advancing head of
the intussusception.

Case Report
An autopsy was performed on a
68-year-old man with a short histo
ry of recent chest pain and a history
of vague abdominal pain. In addi
tion to a recent anterior-wall myo
cardial infarction and pulmonary
edema, the right ureter showed a
swollen area in its middle portion.
On opening the ureter, there was an
intussusception with a small polyp
oid tumour that extended into the
lumen and formed the advancing
head (Fig. 1).

Discussion
Intussusception is the invagina
tion of a segment of a hollow viscus
that is seen most frequently in the
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To the editors. We have no person
al experience with the use of sys
temic corticosteroids for the treat
ment of high-pressure injection in
juries. The article by Phelps, Hast122
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Ureteral Intussusception
by a Transitional Cell
Carcinoma
To the editors. Ureteral intussus
ception was found during an autop
sy performed on an elderly man

FIG. 1. Ureteric intussusception by
small polypoid tumour.
For prescribing information see page 182 —►
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THE FIRST AND ONLY
I.V. FLUOROQUINOLONE
T Broad spectrum coverage*1 for th e tre a tm e n t of
nosocomial infections
• Excellent gram negative coverage
• Provides gram positive activity
T Indicated for a wide range of difficult infections1
• Respiratory tra c t
• Urinary tra c t
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gastrointestinal tract. Lymphoid hy
perplasia or tumours form the ad
vancing head of intussusception.
Intussusception of the ureter is a
rare lesion, and the same mecha
nism may apply to the ureter when
mechanical stimuli cause forced pa
rietal sliding.1 Most cases are due to
benign papillomas, fibroepithelial
polyps and ureteric calculi.12 Very
few are caused by transitional cell
carcinoma. This case represents an
interesting incidental finding during
the postmortem examination of an
elderly man with ischemic heart
disease. His history revealed only
vague abdominal pain. Some of the
recognizable symptoms and signs of
ureteric intussusception include he
maturia, colicky pain and dilatation
of the ureter. A retrograde pyloretrogram is useful in the diagnosis.1
Jasim M. Radhi, MB, MRCPath
Pathologist
The Moncton Hospital
135 MacBeth Ave.
Moncton, NB
E 1C 6Z 8
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Open Cholecystectomy:
an Acceptable Alternative?
To the editors. Laparoscopic chole
cystectomy has quickly become a
popular procedure with both pa
tients and surgeons, but its benefits
have never been asssessed in a
prospective randomized trial. Short
ened recovery times appear to be
the principal advantage of this tech
124
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nique. However, in my experience,
an open cholecystectomy can be
performed more quickly, and recov
ery time can approach that for
laparoscopic cholecystectomy.
Many cholecystectomies can be
performed through a 3- to 4-cm
incision. No length is “promised”
to the patient, however, and it is
explained that the most important
thing is that the procedure be done
safely. Lately I have taken pains to
avoid cutting any rectus muscle.
Simple incision of the rectus
sheaths often allows bilateral retrac
tion with blunt finger dissection, or
the entire rectus muscle can be
pushed to the lateral aspect. In very
muscular individuals this may not
be possible. A self-retaining retrac
tor (e.g., Bookwalter; Codman and
Shurtleff Inc., Randolph, Ma.) can
be invaluable, even with a small
incision.
At the conclusion of the proce
dure and before closure, an inter
costal nerve block is performed.
The location of the intercostal
nerve can be determined by placing
a hand against the ribs on the
peritoneal side. Bupivacaine (0.5%)
with epinephrine is injected along
several rib spaces to give the pa
tient good pain control for the
critical first few hours after sur
gery.
Perhaps the reason patients suf
fer postoperative ileus after open
cholecystectomy is that the abdomi
nal cavity takes longer to absorb air
than it does to absorb the carbon
dioxide used to insufflate the abdo
men for laparoscopy. This residual
air may prevent early function of
the gastrointestinal tract. Before
closure, 1 insert a cannula (often the
same one used to perform intraop
erative cholangiography) and “wash
out” the abdominal cavity with car
bon dioxide as the posterior rectus
sheath is closed. This has given
very good results; usually bowel
sounds are apparent the same even

ing, and patients can eat a regular
meal the following day.
For years I have routinely used
the Abott PCA pump (Abbott Labo
ratories, Montreal) for patient-con
trolled analgesia. Postoperative self
administration of narcotic analge
sics dramatically increases patient
satisfaction by providing a means of
immediate control over discomfort.
It also frees up nursing time.
Not all hospitals have been able
to provide equipment for laparo
scopic cholecystectomy. However,
postoperative morbidity can still be
improved with an open procedure.
R.A. Lane, MD, FRCSC, FACS
Department of Surgery
Ajax and Pickering General Hospital
Ajax, ON
LIS 2J4

A Simple Method
for Laparoscopic
Cholangiography
To the editors. Laparoscopic chole
cystectomy is a new technique that
enjoys increasing popularity. This
minimally invasive method of chole
cystectomy has many advantages
over the conventional approach. Pa
tients have minimal discomfort
postoperatively, shorter hospitaliza
tion, and most are able to resume
work after a 1-week convalescence.
Because of these advantages and
the procedure’s cosmetic appeal,
patient demand is high. Indications
for cholecystectomy remain the
same regardless of the method
used; therefore, approximately 5%
of patients who undergo routine
operation will have concomitant
choledocholithiasis.1
Some surgeons believe that lapa
roscopic cholangiography should be
performed on all patients to rule
out common-duct stones and dem-
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onstrate the anatomy before the
gallbladder is removed.2 4 Other
surgeons employ intraoperative
cholangiography on a selective ba
sis.56 Methods described to perform
laparoscopic intraoperative cholan
giography include needle cannulation of the common bile duct or
gallbladder and cannulation of the
cystic duct. Several catheters and
instruments to maintain catheters
in the cystic duct have been market
ed. These are introduced through
and occupy the midclavicular port
and are often navigated at an angle.
We use a method of cholangiogra
phy that is simple, rapid, inexpen
sive and requires no new equip
ment.

Method
The cystic duct is identified and
isolated. The distal cystic duct is
then clipped. A 16-gauge throughthe-needle Angiocath (20-cm ICATH no. 016140; CharterMed
Inc., Lakewood, NJ) or similar stan
dard single-lumen Intracath is
flushed with saline. Under laparo
scopic viewing the needle is passed
percutaneously into the peritoneal
cavity approximately two fingerbreadths below the right costal
margin and over the cystic duct just
medial to the midclavicular port.
The Angiocath is advanced through
the needle into the peritoneal cavi
ty. The cystic duct is partially divid
ed with scissors, and under direct
vision the Angiocath is guided, as
necessary, by a grasper in the midepigastric port, down the cystic
duct into the common bile duct. An
adequate seal at the insertion site of
the catheter is obtained with a

single clip. Bile is aspirated to dem
onstrate proper positioning, and the
contrast material is introduced.
After a normal cholangiogram has
been obtained, the clip can be re
moved easily with a grasping for
ceps and the Angiocath removed.
Two proximal clips are applied, and
the duct is divided. If common-duct
stones are encountered, several op
tions exist. Small stones can be
removed by transcystic choledo
choscopy. Large stones can be dealt
with by postoperative endoscopic
retrograde cholangiopancreatogra
phy and papillotomy or by conver
sion to an open operation with
formal common-duct exploration.

Results and Conclusion
In our experience, no infectious
complications have occurred at the
site of Angiocath insertion. In a
series of more than 20 laparoscopic
cholangiograms obtained selective
ly, we have been successful in cannulating the cystic duct in all, with
satisfactory radiographs in all but
two patients. This simple technique
of cholangiography requires no ad
ditional instrumentation.
Anthony Ralph-Edwards, MD
Lloyd Smith, MD, FRCSC
Donna Maziak, MD CM
Mervyn Deitel, MD, FRCSC
St. Joseph’s Health Centre
University of Toronto
Toronto, ON
M6R 1B5
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History of Hairmyres
Hospital
To the editors. I am attempting to
write a history of my “old” hospital
where I was a consultant physician
for many years. The hospital is
Hairmyres, which is in East Kil
bride, near Glasgow, Scotland.
During World War II a Canadian
orthopedic unit was located in the
hospital. I thought it was an army
unit, but the National Archives has
informed me that it was staffed by
civilian personnel.
I am anxious to locate any mem
bers of the staff or patients who
may have been associated with the
unit, because I am sure they will
have much to tell.
If any of your readers were mem
bers of this unit or know of some
one who served with it, please write
to me at the address below.
A. Campbell, MD
2 Dunlin Cres.
Craigends
Houston, Renfrewshire
PA6 7JX
UK
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The first
major advance
in the
treatment of
Dukes' D
colorectal
cancer in
30 years2

Leucovorin plus 5-FU is an
effective therapy th at offers
superior response rates and
significant palliative benefits16
*advanced, metastatic or recurrent disease

Significantly improved patient
response compared to 5-FU alone
In a number of clinical trials1-6, 30 to 44% of
patients responded in the Leucovorin followed
by 5-FU treatment groups versus only 7 to 13%
of patients in the groups receiving 5-FU alone.1-6

Leucovorin plus 5-FU is generally
well tolerated by patients
The dose-limiting toxicities, oral mucositis and
diarrhea are generally manageable and reversible,
but should be carefully monitored in elderly
or debilitated patients.5Myelosuppression,
though evident, is not troublesome.3
ft 4
j

Improved therapeutic index
Although Leucovorin may enhance the toxicity
of 5-FU, it also significantly increases the
efficacy of 5-FU, resulting in an improved
therapeutic index.12S

Significant palliative benefits
compared to 5-FU alone
Leucovorin plus 5-FU is associated with signi
ficant improvements in performance status
(measured on the ECOG scale) and symptoms,
which are associated with an improved quality
of life.2And, despite an increase in mucosal tox
icity, weight gain was also more common in the
Leucovorin plus 5-FU arm12, indicating a possible
overall improvement in patient well-being.1
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A therapeutic breakthrough
in the treatment of
advanced colorectal cancer.

The first major advance in the treatment of
Dukes' D colorectal cancer in 30 years12
SINCE LEUCOVORIN MAY ENHANCE THE TOXICITY OF FLUOROURACIL, LEUCOVORIN/ FLUOROURACIL COMBINATION
THERAPY FOR ADVANCED COLORECTAL CANCER SHOULD BE ADMINISTERED UNDER THE SUPERVISION OF A PHYSICIAN
EXPERIENCED IN THE USE OF ANTIMETABOLITE CANCER CHEMOTHERAPY. PARTICULAR CARE SHOULD BE TAKEN IN THE
TREATMENT OF ELDERLY OR DEBILITATED COLORECTAL CANCER PATIENTS AS THESE PATIENTS MAY BE AT INCREASED
RISK OF SEVERE TOXICITY. DEATHS FROM SEVERE ENTEROCOLITIS, DIARRHEA AND DEHYDRATION HAVE BEEN REPORTED
IN ELDERLY PATIENTS RECEIVING LEUCOVORIN AND FLUOROURACIL. CONCOMITANT GRANULOCYTOPENIA AND FEVER
WERE PRESENT IN SOME BUT NOT ALL OF THE PATIENTS.

ACTIONS, CLINICAL PHARMACOLOGY
LEDERLE LEUCOVORIN Calcium (calcium folinate), the calcium salt of folinic acid (citrovorum factor), is a mixture of the
diastereoisomers of the 5-formyl derivative of tetrahydrofolic acid. The biologically active component of the mixture is the (-)-Lisomer It is a metabolite of folic acid and an essential coenzyme for nucleic acid synthesis.
LEUCOVORIN is a reduced form of folic acid, which is readily converted to other reduced folic acid derivatives (e.g.,
tetrahydrofolate). Because it does not require reduction by dihydrofolate reductase as does folic acid, LEUCOVORIN is not affected by
blockage of th is enzyme by fo lic acid antagonists (dihydrofolate reductase inhibitors). This allows purine and thymidine synthesis,
and thus DNA, RNA, and protein synthesis, to occur LEUCOVORIN may lim it METHOTREXATE action on normal cells by competing
with METHOTREXATE for the same transport processes into the cell. LEUCOVORIN rescues bone marrow and gastrointestinal cells
from METHOTREXATE but has no apparent effect on pre-existing METHOTREXATE nephrotoxicity.
LEUCOVORIN is extensively converted to 5-methyltetrahydrofolate in the intestine prior to absorption. In this form, it is a major
component of the total active human serum folate. Oral absorption is saturable at doses above 25 mg.
LEUCOVORIN enhances the cytotoxicity of fluoropyrim idines such as 5-fluorouracil (5 FU) by their metabolites, methylene
tetrahydrofolate and fluorodeoxyuridine monophosphate, form ing a stable ternary complex with thymidylate synthase, and thereby,
decreasing intracellular levels of that enzyme and the product thymidylate. The cell then dies as a result of thymine starvation.

INDICATIONS
For pre-treatment followed by 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal
cancer

CONTRAINDICATIONS
Not to be adm inistered for the treatment of pernicious anemia or other megaloblastic anemias where Vitamin B ^ is deficient.
A hematologic remission may occur white neurologic manifestations continue to progress.

WARNINGS
Cryodesiccated powder reconstituted with Bacteriostatic Water for Injection containing benzyl alcohol should only be used at doses
below 10 m g /n f. (See PRECAUTIONS.)
Treatment-related deaths have been sporadically reported in patients treated w ith LEUCOVORIN plus fluorouracil combination
therapy regimens. In general, diarrhea or stom atitis/m ucositis are the first indications that severe and potentially life-threatening
toxicity could develop. Patients who experience these symptoms white receiving any combination therapy regimen incorporating
LEUCOVORIN plus fluorouracil should be carefully followed and further therapy should be withheld until these symptoms resolve.
LEUCOVORIN enhances the toxicity of fluorouracil. When these drugs are administered concurrently in the pallia!ive therapy of
advanced colorectal cancer the dosage of fluorouracil must be reduced. Although the toxicities observed in patients treated with the
com bination of LEUCOVORIN plus fluorouracil are qualitatively sim ilar to those obsened in patients treated w ith fluorouracil alone,
gastrointestinal toxicities (particularly stomatitis and diarrhea) are observed more comm only and may be more severe in patients
receiving the combination. (See PRECAUTIONS).
Therapy with LEUCOVORIN/fluorouracil m ust not be initiated or continued in patients who have symptoms of gastrointestinal
toxicity of any severity, until those symptoms have resolved. Patients with diarrhea must be monitored w ith particular care until the
diarrhea has resolved, as rapid clinical deterioration leading to death can occur Elderly or debilitated patients are at greater risk for
severe toxicity receiving th is therapy.

PRECAUTIONS
Because of the C a ^ content of LEUCOVORIN solutions, no more than 160 m g of LEUCOVORIN should be injected intravenously
per minute.
If the cryodesiccated powder is reconstituted w ith Bacteriostatic Water for Injection containing 0.9% benzyl alcohol, doses greater
than lO m g /n f are not recommended due to the benzyl alcohol content. If greater doses are required (see DOSAGE &
ADMINISTRATION), LEUCOVORIN Calcium for Injection (cryodesiccated powder) should be reconstituted with Sterile Water for
Injection USP and used immediately, or the preservative-free liquid form, LEUCOVORIN Calcium Injection, should be used.

Drug Interactions
Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and prim idone, and increase the
frequency of seizures in susceptible children.
Preliminary anim al and human studies have shown that small quantities of systemically administered LEUCOVORIN enter the CSF
prim a rily as 5-methyltetrahydrofolate and, in humans, remain 1-3 orders of magnitude lower than the usual METHOTREXATE
concentrations following intrathecal administration. However high doses of LEUCOVORIN may reduce the efficacy of intrathecally
adm inistered METHOTREXATE.
LEUCOVORIN may enhance the toxicity of fluorouracil. (see WARNINGS.)

Pregnancy - Teratogenic Effects
Reproduction studies have been performed in rats and rabbits at doses at least 50 times the human dose and have revealed no
evidence of harm to the fetus due to LEUCOVORIN. There are, however no adequate and well-controlled studies in pregnant woman.
Because anim al reproduction studies are not always p r e d ic ts of human response, this drug should be used during pregnancy only if
clearly needed

Nursing Mothers
It is not known whether th is drug is excreted in human milk. Because many drugs are excreted in hum an milk, caution should be
exercised when LEUCOVORIN is administered to a nursing mother

Pediatric Use
See Drug Interactions.

rapidly eliminated in the urine.
Folic acid has low acute and chronic toxicity in man. No adverse effects haw been noted in adults after the ingestion of 400 mgMay
for 5 m onths or 10 mgAlay for 5 years.
Excessive am ounts of LEUCOVORIN may nullify the chemotherapeutic effect of folic acid antagonists.

DOSAGE AND ADMINISTRATION
LEDERLE LEUCOVORIN Calcium for Injection cryodesiccated powder 50 mg/vial and 350 m g/vial may be used after reconstitution
for intravenous or intramusculuar administration. The liquid injection 350 mg/35 m L is used for intravenous or intramusculuar
administration.
When LEDERLE LEUCOVORIN Calcium is used for LEUCOVORIN pre-treatment followed by 5-fluorouracil (5 FU) in the treatment
of patients with advanced colorectal cancel intravenous administration is employed.
Because of the C a ^ content of LEUCOVORIN solutions, no more than 160 mg of LEUCOVORIN should be injected intravenously
per minute.

Dosage
Advanced Colorectal Cancer
LEUCOVORIN is administered at 200 m g /n f by slow intravenous injection immediately prior to dosing with 370 m g /n f 5 FU
(fluorouracil) by slow intravenous injection, for five consecutive days.
This 5 day treatment course may be repeated at 4 week (28 day) intervals, provided that the patient has completely recovered from
the toxic effects of the prior treatment course.
In subsequent treatment courses, the dosage of fluorouracil should be adjusted based on patient tolerance of the prior treatment
course. The daily dosage of fluorouracil should be reduced by 20% for patients who experienced moderate hematologic or
gastrointestinal toxicity in the prior treatment course, and by 30% for patients who experienced severe toxicity. For patients who
experienced no toxicity in the prior treatment course, fluorouracil dosage may be increased by 10%. LEUCOVORIN dosages are not
adjusted for toxicity.

STABILITY AND STORAGE RECOMMENDATIONS
LEUCOVORIN Calcium Injection (350 mg/35 mL)
Vials of 350 m g /35 mL liquid should be stored at refrigerated temperatures (2-8°C). The liquid formulation should be used
im mediately once removed from refrigeration. Discard any unused portion. Not for m ultidose use. The liquid formulation when
diluted with one of the recommended diluents for intravenous infusion should be used w ithin 24 hours following dilution when
stored at room temperature (15-30°C).

I f 1MTVORIN Calcium for injection (sterile cryodesiccated powder 50 mg/vial, 350 mg/ vial)
Vials of cryodesiccated pcwders should be stored at controllled room temperature (15-30°C).

i) Reconstituted Solutions
Reconstituted solutions for intravenous or intramuscular administration should be used im mediately after reconstitution when
Sterile Water for Injection USP is used as the diluent due to the possibility of microbial contamination during preparation. When
reconstituted with Bacteriostatic Water for Injection USP for intramuscular injection, solutions should be used within 24 hours when
stored at room temperature (15-30°C) or within 72 hours when refrigerated (2-8°C).

ii) Diluted Solutions for IV Infusion
Reconstituted solutions that have been prepared with Sterile Water for Injection USP and then further diluted with one of the
recommended diluents for intravenous infusion should be used within 24 hours following dilution when stored at room temperature
(15-30°C).
Dextrose 5 % and 10% in water
Dextrose 10% in saline
Ringer's Injection USP
Lactated R inged Injection USP
Physiological Saline

AVAILABILITY
Single Dose V ials of 10 mg/mL
Single 35 mL vial. Each vial contains 350 mg LEUCOVORIN as LEUCOVORIN Calcium in solution. Product Code 4545-23.

Vials of Cryodesiccated Powders (50 m g/Vial, 350 mg/Vial)
I . 10 x 10 m L vials. Each 10 mL vial contains 50 m g of LEUCOVORIN as LEUCOVORIN Calcium. Product Code 5330-72.
II. Single 30 mL vials. Each 30 mL vial contains 350 mg of LEUCOVORIN as LEUCOVORIN Calcium. Product Code 4645-77.
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ADVERSE REACTIONS
Allergic sensitization has been reported following both oral and parenteral administration of folic acid.
In combination regimens, the toxicity profile of 5 FU is enhanced by LEUCOVORIN. The most comm on manifestations are
mucositis, stomatitis, leukopenia, and/or diarrhea which may be dose-lim iting. In clinical trials with this drug combination these
toxicities were found to be reversible with appropriate modification of 5 FU administration.

SYMPTOMS AND TREATMENT OF OVERDOSAGE
Folic acid is a water soluble vitamin converted in the body by the action of folate reductase to folinic acid (LEUCOVORIN) which is
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A New Technique for Resection of Liver
T umours
Cyril R. D’Souza, FRCSC, FACS; Harold Prokopishyn, FRCSC, FACS
umours of the liver located at
its periphery often can often be
resected with less than a lobectomy.
Partial hepatectomy, which involves
nonanatomical resection of the liv
er, is often associated with a large
blood loss and prolonged operative
time. To minimize blood loss, sever
al clamps and techniques have been
devised.1-4 All these clamps crush
and are difficult to apply, especially
when the lesion is centrally located.
The disadvantage of all these tech
niques is that removal of the clamp
at the end of the procedure results
in bleeding, which must be stopped
by ligating the bleeding vessels in
dividually. We have devised a tech
nique of partial hepatectomy that is
fast and keeps blood loss to a
minimum. Central and superior le
sions cannot be treated by this
technique and require a lobectomy.
However, with new techniques to
map the hepatic vasculature by
computed tomographic portogra
phy,5 injury to the vessels can be
avoided, and some centrally located
lesions can be resected using this
technique.
The Pringle manoeuvre6 and hemihepatic vascular clamping for he
patic resection, may result in hepa
tocellular injury due to prolonged
ischemia. Moreover, time to per

T

form the resection is limited be
cause the heptic warm-ischemia pe
riod is 10 to 15 minutes for the
Pringle manoeuvre and 30 minutes
for hemihepatic vascular clamping.
Our technique is a modification
of the one described by Matsumata
and colleagues7 that offers better
hemostasis and takes less time.

Technique
When a primary or metastatic
nodule is present and can be resect
ed by a partial hepatectomy, a spot
3 cm to 4 cm central to it is chosen,
and a probe with an eye at one end
is passed through the liver paren
chyma from the dome out through
the inferior surface (Fig. 1). A 6- or
8-mm knitted vascular graft is
threaded through or sutured to the
eye of the needle and pulled into
the liver until the two ends protrude
from its superior and inferior sur
faces. The protruding ends are then
slit into two, and the slit ends are
turned back on themselves to encir
cle the liver both posteriorly and
anteriorly. The ends are clamped
tightly with an artery forceps to
produce tamponade, and this ten
sion can be adjusted during the
resection.

A margin of 5 mm is taken from
the edge of this tourniquet. The
liver is then transected with cau
tery, adjusting the tension on the
grafts if required, to achieve hemos
tasis. Chromic catgut (no. 1) on a
long straight needle or on a large
curved needle is used to insert a
series of horizontal mattress su
tures that enter and exit the graft
both superiorly and inferiorly. In
situations in which the liver paren
chyma is thicker than the length of
the needle, we exit the cut surface
of the liver and reintroduce the
needle and bring it out through the
graft on the other side. When all of
the horizontal mattress sutures are
in place, they are tied firmly to
achieve total hemostasis. We then
sew the two ends of the graft under
tension at the edge of the liver and
remove the artery forceps. A few
000 silk sutures are then inserted
circumferentially from the graft
through the cut end of the liver to
anchor the graft and prevent later
migration. A Penrose drain is ins
erted into the subhepatic space, and
the abdomen closed.
We have used this technique in
one patient. Blood loss was less
than 200 mL and operative time
about 30 minutes. The patient was
followed up for 3 months and had
no adverse effects from the graft.

From the Department o f Surgery, Lethbridge Regional Hospital, Lethbridge. Alta.
Accepted for publication Aug. 27, 1991
Reprint requests to: Dr. C. D'souza, PO Box 1234, Lethbridge, A B T1J 4K1
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FIG. 1. (A) Probe is passed through liver central to lesion. (B) Once graft has been passed through liver, ends are slit. (C) Ends
are clamped, and at end of procedure are sutured to edge of liver. Line of resection is denoted by dashed line. (D,E) Resected
liver with horizontal mattress sutures in place and passing through graft superiorly and interiorly. Graft is also anchored to
liver with several interrupted nonabsorbable sutures.

nique th at reduces bleeding and
operative time in liver resections.
The technique is useful in peripher
al lesions, particularly in segmentectomies and nonanatomical resec
tions of the liver. This technique is
not advocated for extended right
hepatectomies and left hepatectomies because of possible injury to
the hilar vessels, which would com
promise the blood supply to the
remaining lobe. However, preopera
tive mapping of the hepatic vascula
ture by computed tomographic por
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tography can help avoid injury to
these vessels and may make some
lobectomies amenable to this tech
nique.

4.

5.
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Presidential Address, 1991. Specialism
and Generalism in the Future of General
Surgery
John H. Duff, MD, FRCSC
The progressive specialism that has characterized the practice of medicine over the
last 100 years has occurred almost entirely in a scientific context. Societal needs and
social changes have had little influence. As we near the end of the 20th century the
benefits of scientific specialism are being questioned. New historical studies of
specialism have shown that factors other than new knowledge are the driving force
for the creation of some subspecialties. The process by which a new subspecialty is
established requires both a national institute and a certification examination.
Certification is intended to identify those with specific knowledge and skill by
inclusion, but is being perceived increasingly as a process that works by exclusion.
General surgery, one of the few “generalist” disciplines, finds itself at a crossroads.
Further subspecialization with certification will fragment and destroy the discipline.
There are cogent arguments, based on economics and care-delivery issues, to
preserve general surgery. Making this choice will commit general surgeons to
accept the concept of scientific generalism and to the development of the specialty of
general surgery in a social context.
La specialisation progressive qui a caracterise la pratique de la medecine au cours
des 100 dernieres annees, est survenue presque entierement dans un contexte
scientifique. Les besoins de la societe et les changements sociaux n’y ont exerce que
peu d’influence. Au moment ou nous approchons de la fin du 20e siede, les benefices
de la specialisation scientifique sont remis en question. De nouvelles etudes
historiques de la specialisation ont montre que des facteurs autres que la
connaissance constituent la force vive derriere la creation de certaines sous-specialites. Le processus par lequel une nouvelle sous-specialite s’etablit exige la
constitution d’un institut national et un examen de certification. La certification vise
a identifier ceux qui possedent une connaissance et des aptitudes specifiques pour
etre inclus, mais elle est de plus en plus pergue comme un mecanisme d’exclusion.
La chirurgie generale, une des rares disciplines «generalistes,» se trouve a un
carrefour. Une sous-specialisation plus poussee avec certification va fragmenter et
detruire cette discipline. II existe des arguments convaincants, de nature economique ou relies a des problemes de distribution des soins, pour la preservation de la
chirurgie generate. Ce choix va forcer les chirurgiens generaux a accepter le concept
de generalisation scientifique et a developper la speciality de chirurgie generate
dans un contexte social.
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the great honours of
O nebeingof president
of the Canadi
an Association of General Surgeons
(CAGS) is the opportunity to give
the presidential address. The past
presidents, a distinguished group of
community and academic surgeons,
have given scholarly addresses on
many key issues affecting general
surgery, including research, man
power and clinical practice. As
would be expected, they chose to
discuss issues that were prominent
at the time of their presidency. I
have chosen to discuss the rise of
specialism — how it is affecting
general surgery and how we should
deal with this force in the future.
Specialism in our discipline is ram
pant. It is, after all, the opposite of
generalism and is therefore giving
us a real problem of identity. We
have become uncertain of who we
are, what we do and what we want
to do in the future. We are being
bombarded from within and without
by critics who tell us we should be
giving up some of our practice to
“real specialists,” that we should
become gastrointestinal surgeons or
breast surgeons or hernia surgeons,
that general surgery is an anachro
nism, “a dying breed,” likened to a
rudderless ship hopelessly adrift
and about to break up.
Virtually all the major medical
associations, societies and colleges
have identified and debated the
issue of progressive subspecializa
tion. The American College of Sur
geons has suggested a moratorium
CJS, VOL. 35, NO. 2, A P R IL 1992
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on further subspecialization. There
are some problems for surgery in
general but, for general surgery,
this phenomenon threatens the very
survival of the discipline.

The Problems
What are the problems? First,
there are turf wars that increase in
magnitude as fragmentation of
work increases. Second, certifica
tion of new subspecialities is per
ceived more and more as exclusion
ary in terms of referrals, hospital
privileges and legal interpretations.
Third, there are problems with de
livery of care. There is no bet
ter example of this than general
surgery. Our residents are no lon
ger training as true general sur
geons because the services through
which they rotate are increasingly
specialized. Therefore they cannot
provide the broad surgical care de
livered by their predecessors. At the
same time community hospitals
cannot afford to replace retiring
general surgeons with the several
specialists that would be required to
provide the same service. Paradoxi
cally, as our care delivery problems
with specialism increase, the explo
sion of technology and new knowl
edge is providing more and more
opportunities for subspecialization.

Specialism
Although progressive specialism
creates problems, it brings benefits
as well. Therefore in solving the
problem we need to preserve the
benefits. We cannot do this without
understanding the history of spe
cialism in medicine. We need to
know about the forces in our soci
ety that have motivated the trend
from generalism to specialism. Most
of us assume that specialization
occurs in response to a linear
132
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growth in knowledge. When com
plexity reaches a critical point,
subspecialization occurs as a natu
ral and progressive process of occu
pational development. Osier1 be
lieved in this linear concept of spe
cialization but himself wished to
remain a general physician. In 1897
he said that a specialty was scientif
ically important but functionally
limiting.2 He considered a specialist
as someone who dealt with a nar
row segment of medicine. For Os
ier, this no doubt meant some ero
sion of the ideal of whole-patient
care.
Specialism began to change medi
cine at the turn of the century. By
1910, the year of the Flexner re
port, specialist groups were compet
ing for a visible role in the under
graduate curriculum. The politics of
specialization also became clear.
Self-defined groups of experts
asked for inclusion in the curricu
lum, for identifiable teachers and
ultimately for residency training
programs. By the 1940s the num
ber of residencies in North America
exceeded the number of intern
ships.3
It appears, however, that special
ism required more than acceptance
by medical schools and training
programs. Two further steps oc
curred: specialist institutions and
certifying boards. Both, it seems,
were necessary as the final steps in
the creation of a subspecialty.
American and Canadian surgeons
established the American College of
Surgeons in 1913 and ophthalmolo
gists the first specialty certifying
board in 1917. Fellowship in the
American College distinguished
well-prepared surgeons from those
with inadequate and incomplete
training. Board certification in oph
thalmology distinguished an oph
thalmologist from an optician.4
There was an underlying assump
tion that standards would be raised
and the public protected if specialist

physicians were certified by national
organizations. By 1940 there were
16 certifying boards in the United
States. Here, our Royal College of
Physicians and Surgeons of Canada
was both the national institution
and the certifying board.
Looking back, it seems clear that
specialty boards and certification
were necessary to identify those
physicians who were presumed to
practise their discipline at a higher
level of quality. However, as the end
of this century approaches, most of
the problems faced by the first
specialists no longer exist. Yet the
process by which specialism occurs
is unchanged. Quite naturally, hard
questions are now being asked
about specialism. Is it solving any
problems for our profession today?
Is it creating more problems than it
is solving?
Medical historians, sociologists
and others have recently studied the
history of specialism and the forces
that fueled this phenomenon. There
are new interpretations of special
ism that we need to know about to
make decisions about our future.
There is now good evidence that
the knowledge-expansion concept is
not the only explanation for the
rapid growth of subspecialization.
An alternative explanation is based
on control over competition and
markets. In a study of occupational
specialization, Gritzer5 concluded
that the development of markets
and the development of knowledge
occur independently. A new special
ty may develop not as a result of
new knowledge but from standard
ization of existing knowledge to
define such knowledge as distinct
and recognizable. Material factors,
such as technologies or names of
body parts, are used to provide
clarity for professional and public
recognition. Gritzer5 described ex
amples of specialties that were cre
ated by factors other than new
knowledge. The American Ortho-

GENERAL SURGERY: SPECIALISM AND GENERALISM

paedic Association was formed in
1887 with a major goal of bringing
together physicians utilizing surgi
cal or mechnical procedures to treat
deformities and joint problems.
They required recognition as being
different from homeopaths, chirop
odists and instrument makers. The
specialty was not necessitated by an
increase in complexity of knowl
edge required to perform this work
because general surgeons were able
to do it. Initially they did not claim
a rapidly growing body of abstract
knowledge as a basis for their spe
cialty.6 Similarly, the specialty of
radiology was organized around a
technical device. Knowledge came
years before from Roentgen’s dis
covery. Radiology developed by de
fining existing knowledge as dis
tinct and recognizable.5
The Process o f Specialism

What do we know about the
process of specialism in medicine,
(i.e., the steps required to create a
new subspecialty)? Subspecialties
are created by physicians who (a)
self define themselves as experts,
(b) define a particular field of
knowledge and skills, (c) gain pub
lic and professional recognition,
usually through a national organi
zation and (d) convince an institu
tion, in Canada the Royal College,
to accredit training and to certify by
examination. One might think that
for the medicine of today the proc
ess of specialization would be com
plete with the first three steps. But
historically they were not enough.
At the turn of the century these
steps had been taken by self-defined
experts in orthopedics, radiology
and ophthalmology. Despite a very
strong position, these groups found
it necessary to form a certifying
institution.
Today, the final step of accredita
tion and certification is attractive to
get definition of turf approved and

promulgated by an authoritative na
tional institution. Certification iden
tifies those who are competent to
practise in the defined area and, as
a perhaps unintended corollary,
those who may or may not be.
Up to now, the specialism I have
described has been intrinsic to the
scientific outlook in medicine. It is
inextricably related to medical sci
ence. It is specialism in this sense
that has developed so remarkably
since the turn of the century.
Social Specialism

But there is also the social notion
of a specialty. This is a totally
different idea of a specialty and one
that we, as general surgeons, really
need to consider for our future. In
this notion, specialism develops in
response to social need or social
problems. Stevens7 defined this type
of specialism and gave us examples
of the work of early pediatricians in
promoting child health care and of
early gynecologists in promoting
improved maternal welfare. A mod
ern example in Canada is the work
of Pashby,8 an ophthalmologist, in
the prevention of eye injury in
sports.
In this concept, there is the idea
of a specialty providing leadership
for the care of a constituency of
patients. Very few specialties have
or are developing in this way. Osier1
may have had this notion of a
specialty in mind when he espoused
the principle of scientific generalism. But this view of specialty prac
tice was not accepted. Specialties
developed in a purely scientific rath
er than in a social context.
Today there is increasing pres
sure on physicians to become in
volved in social problems such as
escalating costs, manpower, distri
bution of physicians and prevention
of lifestyle disease. Because our
discipline is still “general” in the
Oslerian sense, because we are com

mitted to the whole patient, and,
finally, because we as general sur
geons provide so much of this
country’s surgical care, we must
not ignore this social notion of a
specialty. Both the history and con
cepts of specialism are pertinent to
the future development of general
surgery.
Much has been said and written
about how general surgery is
changing today. Changes in the
practice patterns have been docu
mented by MacLean9 and, in last
year’s presidential address, by Cou
ture.10 Some changes result from
new knowledge and technology, but
many result from the effects of
specialism in which turf and com
petition must be accepted as strong
factors.
As a group, general surgeons
have not had much influence in
affecting or controlling change. Es
sentially we have watched from the
sidelines. Before the CAGS was
formed we did not even have a
forum where we could discuss these
changes. Change has been driven
almost entirely by science and tech
nology with scarcely a thought
given to care delivery. For example,
the Canadian surgical chairmen, the
Royal College Specialty Committee
for General Surgery and the CAGS
have spent countless hours debat
ing the merits of new subspecialties
such as critical-care medicine, sur
gical oncology and colorectal sur
gery. Consider for a moment these
new subspecialties in terms of soci
etal needs, and how very few train
ees will come through their newly
accredited programs. Compare this
with the needs of Canadian commu
nities large and small for general
surgeons and general surgical ser
vices. The discrepancy is obvious.
However, until 1991, there has not
been one agenda item that I can
remember on training requirements
of community general surgeons. We
cannot get off the track of scientific
CJS, VOL. 35, NO. 2, APRIL 1992
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specialism. Science is very impor
tant to us, but this example illus
trates my point about the need to
develop also our specialty in the
social context.

The Future
From now on, if we wish to be
masters of our own fate, we must
make the CAGS a strong voice in
determining how the forces of sci
entific specialism will affect our
discipline. We are inexperienced in
these matters. Unlike all the other
surgical disciplines we have not
gone through the process of sepa
rating from the parent group be
cause in fact we are the parent
group or, more precisely, what is
left of it.
Further, general surgery has no
unique technology, no single body
part or system we can use in our
name to identify turf. We are there
fore vulnerable to the forces of
specialism and must be extremely
careful how we make decisions
about further subspecialization in
general surgery.
To help us do this 1 suggest we
attempt to distinguish fragmenta
tion from true subspecialization.
We should define subspecialization
as a natural result of and response
to growth of knowledge and frag
mentation, on the other hand, as
the development of subspecializa
tion as a result of market, competi

tion and other forces in the absence
of significant new knowledge (Figs.
1 and 2). For the benefit of our
patients we must accept and sup
port the specialism that grows natu
rally from advances in knowledge
and technology. But for the benefit
of our discipline fragmentation
should be opposed. The extreme
examples of fragmentation are one
operation scenarios. Neither the
CAGS nor the Royal College can or
should stop individual surgeons
from limiting their practice to a
fragment of general surgery, such
hernia repair, breast surgery or la
paroscopic cholecystectomy. There
may be some local advantages to
such limitation. However, accep
tance of fragmentation as a general
policy (i.e., equating it with subspe
cialization) would be counterpro
ductive because of obvious deleteri
ous effects on surgical-care delivery
for our whole country.
We also need to analyse the
step-by-step process by which spe
cialism results in a subspecialty and
modify this process when necessary
to preserve general surgery.
Three steps in the process are
still necessary, self-definition, the
formation of a national society and
accreditation of training. The last
step, certification (of special compe
tence), is unnecessary. Inclusion of
those who are interested and skilled
in the new subspecialty area has
already happened by the first three

SUB SPECIALIZATION

FIG. 1. Subspecialization illustrated as
developing with sphere of knowledge
and procedures that are mostly distinct
and new to parent specialty.
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FIG. 2. Subspecialization illustrated as
developing mostly in absence of new
knowledge and procedures. With certi
fication as exclusionary force there is
potential for fragmentation of parent
specialty.

steps. Moreover, the benefits to
patient care have also already oc
curred. The last step, certification,
is redundant. It is also harmful by
its message of exclusion. In reality
certification always subtracts more
from general surgery than the pro
cedures that are unique to the
subspecialty. I believe, therefore,
that the CAGS, while supporting
new areas of subspecialties, should,
for its own preservation, usually
oppose the certification step.
The foregoing arguments that we
can apply knowledge from the his
tory of specialism to formulate ra
tional strategies for benefiting the
specialty of general surgery are
pointless if we believe the critics
who tell us that general surgery
should fragment to anatomically de
fined disciplines. This criticism is
relevant. It forces a consideration of
the concept of generalism.
Is there today and in the foresee
able future a place for a specialty
that is generalist? Should we pre
serve our specialty as general sur
gery? Many will say no. They be
lieve new knowledge and technolo
gy will inevitably create endless new
subspecialties each dealing with
smaller and smaller parts of the
human body. This view ignores to
tally the social notion of a specialty,
who treats the whole patient and
how delivery of surgical care is to
be achieved with current and future
constraints of manpower and facili
ties. It accepts the consequence of
separating the patient from the dis
ease, of no longer seeing the patient
as a whole person.
I am convinced that there is a
very important place today and in
the future for a specialty that is
generalist. Many of the care-deliv
ery problems we face in medicine
will not be solved by the current
trend to fragment. Moreover, now is
perhaps the right time to reinstitute
the social notion of specialism. For
general surgery this would mean
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that in our scientific development
we also take responsibility for sur
gical-care delivery, and that teach
ing and planning policies always
include societal needs and concerns.
If we decide to proceed in this
direction, the CAGS, as our repre
sentative body, should seek aggres
sively to define such a role. Rather
than playing down the general part
of our name we should resolutely
emphasize it and the importance of
scientific generalism in today’s med
icine. In reality, we have always had
this role. We have assumed it in the
management of trauma. We are the
surgical discipline most involved in
critical-care medicine, and we as
sume leadership in managing gener
al problems such as infection, nutri
tion and shock. This generalist role
is the reason general surgeons are
so crucial in the community and
teaching hospitals and why we are
hearing so many concerns ex
pressed about the impending short
age of surgeons for communities.
Governments are also expressing
such concerns. This generalist func
tion should give our discipline great
influence in the medical care sys
tem. It is a role that general surgery
has always had but has not played
to full advantage. Our colleagues in
the true subspecialties are more and
more becoming technically oriented
and, although technology is an im
portant part of our specialty, a
major role within surgery is still
that of the generalist. We should
aggressively maintain and strength
en this role but still draw on the
skills of our subspecialist col
leagues to provide surgical care
that is appropriate for the many
communities in Canada.
The CAGS needs to determine
from its members, particularly
those in community practice, what
general surgeons should be doing
to provide optimal surgical-care de
livery. This is more than we can get
from the valuable studies of Cou

ture and MacLean because these
show essentially what we have been
forced into by accelerating special
ism. Once defined, the CAGS must
work with the Royal College, uni
versities and governments to make
sure that young surgeons are
equipped to provide the breadth of
care appropriate to the communities
in which they will practise.
General surgery is approaching
very important crossroads. We can
follow the route of scientific special
ism. This choice will eventually but
inevitably lead to the break up of
our discipline. The other choice is
to reaffirm the generalist nature of
our discipline. This would not mean
any lessening of scientific develop
ment. We would in fact be restoring
Osier's scientific generalism. This
choice would commit us in our
practice and teaching to maintain
the whole patient concept. It would
also commit us to see that the
future development of our specialty
occurs in the social context.
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To demonstrate the advantages of a 1.8% hypertonic saline
solution (HS) over a Ringer’s lactate solution (RL) during and
after major intra-abdominal surgery, 28 patients were
randomly allocated to one of two groups as follows: 13
patients received RL and 15 patients received HS. All patients
were studied preoperoperatively, peroperatively and
postoperatively for 72 hours. Peroperatively RL or HS were
infused at a rate sufficient to maintain a pulmonary capillary
wedge pressure (PCWP) and central venous pressure (CVP)
within 3 mm Hg of the initial value. The left ventricular
end-diastolic volume index (LVEDVI) was calculated from
determination of stroke index and ejection fraction with a
mobile gamma camera. Biopsy specimens were taken from the
rectus abdominis muscle for evaluation of edema.
The two groups of patients were comparable for age, length
of surgery and length of aortic cross-damping. Preoperatively
natremia, serum osmolarity, PCWP and LVEDVI were similar
in both groups. A significant (p = 0.01) difference was noted,
during and after surgery, between the sodium levels in the two
groups, but the levels remained within normal limits. Serum
osmolarity remained similar for the two groups (p = 0.49).
During and after surgery, PCWP (p = 0.1) and CVP (p = 0.7)
remained within 3 mm Hg of the initial values with no
significant difference between the two groups. The HS group
received significantly (p = 0.002) less liquid than the RL
group. At the end of surgery, the LVEDVI dropped in both
groups. This drop was significantly (p = 0.04) more important
in the RL group than in the HS group. Consequently, because
the PCWP did not change, cardiac compliance decreased in
both groups but significantly (p = 0.04) more in the RL
group.
The authors conclude that hypertonic saline 1.8% solution
showed a clear advantage over the Ringer’s lactate solution.
With HS, less free water was infused, resulting in less
muscular edema. Cardiac compliance was also less altered. The
authors present evidence that LVEDVI is a more sensitive
predictor of hemodynamic status than PCWP and can be easily
measured peroperatively and postoperatively.
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Dans le but de demontrer les avantages d’une solution salee
hypertonique a 1,8 % (SH) sur la solution lactate de Ringer
(LR) durant et apres une chirurgie abdominale majeure, 28
patients ont ete repartis au hasard selon deux groupes : 13
patients ont re?u le LR et 15, le SH. Tous les patients ont ete
etudies avant, pendant et apres l’operation pendant 72 heures.
Dans la periode peroperatoire, le LR ou le SH ont ete perfuses
a un taux suffisant pour maintenir une pression capillaire
pulmonaire (PCP) et une pression veineuse centrale (PVC) a
moins de 3 mm Hg des valeurs initiales. L’indice de volume
telediastolique gauche (IVTG) fut calcule par determination de
l’index systolique et de la fraction d’ejection a l’aide d’une
camera a rayons gamma mobile. Des biopsies du grand droit
de 1’abdomen furent prelevees pour evaluation de l’oedeme.
Les deux groupes etaient comparables pour Page, la duree
de chirurgie et la duree de clampage de l’aorte. En preoperatoire, la natremie, l’osmolarite serique, la PCP et 1’IVTG
etaient semblables dans les deux groupes. Une difference
significative (p = 0,01) a ete observee, durant et apres la
chirurgie, dans le taux de sodium des deux groupes mais les
niveaux sont demeures a l’interieur des limites normales.
L’osmolarite serique est demeuree semblable entre les deux
groupes (p = 0,49). Durant et apres la chirurgie, la PCP (p =
0,1) et la PVC (p = 0,7) sont demeurees a moins de 3 mm Hg,
sans differences significatives entre les groupes. Le groupe
SH a re?u significativement moins de liquide que le groupe LR
(p = 0,002). A la fin de la chirurgie, 1’IVTG s’est abaisse dans
les deux groupes. Cette baisse a ete significativement (p =
0,04) plus marquee dans le groupe LR que dans le groupe SH.
Done, puisque la PCP n’avait pas change, la compliance
cardiaque s’est abaissee dans les deux groupes mais significa
tivement plus (p = 0,04) dans le groupe LR.
Les auteurs concluent que la solution saline hypertonique a
1,8 % a demontre un net avantage sur la solution lactate de
Ringer. Avec la SH, moins d’eau libre a ete perfusee,
occasionnant moins d’oedeme musculaire. La compliance car
diaque fut egalement moins affectee. Les auteurs presentent
une preuve que 1’ITVG est un facteur previsionnel plus
sensible de l’etat hemodynamique que la PCP et qu’il peut
facilement etre mesure en per et en postoperatoire.
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luid replacement for patients
who undergo major intra
abdominal surgery consists of crys
talloid solutions. This frequently re
sults in generalized edema postoperatively. The use of colloid solu
tions rather than crystalloid solu
tions1 has not been shown to be
beneficial. The high cost of colloid
solutions has curtailed their use in
clinical practice.2 The efficacy of HS
in burn patients3 or in patients with
hemorrhagic shock has been well
demonstrated.4-5 Hypertonic solu
tions were shown to be effective
perioperatively.6 In dogs, infusion
of Ringer's lactate solution (RL) can
lead to edema of striated muscles,
including the cardiac muscle.7 This
phenomenon can decrease cardiac
compliance. Questions then arise
regarding the use of cardiac filling
pressures to monitor hemodynamic
status.8-10
This study was designed to deter
mine if the amount of free water
administered as crystalloids could
be decreased during major abdomi
nal surgery by the use of HS. The
effects on striated muscle and cardi
ac compliance of infusing less free
water are demonstrated.

F

Patients and Methods
The protocol for clinical investi
gation was accepted by the ethics
and research committee of Hopital
St-Frangois d’Assise. Patients were
considered for the study if they
were scheduled to undergo elective
intra-abdominal aortic surgery and
had signed a consent form. Exclud
ed were patients who had an abnor
mality of a cardiac valve, liver fail
ure, pacemaker, shock, septicemia
or presence of myocardial ischemia
less than 24 hours before the study.
Twenty-eight patients formed the
study group. Patients were divided
consecutively, with a random allo
cation chart, into two groups: 13
140
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patients received HS (250 mmol
sodium, 70 mmol lactate, 209 mmol
chloride, 4 mmol potassium, 3
mmol calcium — osmolarity 514
mOsm/L) and 15 patients received
RL (130 mmol sodium, 28 mmol
lactate, 109 mmol chloride, mmol
potassium, 3 mmol calcium — os
molarity 274 mOsm/L).
The following hemodynamic pa
rameters were measured: mean ar
terial pressure (MAP); central ve
nous pressure (CVP); mean pulmo
nary artery pressure (MPAP); pul
monary artery wedge pressure
(PWP); and cardiac output (CO).
These measurements were made
every 30 minutes during surgery
and every 6 hours after until the
morning of postoperative day 3.
From these hemodynamic parame
ters, the following values were cal
culated: stroke volume (SV); stroke
index (SI); left ventricular stroke
work index (LVSWI); right ventric
ular stroke work index (RVSWI);
and left ventricular end-diastolic
volume index (LVEDVI); and cardi
ac index (Cl).
Biochemical and hematologic
measurements (hematocrit and he
moglobin, serum electrolyte, serum
creatinine, blood urea nitrogen
(BUN) and plasma glucose levels,
and serum osmolarity (measured
with a freezing-point osmometer),
along with arterial blood gas (ABG)
measurements were made at the
same intervals used in the hemody
namic monitoring. If two consecu
tive measurements of serum os
molarity were greater than 330
mOsm/L, or if two consecutive
serum sodium values were greater
than 150 mmol/L, the hypertonic
solution was stopped, and fluid re
placement was continued with RL.
Isotopic ventriculography was
performed before surgery, peroperatively (before, during and after aor
tic clamping) and postoperatively (2
hours postoperatively and daily for
3 days), using a mobile gamma

camera (APEX 209MA; Elscint Ltd.,
Haifa, Israel).
A chest x-ray film was obtained
before surgery and 2 hours postop
eratively, then daily for 3 days.
Biopsy specimens of the rectus
abdominis muscle were taken at the
beginning and at the conclusion of
surgery. The muscle water incre
ment was determined by weighing
the specimens before and after they
were dried in an oven at 80°C for
72 hours.7
During surgery, blood loss was
replaced on a volume-for-volume
basis with packed red blood cells.
Additional fluid (HS or RL) was
administered during surgery to
maintain CO equal to the preopera
tive level and cardiac filling pres
sures (CVP and PWP) within 3
mm Hg of the preoperative values.
After operation, all patients were
transferred to the intensive care
unit and received 5% dextrose in
0.25 N saline as a maintenance
solution, given at a daily rate of 30
mL/kg. Additional HS or RL (ac
cording to the randomization) was
given to maintain cardiac filling
pressures and CO at preoperative
levels. This was continued until
8:00 of postoperative day 2. Five
percent dextrose in 0.45 N saline
was subsequently used for all fluid
requirements. Body weight and
fluid intake and output were record
ed daily. Cardiac compliance was
evaluated by comparing variations
in PWPs with variations in LVEDVIs.
Student’s t-test was used to com
pare the averages of each group.
The curves for different variables
were compared and a p value less
than or equal to 0.05 was consid
ered significant.

Results
Preoperatively the cardiac and
biochemical parameters of the two
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groups were not significantly differ
ent. The groups were comparable
for age, duration of surgery and
duration of aortic clamping (Table
I). Blood loss was slightly, but not
significantly, different (p = 0.06).
Patients in the RL group received
more transfusions, therefore the
fluid deficit (blood loss minus trans
fusions) was comparable (p = 0.94)
for each group. No significant dif
ference was found between the two
groups with respect to the hemody
namic values (MAP, Cl, SI, CVP,
PWP, LVSWI, RVSWI) (Figs. 1 to
5). Urinary output was comparable
throughout the study.
During the operation, those pa
tients who received RL needed
5900 ± 1600 mL to maintain cardi
ac output and cardiac filling pres
sures (Table II). This amount was
significant (p = 0.002) compared

with the 3200 ± 350 mL infused in
the HS group. The net difference
between the two groups was 2600
mL. This difference reached 4100
mL (p = 0.0003) on the morning of
postoperative day 2.
Study of the muscle biopsy speci
mens revealed a greater, but insig
nificant (p = 0.50), increase in
muscle water in the RL group
(3.3%) compared with the HS group
(1.7%) (Fig. 6).
The LVEDVI was calculated by
dividing SI by the left ventricular
ejection fraction. It was plotted as a
function of time for each group
(Figs. 7 and 8). PWP values are
shown on the same graphs. Maxi
mum decrease in compliance of the
left ventricle was observed after
clamping (decrease in LVEDVI
while PWP remained stable). Values
gradually returned to normal by the

T a b le 1. Patient Data
C h aracteristic

R in g e r's la ctate
solution

Age, yr
Operative tim e, m in
A ortic clam p tim e, m in
Blood loss, m L
Transfusions, units
Fluid deficit, m L

6 2 .4
210
98
1731
3.4
38

±
2.5
± 28
± 18
±203
±
1.3
±102

H ypertonic
solution

58 .7
189
84
1257
2.5
23

Values are m ean ± SEM.

FIG. 1. Central venous pressure (mm Hg) remained compara
ble for both groups (p = 0.112). Preop = preoperatively, HI =
1 hour after beginning operation, H2 = 2 hours after
beginning operation, H3 = 3 hours after beginning operation,
end = immediately after operation, 23:00 = 23:00 on day of
operation. Black curve = Ringer’s lactate solution (RL),
hatched curve = hypertonic solution (HS).

±
2.1
± 21
± 13
±143
±
1.2
± 87

p v a lu e
0 .2 7
0 .5 3
0 .8 5
0 .0 8
0 .0 7
0 .9 4

morning of postoperative day 2.
Although the decrease in LVEDVI
was consistently greater in the RL
group (from 65 mL to 45 mL) than
in the HS group (from 66 to 54
mL), the difference between the
two groups was not significant, ex
cept during aortic cross-clamping

(P-0.01).
Osmolarity and serum sodium
values (Figs. 9 and 10) of the RL
group gradually decreased postoperatively but did not drop by more
than 10 mOsm/L and 5 mmol/L,
respectively, from the preoperative
values. The reverse was found in
the HS group. The most significant
difference (p = 0.0001) was noted
at the end of surgery. However, the
values measured for each group
remained within normal limits.
There was one death from pulmo
nary embolism in the RL group on
postoperative day 5. Otherwise
there were no major complications.
No complication attributable to the
use of HS was noted.

Discussion
Patients who undergo aortic ab
dominal surgery usually require 5
to 6 L of RL during operation.1112

FIG. 2. Pulmonary wedge pressure (PWP) (mm Hg) remained
comparable for both groups (p = 0.221). Abbreviations as for
Fig. 1.
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Our study addressed the possibility
of reducing the volume of water
infused by using HS. We observed
clinically and statistically significant
differences during the operative and
postoperative periods (Table II).
The two groups had comparable
perioperative characteristics (Table
I) and hemodynamic values (Figs. 1
to 5). The only difference was in
blood loss. However, replacement
with packed red blood cells resulted
in a fluid deficit that was almost the
same ( p = 0.94) for each group
(Table I). Because the difference in
fluid deficit between the two groups
was not significant, it is unlikely
that replacement of this deficit with
plasma rather than saline would
change the significant difference in

fluid administration between the
groups.
Although hypertonic (1.8%) the
HS posed no problem of hyperna
tremia. This is attributed to move
ment of intracellular water toward
the extracellular compartment
caused by the osmotic effect of the
hypernatremic solution. This en
dogenous movement of free water
means that less water is needed to
maintain stable hemodynamic pa
rameters.
The results of muscle biopsies
indicated a major difference (1.7%
for HS, 3.3% for RL) with respect
to the increase in muscle water
(Fig. 6). However, statistical signifi
cance was not achieved (p = 0.50),
perhaps because of the small num

g-m /m *

ber of patients in the study (type
II error) or dispersion of values
(SEM = 1.7).
In dogs, the increase in water
measured in the striated muscles is
comparable to that measured in the
cardiac muscle.7 This could explain
the greater decrease in cardiac com
pliance in the RL group.
Our study raises questions re
garding the use of the Swan-Ganz
catheter because we noted per- and
postoperative alterations in cardiac
compliance in all our patients. The
only hemodynamic parameter that
varied significantly was cardiac
compliance (decrease in LVEDVI
while PWP remained unchanged).
We believe that measurement of
LVEDVI could be particularly help-

mL/beat-m-2

TIME
FIG. 3. Left ventricular stroke work index (LVSW I, g-m/m2)
remained comparable for both groups ( p = 0.221). Abbrevia
tions as for Fig. 1.

FIG. 5. Cardiac index (L/min-m-2) remained comparable for
both groups (p = 0.221). Abbreviations as for Fig. 1.
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FIG. 4. Stroke index (mL/beat-m-2) remained comparable for
both groups (p = 0.221). Abbreviations as for Fig. 1.

FIG. 6. Percentage increase in muscle water (mean ± SEM).
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ful in hemodynamically unstable pa
tients because it directly assesses
cardiac volumes instead of approxi
mating them by measuring cardiac
filling pressures with the SwanGanz catheter.
Highly hypertonic solutions

Table II.

(1200 m m ol/L of sodium) are effec
tive in emergency situations.4’5-13
However, they are used only in
small amounts because hyperna
tremia can occur. We selected a less
hypertonic solution (1.8%), contain
ing lactate, that can be used over a

longer period (48 hours). We added
78 mmol of lactate per litre HS
solution to decrease the am ount of
chloride and avoid risk of hyper
chloremic acidosis.
Hypertonic solutions can also
lead to dysfunction of the central
nervous system, acute renal failure
or hypokalemia. We did not observe
these complications, likely because
we used a less hypertonic solution
(1.8%). At the end of the operation
and throughout the postoperative
period, we found significant differ
ences between the two groups in
serum sodium values and serum
osmolarity values (p = 0.001) (Figs.

V o lu m e (m L ) o f S o lu t io n s G iv e n E a c h D ay

Ringer’s lactate
solution

Hypertonic
solution

S u rg e ry

5 8 76 ± 647

3 243 ± 347

0 .0 0 2

Day 1

7 824 ± 7 1 3

4 483 ± 3 93

0 .0 0 2

Time

p value

Day 2

11 7 5 6 ± 8 4 2

7 634 ± 369

0 .0 0 1

Day 3

14 3 5 9 ± 9 3 9

10 6 3 5 ± 5 0 1

0 .0 0 2

V a lu e s a re m e a n ± S E M .

FIG. 7. Cardiac compliance (volume:pressure ratio) over
course of study in RL group. Preop = preoperative, indue =
after induction of anesthesia, post-damp = time of postaortic
clamping, end = immediately after operation, ICU = 1 hour
after operation in intensive care unit, O = pressures (mm Hg),
+ = volumes (mL).

mmoL/L

m O s m /L

pre op H1

H2

FIG. 8. Cardiac compliance (volum eipressure ratio) over
course of study in the HS group. Abbreviations as for F ig 7.

H3

end

2 3 :0 0

DAY 1

DAY 2

D AY 3

TIME
FIG. 9. Serum osm olarities (mOsm/L) of both groups over
course of study. Difference between groups during operation
and postoperative period was statistically significant (p =
0.0001). Abbreviations as for Fig. 1.

p re o p H1

H2

H3

end

2 3 :0 0

DAY 1

DAY 2

DAY 3

T IM E
FIG. 10. Serum sodium levels (m m ol/L ) o f both groups over
course o f study. Difference between groups during operation
and postoperative period was statistically significant (p =
0.0001). Abbreviations as for Fig. 1.
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9 and 10). However, these varia
tions remained within normal limits.
No patient required discontinuation
of HS during the operation. One
patient had his infusion of HS
stopped 24 hours postoperatively
because serum sodium levels on two
consecutive measurements were
judged to be at the upper limit of
acceptable values.
In summary, the HS showed a
clear advantage over RL because
less free water was infused, result
ing in less muscle edema. Cardiac
compliance was also altered to a
lesser degree. Careful monitoring
showed no ill effects from use of
the solution. We suggest that
LVEDV1 is a more sensitive predic
tor of hemodynamic status than
PWP and that it can be measured
easily pre- and postoperatively.
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SESAP VII Question / Question SESAP VII
Item 162
Which of the following statements about intraoperative ultrasound examination is NOT true?

(A) It is as accurate as operative cholangiography for detecting common bile duct stones
(B) It helps to determine resectability of pancreatic tumors
(C) It is useful to detect small pancreatic endocrine tumors
(D) It provides more precise information about resectability of liver tumors than preoperative evaluation
alone in 30% of patients
(E) It can be used instead of retroperitoneal node dissection for staging of cancer of the testicle.

Select the one answer that is best of the five given.
For the critique of Item 162 see page 172.
(Reproduced by permission from SESAP ’9 2 -9 3 Syllabus; Surgical Education and Self-Assessment Program
No. 7. For enrolment in the Surgical Education and Self-Assessment Program No. 7, please apply to the
American College of Surgeons, 55 E Erie St., Chicago, IL 60611.)
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Extracorporeal Shockwave Lithotripsy
of Gallstones: Clinical Experience
With 170 Patients
Y-M. Dion, MD, MSc, FRCSC, FACS;* J. Morin, MD, FRCSC;* W. Fraser, MD, FRCSCt
Between Jan. 19, 1989 and Nov. 23,1990, 170 patients with symptomatic
cholelithiasis were evaluated for possible treatment by extracorporeal shockwave
lithotripsy (ESWL). Thirty-one patients were not eligible for treatment, 28 (16%)
because of nonvisualization of gallstones by ultrasonography and 3 (2%) because
polyps were erroneously diagnosed on ultrasonography. Thirteen (8%) patients
failed to comply with the protocol, leaving 126 patients for assessment. At the time
of writing, the treatment success rate is 57% at 6 months and 69% at 9 months.
Treatment failed in 21 (17%) patients because of unsatisfactory fragmentation in 16
(13%) patients, frequent biliary colic in 3 (2%) patients, acute pancreatitis in 1 (0.8%)
patient and severe bile-salt-induced diarrhea in 1 (0.8%) patient. Complications
included biliary colic (40 patients), mild diarrhea on bile salts (24 patients), severe
diarrhea (1 patient), macroscopic hematuria (4 patients), acute pancreatitis (2
patients) and vagal shock (1 patient).
This study demonstrates the effectiveness (87%) of the lithotripter in reducing
gallstones to fragments 5 mm in diameter or smaller. However, complete
disappearance of these fragments with adjuvant bile-salt therapy may take many
months.

Du 19 janvier 1989 au 23 novembre 1990, 170 patients souffrant de cholelithiase
symptomatique ont ete evalues en vue d’un eventuel traitement par lithotripsie
extracorporelle a l’aide d’ondes de choc (LEOC). Trente-et-un patients n’ont pas
rencontre les criteres d’admissibilite, 28 (16 %) a cause de l’impossibilite de
visualiser les calculs a l’echographie et 3 (2 %), parce que des polypes furent
diagnostiques par erreur a l’echographie. Treize patients (8 %) n’ont pas suivi le
protocole, ce qui laisse 126 patients pour 1’evaluation. Au moment de ce rapport, le
taux de succes etait de 57 % apres 6 mois et de 69 % apres 9 mois. Le traitement
echoua chez 21 patients (17 %). Les causes sont les suivantes : fragmentation
insuffisante, 16 (13 %), coliques biliaires frequentes, 3 (2 %), pancreatite aigue, 1
(0,8 %) et diarrhee severe causee par les sels biliaires, 1 (0,8 %). Les complications
comprennent: coliques biliaires (40 patients), diarrhee legere sous sels biliaires
(24), diarrhee severe (1), hematurie macroscopique (4), pancreatite aigue (2) et choc
vagal (1).
Cette etude demontre l’efficacite (87 %) du lithotriteur pour briser les calculs
biliaires en fragments de 5 mm ou moins. Toutefois, la disparition complete de ces
fragments a l’aide de sels biliaires peut s’echelonner sur plusieurs mois.

From the *Department o f Surgery, Hopital Saint-Frangois d ’Assise, Quebec, Que. and the
fDepartment o f Preventive and Social Medicine, Universite Laval, Quebec, Que.
Presented at the 14th annual meeting o f the Canadian Association o f General Surgeons, held in
conjunction with the 60th annual meeting o f the Royal College o f Physicians and Surgeons o f
Canada, Quebec, Que., Sept. 21, 1991
Accepted for publication Dec. 19, 1991
Reprint requests to: Dr. Y-M. Dion, Department o f Surgery, Hopital Saint-Frangois d ’Assise, 10,
rue de I'Espinay, Quebec, PQ G IL 3L5

xtracorporeal shockwave litho
tripsy is a treatment modality
that has recently been introduced in
some centres to manage patients
suffering from symptomatic choleli
thiasis. The first published series
was that of Sackmann and col
leagues1 who reported their experi
ence with 175 patients. The excel
lent results reported in that study
led to a marked increase in interest
in ESWL as an alternative to sur
gery for treatment of choleli
thiasis.2-6 We report our experience
with 170 patients.

E

Patients and Methods
Between Jan. 19, 1989 and Nov.
23, 1990, 170 patients (124 wom 
en, 46 men), varying in age from 23
to 76 years (average 46 years) were
entered into the ESWL protocol.
The clinical protocol was approved
by both the Health Protection
Branch (HPB) of Health and Wel
fare Canada and by the research
committee of our hospital.
The following criteria were neces
sary for inclusion in the study:
symptomatic cholelithiasis; a gall
bladder that opacified at oral chole
cystography; and the presence, on a
plain x-ray film of the abdomen, of
three or less radiolucent stones
with a maximum total diameter o f 3
cm.
The following criteria excluded
the patient from the study: frequent
biliary colic; a bleeding diathesis or
consumption of anticoagulants; and
noncompliance to treatment proto
col.
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Treatment Protocol

For 2 weeks before ESWL all
patients were given oral bile salts
(Jouveinal, Montreal) (Fig. 1). These
were continued for 3 months after
-..ie gallbladder had been declared
free of stone fragments or for a
maximum of 24 months. The first
85 patients received a combination
of chenodeoxycholic acid (7 m g/kg
daily) and ursodeoxycholic acid (8
m g /k g daily), whereas the remain
ing 85 were given ursodeoxycholic
acid only (10 m g/kg daily), accord
ing to the updated recommenda
tions of the HPB.
Before lithotripsy, the patient’s
history was obtained and physical
examination performed. The follow
ing tests were done: complete blood
count, measurement of the platelet
count, prothrombin time, partial
thromboplastin time and levels of
serum aspartate aminotransferase,
serum alanine aminotransferase,
serum alkaline phosphatase, serum
bilirubin, serum amylase and serum
lipase, and urinanalysis. Baseline
ultrasonography of the gallbladder
and biliary tree, oral cholecystogra
phy and a flat plate of the abdomen
were obtained to determine eligibili
ty for treatment.
A piezoelectric lithotripter was
used (EDAP International, Marne la
Vallee, France). ESWL was per
formed with the patient in the

prone position. The patients fasted
from the midnight before the proce
dure. The duration of treatment did
not exceed 60 minutes. A discharge
frequency of 10 H z/s and an inten
sity of 100% were selected. Intrave
nous analgesia (a combination of
midazolam, 1 to 2 mg, and fentanyl
citrate, 50 to 100 mg) was provided
by the anesthetist as required.
One day after ESWL, patients
underwent ultrasonography, and
blood tests were repeated. If stone
fragments were 5 mm or less in
their largest diameter, patients were
maintained on bile salts for 3
months, at which time they under
went repeat assessment — history
taking and physical examination,
ultrasonography and blood tests.
Bile salts were continued for 3
months after ultrasonography dem
onstrated a gallbladder free of
stones. Patients were reassessed at
6-month intervals (Fig. 1).
When fragments exceeded 5 mm
in their largest diameter after the
first ESWL, the patient was sched
uled for a repeat session of ESWL 6
weeks later. Patients were advised
that they might require up to four
lithotripsy sessions before gall
stones were fragmented satisfactori
ly. After that, the inability to obtain
stone fragments 5 mm or smaller in
diameter was considered a treat
ment failure, and patients were of
fered another treatment modality.

FIG. 1. Extracorporeal shockwave lithotripsy (ESWL) treatment protocol.
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Treatment failure was defined as
the occurrence of any of the follow
ing:
• Presence of fragments larger
than 5 mm in diameter after four
lithotripsy sessions.
• Presence of fragments in the
gallbladder after 24 months of fol
low-up.
• Complications requiring an al
ternative treatment.
Treatment success was defined as
complete disappearance of gall
stones from the gallbladder. ESWL
success was defined as fragmenta
tion of gallstones to sizes 5 mm in
dimension or less.
Patients were questioned at each
follow-up visit for side effects of
ESWL or bile-salt administration.
They were also advised to report
immediately any troublesome side
effects.
Noncompliance was defined as
the patient’s desire to interrupt the
study for personal reasons, usually
distance from site of treatment, in
ability to pay for bile salts or refusal
of subsequent ESWL.
For 11 patients the pretreatment
data concerning the size and num
ber of stones were lost after these
patients had been confirmed as can
didates for treatment.

Results
In 140 patients the stone diame
ter varied from 0.5 cm to 2 cm
whereas in 30 patients the diameter
varied from 2.1 cm to 3 cm. One
hundred and thirty-one patients had
one stone, 31 patients had two
stones and 9 patients had three
stones.
The distribution of patients with
respect to outcome following as
sessment or treatment, or both, is
summarized in Fig. 2.
Thirty-one of the 170 patients
were ineligible for ESWL, 28 be
cause of nonvisualization of the

EXTRACORPOREAL SHOCKWAVE LITHOTRIPSY

gallstone by the ultrasound unit of
the lithotripter and 3 because of an
error in the preoperative ul
trasonography (polyps rather than

gallstones were identified) (Fig. 2).
Thirteen other patients were ex
cluded because of noncompliance
with the treatment protocol (Fig. 2)

Patients entered into protocol
(n = 170)

Ineligibility for ESWL
(n = 31)
Nonvisualization error
in ultrasonographic
diagnosis

Continuing therapy
(n = 139)

Noncompliance
with protocol
(n = 13)

ESWL completed

Protocol completed
(n = 82)

In follow-up with bile salts
gallstone fragments < 5 mm
(n = 44)

Successes
(n = 61)

(n = 126)

Treatment failures
(n = 21)

FIG. 2. Outcome for 170 patients entered into study.

— 5 because of distance, 4 because
of inability to pay for bile salts and
4 because they stopped taking bile
salts for personal reasons other
than side effects.
ESWL was completed on 126
patients who were left for evalua
tion of treatment in the present
study (Fig. 2). Of these, 21 (17%)
patients were identified as treatment
failures (Table I). The success rate
(dissolution of stones) at 6 months
was 57% and at 9 months 69% (Fig.
3). The ESWL success rate was
87% (Fig. 3). Because failures oc
curred before follow-up, only 105
patients were followed up (Fig. 4).
Forty-four patients had stone
fragments 5 mm in diameter or
smaller and took bile salts orally.
The number of ESWL treatments
required varied from one to four.
Among the patients with successful
ESWL, 55 had one session, 30 had
two sessions, 15 had three sessions
and 5 had four sessions. One pa
tient had a recurrence 12 months
after the procedure, and bile salts,
taken orally, were prescribed.
Complications after ESWL were
evaluated in 150 patients (Table II).
The patient who suffered vagal
shock at the beginning of her first
ESWL session had no problem at a
second session. This was probably a
consequence of apprehension and
analgesia. Complications caused no
long-term morbidity, and there were
no deaths.
Most of the patients received an
algesia intravenously because of
some discomfort created by shock
waves when delivered according to
T a b l e 1 . Failures A fte r E xtracorporeal
S hockw ave L ith o trip s y (ESW L) in 126
P atients
C ause

Fragm ents > 5 m m
a fte r ESWL
Frequent b ilia ry co lic

FIG. 3. Success rates for 126 patients who completed ESWL. Black bars = failures,
dotted bars = dissolution (cumulative rates), hatched bars = fragments smaller than
5 mm in dimension.

Acute pancreatitis
Severe diarrhea (bile
s a lts)

P a t ie n t s , n o . ( % )

1 6 ( 1 2 .7 )
3 ( 2 .4 )
1 ( 0 .8 )
1 ( 0 .8 )
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the parameters previously men
tioned. An anesthetist was present
during the whole procedure. Two
patients requested no analgesia for
their second and third ESWL.

Discussion
Of the 28 patients who were
ineligible for the treatment because
the ultrasound unit of the lithotripter failed to visualize the gallstone,
most were obese women or, more
rarely, muscular men. There ap
pears to be a significant learning
curve in the use of this proce
dure.78 We also agree with Nahrwold and colleagues9 that the
“ greatest technical drawback to
ESWL is the diminished quality of
ultrasound visualization.” They
mentioned that the images pro
duced by most lithotripters do not
approach the clarity achieved with
diagnostic ultrasonography. In the
present series, it was common for
the stones or their fragments to be
only faintly visualized at the begin
ning of treatment. Only after a few
minutes of treatment was the gall
bladder visualized in these cases.

This was probably due to deposition
on the mucosa of sand-like material
from the disintegrating gallstones.
Technical improvements such as
better ultrasound imaging will like
ly render gallstone lithotripsy more
effective. Many of our patients in
whom lithotripsy failed had their
gallstones pulverized to fragments
measuring 7 to 9 mm in size. An
improved ultrasound unit would
have allowed us to visualize these
fragments better and reduce their
size more efficiently.
Noncompliance is related to the
duration of treatment required. Pa
tient reluctance to continue biliary
salts for many months may endan
ger the viability of the technique,
especially in view of the emergence
of new surgical techniques like la
paroscopic cholecystectomy.10
Although passage of fragments
of 5 mm or smaller has been shown
to occur,11'12 the main mechanism
allowing restoration of a gallstonefree gallbladder is probably gall
stone dissolution. It appears that
bile salts are not ideal solvents. In
our series some patients with ade
quate lithotripsy still had fragments
of stone in their gallbladders 6, 9

N U M B E R O F P A T IE N T S

and 12 months later (Fig. 3). Also,
because bile salts act preferentially
on cholesterol stones, patients with
such stones are expected to respond
better than those with mixed
stones. There may be a place for
contact dissolution of gallstones by
solvents. Neubrand and colleagues13
are currently evaluating adjuvant
solvent (methyltertbutyl ether) ther
apy at the same time ESWL is
given. Using a combination of sol
vents (proved nontoxic when inject
ed into gallbladders of live dogs) we
were able to obtain complete disso
lution of cholesterol as well as
pigmented gallstones in vitro in less
than 4 hours when ESWL had
reduced fragment size to 5 mm or
less.14
Provided that strict inclusion crit
eria are applied,15'16 ESWL is effec
tive in reducing gallstone diameter
to fragments of 5 mm or less.
Staritz17 showed that in clinical si
tuations with the different lithotrip
sy systems (and adequate energy
levels), only 2% to 3% of stones
cannot be disintegrated. Stones in
two (1.5%) of our patients did not
disintegrate. Those in 14 (11%) oth
ers were not pulverized to frag
ments 5 mm or less in size, but
difficulty in localizing these frag
ments by ultrasonography, as dis
cussed previously, probably con
tributed to this problem. We use a
higher energy level (10 Hz/s) than
our American colleagues (1.5 to 5
Hz/s) using the same lithotripter,
because our studies in vitro showed
a better disintegration of gallstones
at 10 H z/s.7 It has also been
Table II. C o m p lic a tio n s A fte r
E x tra c o rp o re a l S h o c k w a v e L ith o trip s y in
1 2 6 P a tie n ts

.1

3

6

9

12

15

FOLLOW-UP (MONTHS)
FIG. 4. Distribution of 105 patients according to duration of follow-up. Complete
dissolution of gallstones (black bars). Gallstone fragments less than 5 mm in
diameter (hatched bars).
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Complication
B ilia ry c o lic
M ild d ia rrh e a
S evere d ia rrh e a
M a c ro s c o p ic h e m a tu ria
A cu te p a n c re a titis
V agal s h o c k

Patients, no. (% )
4 0 (3 1 .7 )
2 4 (1 9 .0 )
1 ( 0 .8 )
4 ( 3 .2 )
2 ( 1 .6 )
1 ( 0 .8 )
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shown, although not quantitatively,
that abdominal wall and fatty tissue
absorb some energy from the shock
wave, thereby reducing its effect on
gallstones.17 At the energy levels we
use, intravenous analgesia is re
quired for most patients. Actually,
the pain that may be experienced
during the ESWL session disap
pears as soon as delivery of shock
waves is stopped.
Variation in the amount of ener
gy delivered has been invoked to
explain the discrepancy in the re
sults of two studies performed with
the same lithotripter and the same
protocol.18-20 The results obtained
by the Munich group1 are better
than those reported by the inves
tigators of the Dornier National
Biliary Lithotripsy Study in the
United States21 — Sackmann and
colleagues1 showed that, at 6
months’ follow-up, 63% of their
patients had an empty gallbladder,
whereas Schoenfield and associ
ates21 reported an overall success
rate of 20.6% at 6 months. Success
rates from six other groups, at 6
months’ follow-up, varied from 36%
to 75% overall.5
We agree with Delius18 that the
major factor influencing disintegra
tion, provided the energy is kept
constant, is the total volume of the
stones. This was a constant finding
in all series.1-4-21' 23 Stones smaller
than 2 cm are more easily destroyed
than larger ones, which is not sur
prising because the volume of a
30-mm stone is 27 times that of a
10-mm stone.9 According to the
Munich group,1 70% of patients
having one stone smaller than 2 cm
in diameter are free of disease after
1 year and 80% are disease free
after 2 years; 50% of patients with
stones larger than 2 cm are free of
disease at 1 year and 60% at 2
years.
The number of stones is also an
important variable, the results being
less favourable when two or three

stones are present (22% success
rate at 1 year and 60% at 2 years).
Baron and associates23 reported the
results of treatment by the EDAP
LT-01 lithotripter of 323 patients.
They are comparable to those given
by Fromm and Albert6 who treated
243 patients; the overall success
rate at 6 months was 34% and at 9
months was 45%. When there were
solitary stones 2 cm or less in
diameter, 42% of patients were free
of stones at 6 months and 57% at 9
months. The same trend was noted
in our group of patients. Out of 61
patients who had a gallstone-free
gallbladder, 52 had a stone size
ranging from 5 mm to 2 cm. Fortynine of these patients had one
stone, 7 had two stones and 2 had
three stones. Our rate of gallblad
ders free of stones (treatment suc
cess rate) at 6 months’ follow-up
was 57% and at 9 months was 69%
(Fig. 3). Our success rate for gall
stone fragmentation to pieces 5 mm
or less in diameter (ESWL success
rate) was 87% (Fig. 3).
Our complication rate was similar
to that of other series.1-6-21-24
Sackman and colleagues25 recent
ly reported on the rates of gallstone
recurrence after ESWL. Recurrence
rate at 1 year was 9%, rising to 11%
by 1.5 years and not increasing
appreciably after that for 3 years.
Because recurrence is more com
mon in patients with multiple
stones, it is not surprising that
early recurrence rates for lithotripsy
are at the lower end of the spec
trum of recurrence rates reported
for oral dissolution therapy.26' 29
Most of the patients who underwent
successful lithotripsy had single
stones. At present, if one of our
patients is found to have a recur
rence, symptomatic or not, the al
ternatives are either to take bile
salts orally or undergo a repeat
ESWL, depending on the size of the
stone. The patient may also choose
laparoscopic cholecystectomy.

In summary, ESWL appears to be
a relatively safe method for treating
symptomatic cholelithiasis. Al
though biliary colic occurred in 40
of our patients during treatment,
only 3 of them required elective
cholecystectomy because of fre
quent episodes. An excellent ultra
sound targetting system and rigid
inclusion criteria are prerequisites
to decrease patient exclusion and
failure rates. The ideal candidate is
thin and has a solitary radiolucent
gallstone measuring 2 cm or less in
dimension. We believe that frag
mentation alone is insufficient to
lead to a successful result. Adjuvant
therapy is necessary. Candidates for
ESWL, who average approximately
10% of all patients with symptomat
ic cholelithiasis,30-31 should also be
offered laparoscopic cholecystecto
my10 so they can choose between
the two techniques after having
evaluated their respective advan
tages and disadvantages.
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R o le of Intraoperative Ultrasonography
in Hepatic Surgery: a Preliminary Report
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Twenty-four patients who underwent ultrasonography during hepatic surgery in the
22 months from October 1989 to July 1991 were studied prospectively to determine
the value, if any, of intraoperative ultrasonography. For 6 (25%) of the 24 patients
the operative plan was altered because of the ultrasonographic findings. In one of
them resection was extended from a left lateral segmentectomy or sectorectomy to a
left hemihepatectomy. In the other five patients the planned liver procedure was
abandoned. Two of these five patients were cirrhotic — in one of them an additional
metastasis was seen, and in the other there was tumour invasion of the portal vein.
Of the three noncirrhotic patients, one had tumour invasion of the right hepatic
vein, and the other two patients had additional metastases in the caudate lobe
(Couinaud segment 1).
Ultrasonography was found to be useful in 25% of patients who underwent this
investigation during hepatic surgery — it avoided liver resections that would have
failed because of advanced malignant disease.

Une etude prospective portant sur 24 patients qui subirent une echographie durant
une chirurgie hepatique fut realisee au cours de la periode de 22 mois allant
d’octobre 1989 a juillet 1991, dans le but de mesurer l’interet eventuel de cet
examen. Dans 6 cas (25%), le plan operatoire fut modifie a cause des resultats de
l’examen echographique. Chez un des six patients, la resection fut elargie d’une
segmentectomie laterale gauche ou d’une sectorectomie, a une hemihepatectomie.
Chez les cinq autre patients, l’intervention projetee fut abandonnee. Deux de ces
cinq patients etaient cirrhotiques; chez l’un d’eux, une metastase additionnelle fut
decouverte et, chez l’autre patient, il y avait envahissement de la veine porte. Des
trois patients non cirrhotiques, un montrait un envahissemnt de la veine hepatique
droite et, chez les deux autres, des metastases additionnelles furent decouvertes
dans le lobe caude.
L’echographie s’est averee utile chez 25% des patients qui furent soumis a cet
examen lors d’une chirurgie hepatique; elle evita des resections hepatiques qui
auraient ete inutiles a cause de l’etat d’avancement du cancer.
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ecent developments in hepatic
surgery include a better under
standing of surgical anatomy as
described by Couinaud,1 better in
traoperative imaging using intraop
erative ultrasonography and better
methods of liver parenchymal tran
section with the ultrasonic surgical
aspirator (Cavitron; Valleylab Cana
da, Richmond Hill, Ont.).
Since surgeons have been able to
perform segment-oriented liver re
sections for benign and malignant
disease, intraoperative ultrasonog
raphy has assumed an increasing
role in modern liver surgery.
We describe our initial 22-month
experience with intraoperative ul
trasonography in hepatic surgery.

R

Patients and Methods
On Oct. 19, 1989, we acquired
an ultrasound machine (Aloka
SSD-630; Omnium Medical Devices,
Richmond Hill, Ont.) dedicated for
use in the operating room with 5and 7.5-mHz, T-shaped probes ca
pable of performing hepatic ul
trasonography. Between Oct. 19,
1989 and July 31, 1991, 29 pa
tients underwent intraoperative ul
trasonography. The data on all pa
tients were collected prospectively
on a computer database. Twentyfour patients, who formed the study
group, had ultrasonography of the
liver during hepatic procedures; 4
CJS, VOL. 35, NO. 2, APRIL 1992
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patients had hepatic ultrasonogra
phy during laparotomy for other
reasons, and 1 patient had splenic
ultrasonography for a recurrent
congenital splenic cyst during the
course of a partial splenectomy.

Findings
All patients underwent preopera
tive ultrasonography and computed
tomography, and if the tumour
mass was deemed resectable, they
then underwent laparotomy and in
traoperative ultrasonography. In 6
(25%) of the 24 patients who under
went hepatic ultrasonography dur
ing a liver procedure, the operative
plan was altered by the ultrasono
graphic findings. In one of the six
patients resection was extended
from a left lateral segmentectomy
or sectorectomy (segments 2 and 3)
to a left lobectomy or left hemihepatectomy (segments 2, 3, 4A and
4B). In five of the six patients the
proposed resection was cancelled.

FIG. 1. Invasion of trunk of right
portal vein by tumour thrombus (ar
rows), extending from hepatoma in
volving right hepatic lobe. RK = right
kidney.
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Two of the five were cirrhotics: in
one an additional metastasis was
seen and in the other there was
invasion of the portal vein by a
hepatoma (Fig. 1). Of the three
noncirrhotic patients one had inva
sion of the right hepatic vein (Fig.
2) and the other two had caudatelobe metastases. Two (9.1%) of 22
of our noncirrhotic patients had
additional metastases that were de
tected only by intraoperative ul
trasonography. This investigation
of the liver was found useful in one
of four patients who underwent
intraoperative ultrasonography dur
ing nonhepatic surgery. In three
patients it was performed during a
laparotomy for resection of colonic
cancer in the presence of liver me
tastases. In one patient it allowed
an ultrasonically guided biopsy of a
small, deep-seated, nonpalpable
liver lesion during laparotomy for
resection of a distal, common-bileduct carcinoma (Fig. 3). The biopsy
did not reveal a metastatic lesion,
which encouraged us to proceed

FIG. 2. Invasion of branches of right
hepatic vein (RHV) (arrows) by metas
tasis from colorectal cancer occupying
right hepatic lobe.

with dissection. Ultimately, howev
er, the proposed Whipple resection
was abandoned due to invasion of
the portal vein by the tumour.

Discussion
In 1954 Couinaud1 described the
segmental anatomy of the liver in
detail and clearly described the intrahepatic vascular anatomy. How
ever, this knowledge could not be
applied because surgeons had no
method of visualizing intrahepatic
vascular anatomy. But in 1977
when Makuuchi and colleagues2
and later Bismuth and Castaing3
began using intraoperative ul
trasonography to map the in
trahepatic vascular anatomy they
were able to perform segmental
liver resections. The development of
the ultrasonic surgical aspirator,
which allows more precise hepatic
transection, further enhanced the
usefulness of intraoperative ul
trasonography.

FIG. 3. Needle (white central area)
biopsy of small lesion (white arrow)
deep in right hepatic lobe.

INTRAOPERATIVE ULTRASOUND IN HEPATIC SURGERY

Recent literature has demonstrat
ed the value of this method in
detecting small liver metastases es
pecially from colorectal primaries.
Its accuracy in diagnosing liver me
tastases was evaluated by Machi
and colleagues4 at surgery and at
follow-up in 189 patients with colo
rectal cancer. The sensitivity (93%)
of intraoperative ultrasonography
was significantly (p < 0.0001) high
er than that of preoperative ul
trasonography (41%), conventional
computed tomography (47%) and
surgical exploration (66%). Twentytwo of 104 metastatic lesions were
detected in 18 patients, solely by
intraoperative ultrasonography
(9.5% of all patients). The 22 tu
mours were small (< 2 cm in dimen
sion) and nonpalpable during opera
tion. During the postoperative fol
low-up of at least 18 months after
colorectal surgery (median 37.1
months), liver metastases that were
unrecognized during surgery ap
peared in 13 patients (6.9%). Reevaluation based on these follow-up
results indicated that the sensitivity
of intraoperative ultrasonography
decreased to 82% from the original
93%, which was still significantly (p
< 0.0005) better than that of the
other methods. Intraoperative ul
trasonography was capable of iden
tifying 18 (58%) of 31 patients in
whom liver metastases were other
wise unrecognized at operation.
Olsen5 reported on 360 hepatic me
tastases in 63 patients: the sensitivi
ty for detecting hepatic metastases
was 66.1% for preoperative ul
trasonography combined with in
spection and palpation during sur
gery and 98.3% for intraoperative
ultrasonography. Gozzetti and asso
ciates6 demonstrated a sensitivity of
95.4% for intraoperative ul
trasonography in identifying liver
metastases in noncirrhotic patients.
Two (9%) of 22 of our noncirrhotic
patients had additional metastases
that were only detected by intraop

erative ultrasonography. In our ex
perience, 25% of patients (6 of 24)
had the operative plan altered be
cause of new information obtained
by intraoperative ultrasonography.
Eighty-six percent of these patients
(five of six) were spared a liver
resection that would have proved
useless oncologically. In one of the
six patients the procedure was ex
tended to obtain a better tumourfree margin.
Intraoperative ultrasonography
has been found to be an indispensa
ble tool for resecting small hepato
cellular carcinomas. Sheu and col
leagues7 used it in 47 patients to
localize carcinomas less than 5 cm
in size — 45.9% of tumours smaller
than 3 cm and 14.2% of tumours 3
to 5 cm in dimension were invisible
and nonpalpable during laparotomy
and required intraoperative ul
trasonography for detection. By
this method 96.5% of small hepato
cellular carcinomas were detected
compared with 89.6% by preopera
tive ultrasonography and 94.8% by
combined imaging with ultrasonog
raphy, computed tomography, angi
ography and radionuclide scanning.
In our limited experience of cirrhot
ic patients with hepatocellular car
cinomas, two of the three cirrhotic
patients had additional information
revealed by intraoperative ul
trasonography that made resection
not feasible.
Little and Holland8 evaluated the
impact of ultrasonic surgical aspira
tor and intraoperative ultrasonogra
phy on hepatic resection in 50
consecutive liver resections over 5.5
years. They concluded that intraop
erative ultrasonography allowed
more precise surgical planning and
was not associated with an increase
in operative time or postoperative
mortality. Use of the ultrasonic sur
gical aspirator confers a number of
benefits: it reduces blood loss, the
number of transfusions and the
postoperative hospital stay (by a

median of 4.5 days), and it has the
ability to achieve these benefits in
older patients.

Conclusions
On the basis of our initial
22-month experience with hepatic
intraoperative ultrasonography in
24 patients, we advocate routine
use of ultrasonography during he
patic resection because of the addi
tional information gleaned from
that examination. Intraoperative ul
trasonography in combination with
the ultrasonic dissector als allows
precise segmental liver resec ns.
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in combination with 5-fluorouracil

Prescribing Information
ACTION
ERGAMISOL (levamisole hydrochloride) is capable of restoring impaired immune responses
preferentially of the cell mediated type in compromised hosts. Therapeutic doses of lev
amisole restore to normal the functions of monocytes (phagocytes) and T lymphocytes
but do not directly influence B cells.
Levamisole is rapidly absorbed from the gastrointestinal tract following a single oral ingestion
of 150 mg. In patients with neoplastic disease, a mean peak blood level of 0.86 mcg/mL
is attained within 2 hours of intake.
The half-life of elimination of levamisole alone is between 3-4 hours. The metabolites are
eliminated more slowly with a terminal half-life of approximately 16 hours. Levamisole
is extensively metabolized by the liver in man and excreted mainly by the kidneys (70%
over 3 days). Approximately 5% is excreted in the feces. Less than 5% of the unchanged
dose is excreted in the urine and less than 0.2% in the feces.
INDICATIONS
ERGAMISOL (levamisole hydrochloride) is indicated as adjuvant therapy in poor prognosis
malignant melanoma following complete surgical excision and exclusion of metastatic
disease. In such patients, levamisole has been shown to produce an improvement in relapse
free survival and overall survival when compared to observation alone, particularly in patients
aged 55 years or older,
ERGAMISOL is also indicated as adjuvant therapy, in combination with 5-fluorouracil, in
patients with completely resected Dukes’ stage C colon cancer. Evidence of metastatic
disease must be excluded before initiating therapy. In patients with Dukes’ stage C carcinoma
of the colon, a regimen of levamisole plus 5-fluorouracil has been shown to produce sig
nificant reductions in both cancer recurrence and overall death rate.
CONTRAINDICATIONS
Levamisole is contraindicated in patients with a known hypersensitivity to the drug.
WARNINGS
ERGAMISOL (levamisole hydrochloride) has been associated with reversible leukopenia
and agranulocytosis, therefore it is essential that appropriate hematological monitoring
be done routinely during therapy with ERGAMISOL.
Patients should be instructed to report immediately any sudden change in their state of
health which may be manifested by influenza-like symptoms (fever, lassitude, sore throat,
shivering or sweating) so that appropriate hematological testing can be done.
Leukopenia (total WBC below 3000 mm1) is not necessarily a sign of impending agran
ulocytosis; recovery is possible without withdrawal of the drug. However, with a reduced
neutrophil count (less than 20% of the total white blood cell count) levamisole should be
discontinued permanently. (Agranulocytosis is attributed to antibody formation and absorp
tion of immune complexes. This process initiates complement activation and cell lysis;
levamisole itself does not directly damage granulopoiesis.)
The HLA genotype B27 predisposes to the development of agranulocytosis, particularly
in females with concomitant rheumatoid arthritis. The onset is frequently sudden and may
be asymptomatic. Following discontinuation of levamisole, neutrophil counts normalize
within a week to 10 days. There is no evidence that steroids or WBC transfusions are of
significant therapeutic value; prophylaxis of infection during the acute phase of agranu
locytosis should be an important consideration.
PRECAUTIONS
Drug Interactions: The therapeutic effect of levamisole may be antagonized by concomitant
administration of corticosteroids.
Additional caution is necessary when levamisole is used in combination with other drugs
potentially affecting hemopoiesis.
Levamisole has been reported to produce “ ANTABUSE™"-like side effects when given con
comitantly with alcohol.
ADVERSE REACTIONS
Approximately half of all patients treated with ERGAMISOL (levamisole hydrochloride) expe
rience adverse effects of the medication. Due to the intermittent nature of the dosage sched
ule, drug discontinuation may not be necessary for successful resolution.
The adverse reactions observed when levamisole is used in combination with 5-fluorouracil
are consistent with those anticipated if 5-fluorouracil is given alone in a comparable dose
and schedule.
The incidence of adverse reactions for levamisole alone in malignant melanoma patients
and for levamisole plus 5-fluorouracil in colonic cancer patients is presented in the following
table:
LEVAMISOLE
ADVERSE REACTIONS
GASTROINTESTINAL
nausea
vomiting
diarrhea
taste change
anorexia

MELANOMA
24
6
10
1

INCIDENCE (%)
LEVAMIS0LE+5-FU
COLONIC
MAINTENANCE
INDUCTION
37
8
25
2

56
17
47
7

ADVERSE REACTIONS
MUCOCUTANEOUS
stomatitis
dermatitis
severe
alopecia
conjunctivitis
hyperpigmentation
HEMATOLOGICAL
leukopenia
2000 to 4000/mm3
less than 2000/mm!
thrombocytopenia
50000 to 130000/mm3
less than 50000 /mm3
agranulocytosis
MUSCULOSKELETAL
arthralgia/myalgia
NEUROLOGIC
visual change
smell change
headache
dizziness/vertigo
ataxia
anxiety/irritability
depression
insomnia
somnolence
impaired thinking
OTHER
fatigue/weakness
fever
impaired liver function

MELANOMA
1
4

COLONIC
INDUCTION
MAINTENANCE
27
8
1
4
1

28
22
1
22
7
2

38
7

38
2

4
2

18
4

2

4

10

1.4
8

1

2
2
5
4
3
2
2
1
1
2

5

11

1

2

1
1
1
2
1

8

SYMPTOMS AND TREATMENT OF OVERDOSAGE
There is no experience of overdosage with ERGAMISOL (levamisole hydrochloride). At
high doses ERGAMISOL exhibits positive inotropic and chronotropic properties on heart
muscle as well as convulsant properties. General supportive measures are recommended.
DOSAGE AND ADMINISTRATION
In patients with malignant melanoma
ERGAMISOL (levamisole hydrochloride) should be administered at a dose of 2.5 mg/kg
given as a single daily dose, preferably at night, on 2 consecutive days every week. Higher
doses are not recommended as they are associated with increased toxicity and have not
been shown to provide any additional therapeutic benefit.
In patients with Dukes’ stage C carcinoma of the colon
Levamisole plus 5-fluorouracil should be administered only by or under the supervision
of qualified physicians, experienced in cancer chemotherapy, and well versed in the use
of potent antimetabolites.
Therapy with ERGAMISOL may be initiated as soon after resection as patients are able
to tolerate oral medication, but no sooner than one week and no later than five weeks after
surgery.
ERGAMISOL should be administered orally at a dose of 50 mg t.i.d., for three consecutive
days, every two weeks. This therapy should be continued for at least one year.
Administration of 5-fluorouracil should be timed to begin concomitantly with the second
three day course of levamisole. The initial dosage of 5-fluorouracil should be 450 mg/mVday,
given intravenously, for five consecutive days.
Four weeks following the initial five day course of 5-fluorouracil, patients should begin
maintenance therapy on a once weekly basis with an intravenous injection of 5-fluorouracil
at a dose of 450 m g/nf. Treatment should continue for as long as levamisole is administered.
If the patient experiences stomatitis, diarrhea or leukopenia, the weekly 5-fluorouracil admin
istrations should be deferred until these side effects have subsided. If these side effects
are moderate to severe in intensity, 5-fluorouracil should be resumed with a 20% reduction
in the dose.
Dosage Forms:
Availability: ERGAMISOL tablets 50 mg are available in blister packages of 36 tablets.
Storage:
ERGAMISOL tablets 50 mg should be stored at room temperature and pro
tected from moisture and light.
Product monograph available on request.
1. Moertel CG et al. Levamisole and fluorouracil for adjuvant therapy of resected colon
carcinoma. New Engl J Med. 1990;322:352-8.
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Cardiac Surgery After Failed
Percutaneous Mitral Valvuloplasty
L. Normandin, MD; M. Carrier, MD, FRCSC; Y. Leclerc, MD, FRCSC; L.C. Pelletier, MD, FACS, FRCSC
Percutaneous, mitral valvuloplasty (PMV) has been proposed as a safe alternative to
open mitral commissurotomy (OMC) or mitral valvular replacement (MVR) in
selected patients with symptomatic mitral stenosis (MS). Among 146 consecutive
patients who underwent PMV between March 1987 and April 1990, 18 (12%) needed
urgent corrective surgery after the procedure. Of these 18 patients 16 were women
and Z were men. Three patients were of clinical incapacity class II and 15 of class III
and were at an intermediate risk for PMV according to the echo score (mean score
p). The indications for corrective surgery were massive mitral regurgitation owing
to tearing of the anterior leaflet (six patients), cardiac perforation (left atrium in two
patients, left ventricle in three patients), technical failure of PMV (five patients) and
severe atrial shunting (two patients). Operative procedures included MVR (14
patients), cardiac wound suturing only (3 patients) and OMC (1 patient). Operative
mortality (within 30 days) was 22% (4 of 18 patients), distributed equally among
patients needing urgent or elective surgery. When compared with the operative
death rate after OMC (0%) and MVR (3.1%) as the initial treatment for MS during the
same period, the rate for cardiac operation after failed or complicated PMV (22%)
was significantly higher (p = 0.004). Therefore, optimal patient selection and
aggressive corrective surgery are necessary to decrease PMV-related morbidity and
death.

La technique de valvuloplastie mitrale percutanee (VMP) a ete proposee comme
alternative securitaire a la commissurotomie mitrale ouverte (CMO) ou au remplacement de valvule mitrale (RVM) chez des patients choisis souffrant de stenose mitrale
symptomatique (SM). Chez 146 patients consecutifs qui subirent une VMP entre
mars 1987 et avril 1990, 18 (12 %) necessiterent une chirurgie correctrice urgente
apres l’operation. De ces 18 patients, 16 etaient des femmes et 2, des hommes. Trois
patients avaient une incapacity de classe II et 15, une incapacity de classe III et ils
presentaient un risque moyen pour une VMP selon la cote echo (cote moyenne de 8).
Les raisons de ces chirurgies correctrices etaient une regurgitation mitrale massive
due a une dechirure du feuillet anterieur (six patients), a une perforation cardiaque
(de l’oreillette gauche chez deux patients, du ventricule gauche chez trois patients),
a une defaillance technique de la VMP (cinq patients) et a une defaillance auriculaire
grave (deux patients). Les operations pratiquees comprennent le RVM (14 patients),
la suture seulement de la dechirure cardiaque (3 patients) et la CMO (1 patient). La
mortality operatoire (dans les premiers 30 jours) fut de 22 % (4 sur 18 patients),
distribuee de fa?on egale entre les chirurgies urgentes et non urgentes. Comparativement a la mortality operatoire consecutive a la CMO (0 %) ou au RVM (3,1 %)
utilises comme traitement initial de la SM, le taux d’operations cardiaques apres
defaillance ou complication de la VMP (22 %) est beaucoup plus eleve (p = 0,004).
Une selection optimale des patients et une chirurgie correctrice agressive seront
done necessaires pour reduire la morbidity et la mortality reliees a la VMP.

ince the first publication by
Inoue and associates1 in 1984,
percutaneous mitral valvuloplasty
(PMV) has evolved into a safe and
effective alternative treatment for
selected patients with symptomatic
mitral stenosis (MS). Even though
the morbidity and mortality are re
ported to be very low for PMV,2
surgical back-up for immediate op
eration after failed or complicated
PMV should be available. The re
sults of these salvage operations
need to be evaluated because PMV
is rapidly developing into an alter
native to closed or open mitral
commissurotomy (OMC) in the ini
tial treatment of MS.
The purpose of this study is to
evaluate the clinical results of sal
vage surgery required after failed
PMV and to compare the results
with those in patients who initially
underwent OMC or mitral valve
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replacement (MVR) in the same pe
riod.

13 patients) or uncomplicated tech-/
nical failures (inability to dilate) fyn
5 patients).
>'
Hemopericardium due to left atri
al (two) or left ventricul^T (three)
perforation occurred ii> five pa
tients. Six patients buffered an
acute mitral regurgitation following
PMV. In these patients, surgical
exploration displayed tears of the
anterior leaflet (three) or the poste
rior leaflet (one), a par.acommissural
tear (one) or ruptured chordae tendineae (one). Four of the patients
required emergency operation. A
persistent atrial septal defect (ASD)
with left-to-right shunt and pulmonary-to-systemic flow ratio (Qp/Qs)
more than 2 was the indication for
surgical treatment in two patients.
Technical failures included two
patients in whom transseptal cathe
terization could not be performed
and three failures of dilatation be
cause of unfavourable anatomy of
the valve (excessive subvalvular fi
brosis and leaflet calcifications).
Two of these patients had previous
ly undergone a closed mitral com
missurotomy.
Corrective surgical procedures in
group 1 patients included 14 MVRs
and 1 OMC. Three patients with
severe hemodynamic collapse and
signs of cardiac tamponade under
went repair of the perforation as the
only form of treatment. A mechani
cal prosthesis (CarboMedics, Aus
tin, Tex.) was implanted in all cases
of MVR; in addition any ASD pres
ent was closed. Surgical repair of
the mitral valve by suturing the
torn leaflet was not considered at
that time.

pressure and pulmonary vascular
resistances were assessed (Table I).
Group 2

Patients and Methods
Eighteen of 146 consecutive pa
tients, who underwent PMV as an
initial treatment for symptomatic
MS between March 1987 and April
1990, required corrective surgery
for failed or complicated PMV
(group 1). During the same period,
17 patients (group 2) underwent
OMC and 32 patients (group 3) had
an isolated MVR as primary treat
ment for mitral stenosis.
Group 1

Sixteen women and 2 men, aged
28 to 73 years (mean 54 ± 4 years),
presented with either pure MS or
MS associated with a minimal de
gree of regurgitation. Before PMV,
3 patients were in New York Heart
Association (NYHA) functional
class II and 15 were in class III.
The findings on echocardiographic
examination of valve rigidity, thick
ening, calcification and subvalvular
fibrosis were graded, and a cumula
tive echo score according to Abascal and associates3 was established.
A cumulative score of less than 8
was considered favourable for PMV.
In this group, the echo score was
available in 14 patients, half of
them having a score of less than 8.
In addition to echocardiographic
evaluation, hemodynamic measure
ments by transseptal catheterization
were obtained before PMV. Mitral
valve area and gradient, left atrial

One man and 16 women, aged 26
to 72 years (mean 47 ± 12 years)
were operated on for pure MS and
underwent OMC without annuloplasty or other associated proce
dure.
Group 3

Seventeen men and 15 women,
aged 40 to 71 years (mean 56 ± 9)
had pure MS. MVR was required
because of marked destruction of
the subvalvular apparatus in these
patients.
Statistical Analysis

Data are presented as means and
standard deviations. Differences be
tween groups were compared by
analysis of variance or the x2 test.
Statistical significance was estab
lished at the 95% confidence level.

Results
Group 1

Of the 18 patients in group 1
requiring corrective surgery after
failed PMV, 8 were operated on an
emergency (less than 24 hours after
PMV) and 10 on an urgent (average
7 days after PMV) basis. The indica
tions for surgery were either com
plications of the PMV procedure
(catheterization and dilatation) (in
Table I. Preoperative Hemodynamic Measurements

Group
Measurement
Mitral valve area, cm2
Mitral valve gradient, mm Hg
Pulmonary artery pressure, mm Hg
Pulmonary vascular resistance, Woods
Left atrial pressure, mm Hg
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2

1
0.93 ± 0.37
15.5 =b 5.5
34.5 db 10.0
8.66 ± 5.9
25.2 ± 7.0

1.00
14.4
27.5
7.99
20.2

± 0.31
± 5 .4
± 7 .0
± 1.7
± 6 .0

3

p value

0.22
1.05
15.5 =b 5.2
30.8 ± 11.0
9.07 ± 4.6
21.5 ± 5.8

0.7
0.7
0.2
0.4
0.06

db

/

/f

PERCUTANEOUS MITRAL VALVULOPLASTY

Groups 2 and 3
Echocardiographic scores were
not systematically available. Hence
mitral valve area and gradient, left
atrial pressure and pulmonary vas
cular resistance were used to deter
mine the extent of mitral valve
disease. None of these variables
showed a statistically significant dif
ference between the three groups
(Table I).
Deaths
There were four deaths in group
1 (30-day mortality of 22%), as
opposed to none in group 2 and one
in group 3 (3%). The difference
between groups was statistically
significant (p = 0.004). Two of the
deaths in group 1 occurred in pa
tients who underwent emergency
operation. A 73-year-old man died
from massive cerebral anoxia after
closure of a left ventricular perfora
tion and MVR. A 58-year-old
woman died suddenly 12 days after
MVR and an uncomplicated early
postoperative course. Despite he
modynamic stabilization after com
plicated PMV, two patients died at
surgery. A 58-year-old woman
could not be weaned from bypass
after mitral and tricuspid valve re
pair. The other death, a 67-year-old
woman, was due to atrioventricular
disruption after MVR.

Comments
Since 1984, with improvement in
techniques, increased experience
and better patient selection, PMV

has gained in popularity as an effec
tive alternative treatment to OMC
and MVR for symptomatic mitral
stenosis with favourable valve mor
phology. PMV relieves MS by split
ting fused commissures in a similar
way to surgical commissurotomy.
PMV will likely result in functional
and hemodynamic improvements si
milar to OMC. Considering patients
with favourable lesions (pliable leaf
lets without subvalvular disease),
the 2-year rate of freedom from
death, recurrent symptoms and ne
cessity for MVR was 77% with
PMV4 compared with 98% for
OMC.5
Few studies of the surgical find
ings after failed PMV have been
published. Acar, Deloche and
Chachques6 recently reported on 10
patients with hemopericardium (5),
acute mitral insufficiency (3) or per
sistent ASD (2). In three cases, the
mitral valve was repaired with leaf
let suturing. There were no opera
tive deaths or significant morbidity
after these procedures. In the pres
ent study, salvage procedures were
associated with a high mortality
(22%) even after medical stabiliza
tion. The effects on left ventricular
performance of sudden mitral re
gurgitation and shunting from ASD
are highly deleterious and increase
the surgical risk when compared
with primary OMC or MVR.7
A prospective randomized study
comparing PMV with OMC in pa
tients with favourable lesions will
not be available in the near future.8
Meanwhile, better patient selection
afforded by precise echocardio
graphic evaluation and technical im
provements will probably decrease

even more the risks inherent in
PMV. Nevertheless, our study clear
ly shows that the operative mortali
ty of salvage surgery following
failed PMV is significant and em
phasizes the importance of careful
patient selection for PMV.
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NARCOTIC EFFICACY WITHOUT NARCOTIC DRAWBACKS
TORADOL (ketorolac tromethamine) 10 mg tablets
TORADOLIM (ketorolac tromethamine) 15 mg/mL and 30 m g/m l intramuscular injections
THERAPEUTIC CLASSIFICATION
Analgesic Agent
ACTION
Toradol (ketorolac tromethamine) is a non-steroidal anti-inflammatory drug that exhibits analgesic activity. Its mode of
action is to inhibit the cyclo-oxygenase enzyme system, thereby inhibiting the synthesis of prostaglandins, and is consid
ered to be a peripherally acting analgesic. At analgesic doses it has minimal anti-inflammatory and antipyretic activity.
Ketorolac tromethamine is rapidly and completely absorbed when administered by both the oral and intramuscular routes,
and pharmacokinetics are linear following single and multiple dosing.
Steady state plasma levels are attained after one day of Q.I.D. dosing. Based only on pharmacokinetic principles, a faster
attainm ent of the steady state plasma level might be achieved with a loading dose of about twice the maintenance
dose. This occurs when the dosing interval is approximately equal to the drug's half-life.
Following oral administration, peak plasma concentrations of 0.52 to 1.31 mcg/ml occurred 35 minutes after a single lOmg
dose. The terminal plasma elimination half-life ranged between 4.1 and 6.1 hours in healthy adults, while in elderly sub
jects (m ean age: 72 years) it ranged between 3.0 and 6.1 hours. A high fat diet decreased the rate but not the extent
of absorption of oral ketorolac tromethamine, while antacid had no effect.
Following intramuscular administration, peak plasma concentrations of 2.2 to 3.0 m cg/m l occurred an average of 50
minutes after a single 30 mg dose. The terminal plasma half-life ranged between 3.8 and 6.3 hours in young adults and
betw een 4.4 and 8.6 hours in elderly subjects (mean age: 72).
The primary route of excretion of ketorolac tromethamine and its metabolites (conjugates and the p-hydroxy metabo
lite) is in the urine (91.4%) and the remainder is excreted in the feces.
More than 99% of the ketorolac in plasma is protein bound over a wide concentration range.
INDICATIONS
Orally administered Toradol (ketorolac tromethamine) is indicated for the short-term management of mild to moderately
severe pain, including post-surgical pain (such as general, orthopedic and dental surgery), acute musculoskeletal
traum a pain and post-partum uterine cramping pain.
Intramuscular injection of Toradol is indicated for the short-term management of moderate to severe pain, including pain
following major abdominal, orthopedic and gynecological operative procedures.
CONTRAINDICATIONS
Toradol (ketorolac tromethamine) should not be used where there is a known or suspected hypersensitivity to the drug,
Because of the possibility of cross-sensitivity, ketorolac tromethamine should not be used in patients in whom acetylsalicylic a cid (ASA) or other non-steroidal anti-inflammatory agents induce acute asthmatic attacks, urticaria, rhinitis or other
allergic manifestations. Fatal anaphylactoid reactions may occur in such individuals.
Toradol (ketorolac tromethamine) also should not be used in patients with peptic ulcer or active inflammatory disease
of the gastrointestinal system.
WARNINGS
Long-term administration of ketorolac tromethamine oral formulation has shown that this drug shares the risks that other
non-steroidal anti-inflammatory drugs pose to patients when taken chronically. Peptic ulceration, perforation and gas
trointestinal bleeding, sometimes severe and occasionally fatal have been reported during therapy with non-steroidal
anti-inflammatory drugs and may occur with ketorolac tromethamine, both in the presence or absence of previous symp
toms. Elderly and debilitated individuals are most susceptible to these complications, the incidence of which increases
with dose and duration of treatment. Close medical supervision is recom mended in patients prone to gastrointestinal
tract irritation, particularly those with a history of peptic ulcer, diverticulosis or other inflammatory disease of the gastrointestinal
tract. In these cases the physician must weigh the benefits of treatment against the possible hazards.
Patients taking any non-steroidal anti-inflammatory drug including ketorolac tromethamine should be instructed to con
tact a physician immediately if they experience symptoms or signs suggestive of peptic ulceration or gastrointestinal bleeding.
These reactions can occur at any time during the treatment. If peptic ulceration is suspected or confirmed, or if gastrointestinal
bleeding occurs, ketorolac tromethamine should be discontinued and appropriate treatment instituted and the patient
closely monitored.
Ketorolac tromethamine is not recommended for routine use with other non-steroidal anti-inflammatory drugs because
o f the potential for additive side effects.
Use in pregnancy, lactation and labour: The administration of ketorolac tromethamine is not recommended during preg
nancy or lactation.
Ketorolac tromethamine is not recommended for use as an obstetrical preoperative medication or for obstetrical anal
gesia because of the known effects of non-steroidal anti-inflammatory drugs on uterine contraction and fetal circulation.
Use in children: Safety and efficacy in children have not been established. Therefore, Toradol is not recommended for
use in children under age 16.
Use in the elderly: Because ketorolac is cleared somewhat more slowly by the elderly (See PHARMACOKINETICS) who
are also more sensitive to the renal effects of non-steroidal anti-inflammatory drugs, extra caution and the lowest effec
tive dose should be used.
PRECAUTIONS
Renal effects: As with other drugs that inhibit prostaglandin biosynthesis, elevations of blood urea nitrogen (BUN) and cre
atinine have been reported in clinical trials with ketorolac tromethamine. Since ketorolac tromethamine and its metabolites
are excreted primarily by the kidney, patients with significant impairment of renal function (serum creatinine values greater
than 5 m g /d l) should not receive ketorolac tromethamine unless the expected benefits outweigh the risks. In patients
with moderately impaired renal function serum creatinine values ranging from 1,9 to 5.0 m g/d l, the rate of ketorolac
clearance was reduced to approximately half of normal. The total daily dose of ketorolac tromethamine should be reduced
by half in such patients. The disposition of ketorolac in dialysis patients has not been studied.
Patients who are volume depleted because of blood loss or severe dehydration may be dependent on renal prostaglandin
production to maintain renal perfusion and therefore glomerular filtration rate. In such situations the use of drugs which
inhibit prostaglandin synthesis might be expected to further decrease renal blood flow. Caution is advised if ketorolac
tromethamine is used in such circumstances. Close monitoring of urine output, serum urea and serum creatinine is rec
om m ended until the patient is normovolemic.
Hepatic effects: Meaningful elevations (greater than 3 times normal) of serum transaminases (glutamate pyruvate (SGPT
or ALT) and glutamic oxalacetic (SGOT or AST)) occurred in controlled clinical trials in less than 1% of patients. If clinical
signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e g., eosinophilia, rash, etc.),
ketorolac tromethamine should be discontinued, Patients with impaired hepatic function from cirrhosis do not have any
clinically important changes in ketorolac tromethamine clearance. Studies in patients with active hepatitis or cholesta
sis have not been performed.
Fluid and electrolyte balance: Fluid retention and edema have been observed in patients treated with Toradol. Therefore,
as with many other non-steroidal anti-inflammatory drugs, the possibility of precipitating congestive heart failure in
elderly patients or those with compromised cardiac function should be borne in mind. Toradol should be used with cau
tion in patients with cardiac decompensation, hypertension or other conditions predisposing to fluid retention.
Hematologic effects: Ketorolac tromethamine inhibits platelet function and may prolong bleeding time. It does not affect
platelet count, prothrombin time (PT) or partial thromboplastin time (PTT). Patients who have coagulation disorders or
are receiving drug therapy that interferes with hemostasis should be carefully observed when ketorolac tromethamine
is administered, Unlike the prolonged effects from aspirin, the inhibition of platelet function by ketorolac tromethamine
is normalized within 24 to 48 hours after the drug is discontinued.
Blood dyscrasias associated with the use of non-steroidal anti-inflam m atory drugs are rare, but could occur with
severe consequences.
Infection: In common with other anti-inflammatory drugs, ketorolac tromethamine may mask the usual signs of infection.
Drug Interactions: Toradol (ketorolac tromethamine) is highly bound to human plasma protein (mean 99.2%) and bind
ing is independent of concentration.

Prothrombin time should be carefully monitored in all patients receiving oral anticoagulant therapy concomitantly with
ketorolac tromethamine,
Ketorolac tromethamine does not alter digoxin protein binding,
In vitro studies indicated that a t therapeutic concentrations of salicylates (300 mcg/mL), the binding of ketorolac
tromethamine was reduced from approximately 99.2% to 97.5%. Therapeutic concentrations of digoxin, warfarin,
acetaminophen, phenytoin, tolbutamide and piroxicam did not alter ketorolac tromethamine protein binding. Since ketoro
lac tromethamine is a highly potent drug and present in low concentrations in plasma, it would not be expected to displace
other protein-bound drugs significantly.
There is no evidence in animal or human studies that ketorolac tromethamine induces or inhibits the hepatic enzymes
capable of metabolizing itself or other drugs. Hence, it would not be expected to alter the pharmacokinetics of other
drugs due to enzyme induction or inhibition mechanisms.
Ketorolac tromethamine mildly reduces the diuretic response to furosemide in normovolemic subjects. Inhibition of renal lithium
clearance leading to an increase in plasma lithium concentration and potential lithium toxicity has been reported with some
non-steroidal anti-inflammatory drugs. The effect of ketorolac tromethamine on lithium plasma levels has not been studied.
Concomitant administration of methotrexate and some non-steroidal anti-inflammatory drugs have been reported to
reduce the clearance of methotrexate, enhancing the toxicity of methotrexate. The effect of ketorolac tromethamine
on methotrexate clearance has not been studied.
There is limited experience on concurrent administration with morphine. Available information shows no evidence of adverse
interactions. The extent of a possible narcotic-sparing effect of ketorolac tromethamine is currently under investigation.
ADVERSE EFFECTS
Toradol tablets: The incidence of adverse reactions in approximately 600 patients and subjects receiving short-term oral
therapy (less than 2 weeks) with Toradol (ketorolac tromethamine) are listed below. The most common adverse effects include:
Gastrointestinal: dyspepsia (2%), gastrointestinal pain (2%), nausea (2%). Central nervous system: headache (2%), dizzi
ness (2%).
The following adverse events are rare but have been reported (less than 1%): Gastrointestinal: flatulence, gastritis.
Respiratory: dyspnea. Dermatologic: urticaria, rash, pruritus. Metabolism/nutritional: edema. Body as a whole: asthenia.
Hemic and lymphatic: purpura. Musculoskeletal: myalgia.
Toradol IM: The adverse reactions listed below were reported to be probably related to Toradol IM in clinical trials in which
patients received up to 20 doses of 30 mg of intramuscularly administered Toradol over a period of up to five days.
Incidence between 3 and 9%: Gastrointestinal: nausea, dyspepsia, gastrointestinal pain. Central nervous system: drowsiness.
Incidence between 1 and 3%: Gastrointestinal: diarrhea. Central nervous system: dizziness, headache, sweating. Body as
a whole: edema. Injection site pain was reported by 2% of patients in multi-dose studies (vs. 5% for morphine control group).
Incidence 1% or less: Gastrointestinal: constipation, flatulence, gastrointestinal fullness, liver function abnormalities,
melena, peptic ulcer, rectal bleeding, stomatitis, vomiting. Body as a whole: asthenia, myalgia. Cardiovascular: vasodi
latation, pallor, Hemic and lymphatic: purpura. Nervous system: dry mouth, nervousness, paresthesia, abnormal thinking,
depression, euphoria, excessive thirst, inability to concentrate, insomnia, stimulation, vertigo. Respiratory: dyspnea,
asthma. Urogenital: increased urinary frequency, oliguria. Dermatologic: pruritus, urticaria. Special senses: abnormal taste,
abnormal vision.
OVERDOSAGE
The absence of experience with acute overdosage precludes characterization of sequelae and assessment of antido
tal efficacy at this time. In a gastroscopic study of healthy subjects, daily doses of 360 mg given over an 8-hour interval
for each of five consecutive days (3 times the highest recommended dose) caused abdominal pain and peptic ulcers
which recovered after discontinuation of dosing.
DOSAGE AND ADMINISTRATION
Adults: Dosage should be adjusted according to the severity of the pain and the response of the patient.
Oral: The usual oral dose of Toradol (ketorolac tromethamine) is 10 mg every 4 to 6 hours for pain as required. Doses exceed ing 40 mg per day are not recommended.
Toradol is recommended for short-term use only i.e. for a maximum of a few weeks.
Parenteral: The recommended usual initial dose is 30 mg. Subsequent dosing may be 10 mg to 30 mg every 4-6 hours as
needed to control pain. A lower initial dose may be suitable for patients under 50 kg in body weight, over age 65 years
and/or with less severe pain at baseline. In the initial post-operative period, more frequent dosing (e.g., every 2 hours)
may be employed, but the total daily dose should not exceed 120 mg. Dose above 120 mg could cause drug toxicity
(see Warnings & Precautions). If supplemental analgesia is required, a concomitant low dose of opiate can be used.
The administration of continuous multiple daily doses of Toradol IM should not exceed 5 days for Injection dosing. There
has been limited experience with dosing for more than 5 days since the vast majority of patients have transferred to oral
medication or no longer required analgesic therapy after this time.
Directions for use: Insert the plunger into the syringe barrel and thread it onto the screw. WITHOUT REMOVING THE NEEDLE GUARD,
apply quick, firm pressure to the plunger to break the inner seal (you will feel it let go). Pull back on the plunger slightly to relieve
pressure. Remove the needle guard by twisting as you pull. Use the unit as you would a normal syringe. Dispose of properly.
CONVERSION FROM PARENTERAL TO ORAL THERAPY
Toradol tablets may be used either as monotherapy or as follow-on therapy to parenteral ketorolac. In the latter case,
the total combined daily dose of ketorolac should not exceed 120 mg on the day the change of formulation is made,
this includes a maximum of 4 o f the 10 mg tablets.
Toradol (ketorolac tromethamine) is a Schedule F drug.
COMPOSITION
Toradol Tablets: Each Toradol tablet contains ketorolac tromethamine, the active ingredient, with microcrystalline cel
lulose, lactose and magnesium stearate. The coating suspension contains hydroxy-propyl-methylcellulose, titanium
dioxide and polyethylene glycol.
Toradol IM: Toradol IM is available for intramuscular administration as: 15 mg in 1 mL (1.5%), or 30 mg in 1 mL (3%) of ketoro
lac tromethamine in sterile solution. The 15 mg/mL solution contains 10% (w/v) alcohol, USP, and 6,68 mg sodium chloride
in sterile water. The 30 mg/mL solution contains 10% (w/v) alcohol, USP and 4.35 mg sodium chloride in sterile water. The
pH is adjusted with sodium hydroxide a hydrochloric acid. The sterile solutions are clear and slightly yellow in colour.
STABILITY AND STORAGE RECOMMENDATIONS
Toradol Tablets: Store at room temperature. The blister package tablets should be protected from light.
Toradol IM: Store a t room temperature with protection from light.
AVAILABILITY OF DOSAGE FORMS
Toradol (ketorolac tromethamine) is available as 10 mg white round film coated tablets with one side printed in red with
TORADOL inside a bold T and the other side with Syntex. Toradol (ketorolac tromethamine) 10 mg tablets are available
in bottles of 100 and 500 tablets.
Toradol IM is available in 1 mL syringes containing 15 or 30 mg/mL of ketorolac tromethamine.
Product Monograph available on request.
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T h e Mitroflow Pericardial Bioprosthesis.
Comparison of Early Clinical Performance
in Aortic and Mitral Positions
W.R.E. Jamieson, MD, FACS, FRCSC;* L.C. Pelletier, MD, FACS, FRCSC;t
A.N. Gerein, MD, FACS, FRCSC;* J. Pomar, MD$
Between 1983 and 1987 the Mitroflow pericardial prosthesis was implanted in 354
patients, ranging in age from 14 to 94 years (mean 60.1 years). The early mortality
was 5.7% and the late mortality 2.9% per patient-year. The total cumulative
follow-up was 853 years (mean 2.4 years). Patient survival at 4 years for aortic valve
replacement (AVR) was 81.5% and for mitral valve replacement (MVR) 74.8%.
The overall rate of valve-related complications was 4.8% per patient-year (41
complications): thromboembolism, 15; hemorrhage related to antithromboembolic
therapy, 1; prosthetic valve endocarditis, 15; nonstructural dysfunction, 3; and
structural valve deterioration, 7. At 4 years the freedom from thromboembolism was
91.5% ± 2.7% for AVR and 91.1% ± 4.0% for MVR, from prosthetic valve
endocarditis 93.5% ± 2.3% for AVR and 94.0% ± 2.9% for MVR, from structural
valve deterioration 97.3% ± 2.1% for AVR and 92.6% ± 3.2% for MVR, from
valve-related mortality 96.9% ± 1.4% for AVR and 97.5% ± 1.8% for MVR, and from
reoperation 93.5% ± 2.8% for AVR and 83.1% ± 5.1% for MVR. The freedom from
the composite of all valve-related complications at 4 years was 81.1% ± 4.2% for
AVR and 75.3% ± 2.8% for MVR.
The Mitroflow valve has provided satisfactory clinical performance at the 4-year
evaluation. Structural valve deterioration is greater in the mitral position than in
the aortic position. Long-term evaluation of the Mitroflow valve is necessary to
determine the impact of structural valve deterioration on its clinical performance.

Entre 1983 et 1987, une prothese pericardique Mitroflow a ete implantee chez 354
patients dont l’age variait de 14 a 94 ans (moyenne de 60,1 annees). La mortality
precoce fut de 5,7 % et la mortality tardive, de 2,9 % par annee-patient. Le suivi
cumulatif total fut de 853 ans (moyenne de 2,4 annees). Apres 4 ans, la survie etait
de 81,5 % pour les remplacements de valvules aortiques (RVA) et de 74,8 %, pour les
remplacements de valvules mitrales (RVM).
Le taux de complications reliees a la valvule fut de 4,8 % par annee-patient (41
complications): on note 15 thromboembolies, 1 hemorragie reliee a la medication
antithrombotique, 15 endocardites valvulaires prosthetiques, 3 dysfonctionnement
non structurels et 7 deteriorations de la structure valvulaire. A 4 ans, il y avait
absence de thromboembolie dans 91,5 % ± 2,7 % des RVA et 91,1 % ± 4,0 % des
RVM, d’endocardite valvulaire prosthetique dans 93,5 % ± 2,3 % des RVA et 94,0 %
± 2,9 % des RVM, de deterioration valvulaire prosthetique dans 97,3 % ± 2,1 % des
RVA et 92,6 % ± 3,2 % des RVM, de mortalite reliee a la valvule dans 96,9 % ±
1,4 % des RVA et 97,5 % ± 1,8 % des RVM et de reoperation dans 93,5 % ± 2,8 %
des RVA et 83,1 % ± 5,1 % des RVM. L’absence de l’ensemble des complications
reliees a la valvule apres 4 ans a ete vue dans 81,1 % ± 4,2 % des RVA et 75,3 % ±
2,8 % des RVM.
Apres 4 ans devaluation, la valvule Mitroflow a donne une performance dinique
satisfaisante. La deterioration structurelle est plus grande en position mitrale qu’en
position aortique. L’evaluation a long terme de la valvule Mitroflow est necessaire
pour determiner l’impact de la deterioration sructurelle valvulaire sur sa performan
ce dinique.

ericardial bioprostheses have
been used as valvular substi
tutes since the introduction o f the
standard Ionescu-Shiley pericardial
valve in 1975.1-4 However, concern
about the long-term durability of
some pericardial valves has reduced
their use in recent years.5-14 The
Ionescu-Shiley standard and lowprofile pericardial and Hancock
pericardial prostheses were with
drawn from the market in 1987.
The Mitroflow pericardial prosthesis
and the Carpentier-Edwards peri
cardial prosthesis remain on the
international market. The Carpen
tier-Edwards pericardial aortic
prosthesis will be marketed in the
United States.
The Mitroflow prosthesis is con 
structed from glutaraldehyde-fixed
bovine pericardium sutured onto a
Dacron cloth-covered flexible Delrin
stent. The stent is designed to pro
vide proper cusp shape at low pro
files. The sewing ring comprises
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tungsten-powder-loaded silicone
elastomer for radiographic opacity.
The pericardial tissue is harvested
from local abattoirs in the vicinity
of the manufacturer. The tissue
thickness is matched to the stent
diameter to ensure proper operation
of the cusps. The valves are sub
jected to 100% pulsatile flow test
ing at both high and low rates to
ensure proper closure at all physio
logic flow rates.

Early mortality was 5.7% (20 pa
tients) (Table III): 5.7% (11 pa
tients) for AVR and 6.7% (9 pa
tients) for MVR. There was no
mortality for tricuspid valve replace
ment or multiple valve replacement.
Late mortality was 2.9% per pa
tient-year (25 patients) (Table IV),
expressed as linearized occurrence
rate (AVR 3.2%, MVR 2.7% and
multiple valve replacement 2.5% per
patient-year). The overall cumula
tive patient survival for the three

Methods
Assessment of clinical perfor
mance included the evaluation of
standard valve-related complica
tions: thromboembolism, hemorrh
age associated with antithromboembolic therapy, prosthetic valve endo
carditis, nonstructural dysfunction
and structural valve deterioration.
The definitions for these complica
tions are documented in the
“Guidelines for reporting morbidity
and mortality after cardiac valvular
operations.” 15 The composite indi
ces for valve-related mortality,
valve-related reoperations and valverelated complications (overall valverelated morbidity and mortality)
were used in the evaluation of the
complications.

Findings
Mitroflow prostheses were im
planted in 354 patients between
1983 and 1987 at three centres:
164 in Montreal, 99 in Vancouver
and 91 in Barcelona (Table I). The
mean age of the patients was 60.1
years (range from 14 to 94 years).
There were 194 aortic valve re
placements (AVRs), 134 mitral
valve replacements (MVRs), 1 tri
cuspid valve replacement and 25
multiple valve replacements. The
total cumulative follow-up was 853
years (Table II) (mean 2.4 years).
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centres is depicted in Fig. 1. The
survival rate for AVR was 86.7% ±
2.6% at 3 years and 81.5% ± 3.8%
at 4 and 5 years, and for MVR
87.2% ± 3.3% at 3 years and 74.8%
± 7.2% at 4 years.
The linearized occurrence rate
for valve-related complications was
4.8% per patient-year (41 events).
Valve-related complications are list
ed in Tables V and VI. There were
15 thromboembolic events, 1 he
morrhage related to antithrombo-

T a b le 1. Patient Population
T y p e o f v a lv e
r e p la c e m e n t

N o . o f p a tie n ts
Vancouver

A ortic
M itral
Tricuspid
M u ltip le

54
39
1
5

Total

99

M o n tre a l

B a r c e lo n a

T o ta l

80
10

19

1

194
134
1
25

164

91

354

60
85
—

—

T a b le It. C um ulative Follow -up
T y p e o f v a lv e
r e p la c e m e n t

A o rtic
M itral
Tricuspid
M u ltiple
Total

N o . o f p a t ie n t- y e a r s
M o n tre a l

B a r c e lo n a

T o ta l

86.1
71.0
3.1
11.6

174.7
211.0

21 0 .5
16.4

65.5

3.1

47 1.3
298.4
3.1
80.2

171.8

45 1.2

23 0.0

853.0

V ancouver

—

—

T a b le I II . Early M o rta lity
T y p e of v a lv e
re p la c e m e n t

A ortic
M itral
Tricuspid
M ultiple
Total

N o . o f e a r ly d e a th s
V ancouver

M o n tre a l

B a r c e lo n a

T o ta l

5
1

1
7

5
1

11
9

—

—

—

—

—

—

—

—

6

8

6

20

B a r c e lo n a

T o ta l

7
1

15
8

T a b le IV . Late M o rta lity
T y p e of v a lv e
r e p la c e m e n t

Aortic
M itral
Tricuspid
M ultiple
Total

N o . o f la t e d e a th s
V ancouver

M o n tre a l

5
6

3
1
—

—
4

—

—

2
13

—

—

2

8

25

MITROFLOW PERICARDIAL BIOPROSTHESIS

embolic therapy, 15 instances of
prosthetic valve endocarditis and 7
instances of structural valve deteri
oration. In addition, there were
three cases of nonstructural dys
function, all periprosthetic leaks.
Seventeen patients required
valve-related reoperation (Tables VII
and VIII) and 2 of them required an
additional reoperation — for mitral
insufficiency (1 for a suture over a
stent post and 1 for redundant
pericardial tissue, a manufacturing
defect) — for an overall total of 19
reoperations. Eight aortic valve re
replacements and nine mitral valve
re-replacements were required. Of
the 17 reoperations, 9 were for
prosthetic valve endocarditis, 1 for
nonstructural dysfunction and 7 for
structural valve deterioration.
Of the 43 deaths, early and late,
only 7 were valve-related (Tables IX
and X). The valve-related complica
tions and composites of complica
tions are shown in Figs. 2 to 7. The
small number of MVRs (25) was not
analysed in the same manner.
The freedom from thromboembo
lism at 3 to 4 years for AVR was
91.5% ± 2.7% and for MVR 91.1%
± 4.0% (Fig. 2).
Freedom from prosthetic valve
endocarditis for AVR was 95.1% ±
1.7% at 3 years and 93.5% ± 2.3%
at 4 years and for MVR 94.0% ±
2.9% at 3 and 4 years (Fig. 3).

T a b le V. V a lv e -R e la te d C o m p lic a tio n s (E v e n ts )
T y p e of v a lv e re p la c e m e n t*

V a lv e -re la te d
c o m p lic a tio n s

AVR

T h ro m b o e m b o lis m
H e m o rra g e re late d to
a n tith ro m b o e m b o lic
th e ra p y
P ro s th e tic va lve e n d o c a rd itis
N o n s tru c tu ra l d y s fu n c tio n
S tru c tu ra l v a lv e d e te rio ra tio n
R e o p e ra tio n

MVR

10

1
10
1
2
8

T o ta l

5

15

5
2
5
11

1
15
3
7
19

—
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FIG. 1. Survival in 354 patients with
Mitroflow pericardial prosthesis, 1983
to 1987. AVR = aortic valve replace
ment, MVR = mitral valve replace
ment.
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Freedom from structural valve
deterioration for AVR was 99.3% ±
0.7% at 3 years and 97.3% ± 2.1%
at 4 years and for MVR 92.6% ±
1.4% at 3 and 4 years (Fig. 4).
Freedom from valve-related reop
eration was 95.8% ± 1.6% at 3
years and 93.5% ± 2.8% at 4 years
for AVR and 83.1% ± 5.1% at both
3 and 4 years for MVR (Fig. 5).
Freedom from valve-related mor
tality was 96.9% ± 1.4% for AVR
and 97.5% ± 1.8% for MVR at 3
and 4 years (Fig. 6). Freedom from
all valve-related complications for
AVR was 85.6% ± 3.0% at 3 years
and 81.1% ± 4.2% at 4 years and
for MVR 75.3% ± 5.8% at 3 and 4
years (Fig. 7).

Discussion
Glutaraldehyde-preserved bovine
pericardium has been used to for
mulate valvular bioprostheses since
1971.5-13 The standard Ionescu-

Shiley pericardial valve was intro
duced in 1975 and the low-profile
valve in 1981. Most of the informa
tion on clinical performance relates
to the standard prosthesis. The
Hancock pericardial, the Mitroflow
pericardial and the Carpentier-Edwards pericardial prostheses were
introduced before 1982. The Ionescu-Shiley and Hancock prostheses
were withdrawn from the market in
1987 because of greatly altered
durability.
The primary advantage of peri
cardial prostheses over porcine bio
prostheses has been superior he
modynamics.16’17 The hemodynamic
performance of pericardial prosthe
ses makes them alternatives to
small aortic prostheses in patients
with small aortic annuli.
The factors contributing to fail
ure of the Ionescu-Shiley valve
prostheses have been documented
extensively.7’12'18-21 The primary
mode of failure is leaflet tear, with
or without dystrophic calcification,

at the site of the commissural align
ment suture. There is high mechan
ical stress near the stent concen
trated around the holding suture.
Abrasion of leaflet tissue also oc
curs when the leaflet comes in
contact with the cloth covering on
the edge of the stent. The lack of
endothelial tissue ingrowth often
contributes to the abrasions. Walley
and Keon12 reported on the Iones
cu-Shiley standard explanted aortic

lism.

T a b le IX . C au se s o f V a lve -R e la te d D eath
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a n tlth ro m b o e m b o lic
th e ra p y
P ro s th e tic va lve e n d o c a rd itis
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1
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2
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FIG. 3. Freedom from prosthetic valve
endocarditis.
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FIG. 4. Freedom from structural valve

MITROFLOW PERICARDIAL BIOPROSTHESIS

and mitral prostheses. They found
28 perforations and 56 cuspal tears
in 28 prostheses.
The Ionescu-Shiley low-profile
prosthesis was designed to lessen
the potential for leaflet cusp stress
at the suture site by the use of a
flexible stent and modified commis
sural sutures, but Walley and asso
ciates1314 identified failures with
stress at the suture site. Schoen
and colleagues20 identified designrelated cuspal tears and commissur
al perforations with some degree of

FIG. 5. Freedom from reoperation.

FIG. 6. Freedom from valve-related
mortality.

FIG. 7. Overall freedom from valverelated complications.

calcific tissue degeneration. Several
other investigators have found cus
pal thickening with collagen separa
tion and infiltration of an amor
phous protein-like matrix, often
with calcification.2021 Gabbay and
associates22 identified mechanical
factors contributing to failure. In
addition, certain design features
contribute to excessive tissue fa
tigue on cusp closure.
There have been several reports
on the performance of the Mitroflow pericardial prosthesis.23-28 Revuelta and associates25 reported
that freedom from structural valve
deterioration was 95% at 5.5 years,
and Loisance and colleagues27 re
ported a freedom of 95.2% at 5
years. Our experience is similar. We
found degeneration of mitral pros
theses more common than that of
aortic prostheses. There were two
aortic and five mitral failures, repre
senting freedom from structural
valve deterioration at the 4-year
interval of 97.3% for AVR and
92.6% for MVR. Revuelta and asso
ciates25 also noted a preponderance
of mitral prosthetic failures. Hassoulas and Rose28 identified mitral
failures in Chacma baboons and
found that the characteristics of the
Mitroflow prosthesis were no better
than those of the Ionescu-Shiley
prostheses. Nakano and col
leagues24 noted a predominance of
mitral failures in a biologic valve
population consisting of nearly 50%
Ionescu-Shiley prostheses.
Design appears to be very impor
tant, perhaps most important, in
the durability of pericardial prosthe
ses. Goldman and colleagues6 re
ported a much higher failure rate
with the Hancock pericardial pros
thesis than with the Ionescu-Shiley
prostheses. Recently, Pelletier and
associates29 reported superior re
sults with the Carpentier-Edwards
pericardial aortic prosthesis. The
design concepts used in the fabrica
tion of pericardial prostheses are

likely to be proven the most impor
tant factor in extending durability.
The incidence of structural valve
deterioration with both porcine and
pericardial bioprostheses at the
4-year interval provides some indi
cation of the durability of the vari
ous prostheses.1-430'31 Gabbay and
associates2 reported that the free
dom from structural valve deteriora
tion with the Ionescu-Shiley stan
dard pericardial prosthesis in the
mitral position was 80% at 4 years.
On the other hand, Gallo and col
leagues3 found that the freedom
from structural valve deterioration
with the use of this prosthesis in
the aortic position at 4 years was
93.5%. The durability of the Mitro
flow prosthesis appears to be supe
rior to that of Ionescu-Shiley pros
theses. Brais and colleagues,4 in
their experience with this prosthe
sis, reported results similar to ours.
The influence of age on the inci
dence of structural valve deteriora
tion can be a factor with the Mitro
flow prosthesis; the mean age in the
series of Gabbay and associates2
was 52 years whereas in our series
it was 60 years. The potential of
superior performance of the Mitro
flow prosthesis over the IonescuShiley prostheses, especially in the
aortic position, will be assessed by
further long-term follow-up. The
freedom from structural valve dete
rioration with porcine bioprostheses
is approximately 97% to 98% for
both aortic and mitral prostheses at
4 years;31 hence their potentially
superior performance, especially in
the mitral position, to pericardial
prostheses.
The Mitroflow pericardial pros
thesis has afforded patients a very
satisfactory quality of life with a
low rate of valve-related complica
tions. The incidence of primary tis
sue failure or structural valve dete
rioration is low, especially in the
aortic position. However, its related
structural valve deterioration in the
CJS, VOL. 35, NO. 2, APRIL 1992
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mitral position may be slightly less
than that for porcine bioprostheses.
Its clinical performance with regard
to other valve-related complications
is no different from that of porcine
bioprostheses.30'31
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Cardiac Preservation by Continuous
Perfusion of the University of Wisconsin
Solution
S.J. Jackson, MD; L.Q. Pu, MD; A. Guerraty, MD, FRCSC, FACS; J.F. Symes, MD, FRCSC, FACS
Recent studies have shown that the University of Wisconsin (UW) solution may be
superior to standard solutions in preserving the isolated heart before
transplantation. The authors compared the UW solution with a modified KrebsHenseleit solution in a continuous hypothermic coronary perfusion model. Hearts
from mongrel dogs were rapidly excised after hyperkalemic arrest with standard
cardioplegia and were mounted in a perfusion apparatus for 24 hours. Twelve hearts
were perfused with the Belzer UW solution (group 1), and 15 hearts were perfused
with a modified Krebs-Henseleit solution (group 2). The hearts were transplanted
in a cross-circulation model, and parameters of function (developed pressure [dP]
and rate of pressure development [±dP/df]) were measured. Mean (± SEM)
developed pressure was 80 ± 7 mm Hg in group 1 and 56 ± 9 mm Hg in group 2
(p < 0.05). The + dP /df was 1433 ± 1 2 6 mm H g /s in group 1 and 843 ± 1 5 4
mm H g/s in group 2 (p < 0.005), and the - d P /d tw a s 958 ± 110 mm H g/s in
group 1 and 676 ± 106 mm H g/s in group 2 (p < 0.05).
The UW-preserved hearts also required fewer defibrillations (0.75 ± 0.13) to
establish a stable rhythm than the control hearts (5.87 ± 2.07, p < 0.02). There
were no significant differences in weight gain, coronary resistance or creatine
phosphokinase levels between the two groups. The authors conclude that the UW
solution provides better preservation of function than a modified Krebs-Henseleit
solution for continuous coronary perfusion.

Des etudes recentes ont indique que le solute de l’Universite du Wisconsin (UW) est
peut etre superieur aux solutes standards pour preserver le coeur isolee avant
transplantation. Les auteurs ont compare le solute UW a un solute de KrebsHenseleit modifie dans un modele de perfusion coronarienne hypothermique
continue. Les coeurs de chiens batards ont ete rapidement excises apres arret
hyperkaliemique a l’aide d’une solution de cardioplegie classique, et montes sur un
appareil de perfusion pour 24 heures. Douze coeurs ont ete perfuses avec la
solution de Belzer UW (groupe 1) et 15 coeurs avec une solution de KrebsHenseleit modifiee (groupe 2). Les coeurs ont ensuite ete transplants dans un
modele a circulation croisee, et les parametres fonctionnels mesures (pression
developpee [dP] et vitesse de croissance de la pression intraventriculaire [±dP/df]).
La pression moyenne developpee (± ecart type) a ete de 80 ± 7 mm Hg dans le
groupe 1 et de 56 ± 9 mm Hg dans le groupe 2 (p < 0,05). La +dp/df a ete de
1433 ± 1 2 6 mm H g/s dans le groupe 1, par rapport au 843 ± 1 5 4 mm H g/s
du groupe 2 (p < 0,005), alors que la - d P / d f etait de 958 ± 1 1 0 mm H g/s dans
le groupe 1 contre les 676 ± 1 0 6 mm H g /s du groupe 2 (p < 0,05).
Les coeurs conserves dans la solution UW ont aussi necessite moins de
defibrillation (0,75 ± 0,13) pour retablir un rythme stable que les coeurs temoins
(5,87 ± 2,07, p < 0,02). On n'a constate aucune difference significative entre les
deux groupes en ce qui a trait au gain ponderal, a la resistance coronarienne ou aux
taux de creatine phosphokinase. Les auteurs concluent que la solution UW offre une
meilleure preservation de la fonction cardiaque qu’une solution de Krebs-Henseleit
modifiee, pour la perfusion coronarienne continue.

ne of the major factors limiting
the availability of donor organs
for heart transplantation remains
the need to limit ischemia time to
less than 6 hours. With improved
technical results and immunosup
pressive regimens, which include
cyclosporine, much research is now
centred on improving donor organ
preservation. Present preservation
techniques, which involve cardioplegic arrest and immersion in iced
saline, have not changed substan
tially since long-distance transporta
tion of donor hearts first became a
reality.1 Prolonged preservation
would allow a larger donor pool and
more detailed tissue typing and
could transform the recipient opera
tion into a more elective procedure
as is now the case with renal trans
plantation. Several methods of pres
ervation have been developed that,
in animal models, increase the pres
ervation time to over 24 hours.2-4
A variety of preservation solu-
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tions have been developed in an
attempt to prolong graft preserva
tion. One solution, developed at the
University of Wisconsin (UW), has
shown good results when used for
preservation of liver, kidney and
pancreas transplants.5-7 This solu
tion was designed to protect the
organs from the effects of ischemia,
such as oxygen-free-radical produc
tion, cell swelling and the depletion
of intracellular high-energy phos
phates.8 A few reports have indicat
ed the superiority of the UW solu
tion over standard solutions when
used to preserve the heart,3'9-10
whereas other reports show no dif
ference.11-13 In this study, we com
pare the UW solution with a modi
fied Krebs-Henseleit solution in a
canine model using continuous hy
pothermic coronary perfusion.

Materials and Methods
Twenty-seven mongrel dogs,
weighing 15 to 30 kg, were anes
thetized with sodium pentobarbital
(30 m g/kg) and given positivepressure ventilation. Through a left
thoracotomy, the brachiocephalic
trunk and left subclavian artery
were ligated and divided after hepa
rin was given intravenously. The
heart was excised rapidly after hyperkalemic cardioplegic arrest (Ta
ble 1). The heart was then weighed
and mounted in our perfusion de
vice that supplies continuous coro
nary perfusion through the aortic
root.14 The perfusate consisted of
Table 1. Composition of Cardioplegia
Solution Used to Arrest Donor Heart
Content

Units

Na+, mmol
K+, mmol
Cl- , mmol
Ca++, mmol
HC03- , mmol
Dextrose, g/L
Lactate, mmol
Lidocaine, mg/L

140
20
116
2.2
21
14
25
200
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for 1 hour, a balloon was inserted
into the left ventricle through the
apex. The balloon was inflated with
saline in 5-mL increments while
developed pressure (dP) and rate of
pressure development (±dP/dfj
were measured and recorded with a
pressure transducer and a Beckman
multichannel recorder (Beckman In
struments, Schiller Park, 111.). A
biopsy of the apical myocardium
was then done and the specimen
analysed under light microscopy.
All dogs received humane care in
accordance with guidelines provided
by the Canadian Council of Animal
Care.

the Belzer UW organ-preservation
solution in 12 dogs (group 1) or a
modified Krebs-Henseleit solution
in 15 dogs (group 2) (Table II). The
perfusate was circulated through
the system by a Sams roller pump,
and the flow was adjusted to keep
perfusion pressures at 18 to 20
cm H20. The solution was kept at a
temperature of 5° to 10°C and
oxygenated with a membrane oxy
genator. The partial pressure of
oxygen Po2 was kept above 500
mm Hg and the pH between 7.30
and 7.50 by altering the carbon
dioxide flow rates. The heart was
perfused for 24 hours, and perfu
sate flow and pressure were mea
sured at 6-hour intervals. After 24
hours, the heart was weighed, and
then, in an iced saline bath, a mitral
valvectomy and atria! septectomy
were performed. The posterior atrial
walls were then sutured to form a
common atrium. The heart was
heterotopically transplanted to the
neck of a recipient dog by anas
tomosing the carotid artery of the
recipient to the donor aorta (for
arterial inflow), and the jugular vein
to the pulmonary artery (for out
flow). The heart was electrically
defibrillated (if necessary). After sta
ble cardiac rhythm was established

Results
The pressures developed and the
rates of pressure development
(±dP/df) (Fig. 1) are expressed as
means ± SEM. The hearts perfused
with the UW solution (group 1)
showed better recovery. The dP
after reperfusion in group 1 was 80
± 7 mm Hg and in group 2 was 56
± 9 mm Hg (p < 0.05). The
+dP/df of left ventricular pressure
was 1433 ± 126 mm H g/s for
group 1 and 843 ± 154 mm H g/s
for group 2 (p < 0.005). The

Table II. Composition of 1 Litre of the Two Perfusate Solutions
Content
Na+, mmol
K+, mmol
Cl- , mmol
Ca++, mmol
MgS04, mmol
HC03- , mmol
P04, mmol
Glucose, g
Albumin, g
THAM,g
Pentastarch, g
Lactobionate, g
Raffinose pentahydrate, g
Adenosine, g
Allopurinol, g
Glutathione (reduced), g
Insulin (regular), units
Dexamethasone, mg
Penicillin G, units

Group 1
University of Wisconsin Solution
30
125
-

5
-

25
-

50
35.83
17.83
1.34
0.136
0.922
40
16
200 000

Group 2
Krebs-Henseleit Solution
143
5.9
123
0.167
0.6
25
1.2
2
25
0.25
-

-

CARDIAC PRESERVATION BY CONTINUOUS PERFUSION

—dP/dt was 958 ± 1 1 0 mm H g/s
for group 1 and 676 ± 106
mm H g/s for group 2 (p < 0.05).
All hearts gained weight over the
24 hours, and both groups demon
strated similar increases (Table III).
Coronary vascular resistance in
creased in both groups, but there
was no significant difference be
tween them. Creatinine phosphokinase (CPK) was measured in the
perfusate at 1, 12 and 24 hours,
but there was no significant differ
ence in the amount of CPK liberat
ed. The UW-preserved hearts re
quired fewer defibrillations and
often resumed a spontaneous, sta
ble rhythm without the need of
electrical defibrillation. Group 1 re
quired 0.75 ± 0.13 defibrillations,
whereas group 2 required 5.87 ±
2.07 defibrillations (p < 0.02). Both
groups of hearts showed mild to
moderate interstitial edema when
examined under light microscopy.

because the ion gradient across the
membrane is lower. This would pre
serve energy stores. The addition of
allopurinol and glutathione to the
solution should minimize damage
from oxygen-free radicals. The addi
tion of adenosine provides a sub
strate for ATP production after re
perfusion. Cell swelling should be
minimized by the addition of a
high-molecular-weight anion, pentastarch, which is similar to hydroxyethyl starch and will not permeat
the cell membrane.
The UW solution is effective in
preserving the kidney, liver and
pancreas and has been used clinical
ly with good results.5-7 Attempts
have been made to preserve the
heart by either cold storage or
perfusion with UW solution.3-9-13

We have previously preserved the
canine heart by continuous perfu
sion with a modified Krebs-Henseleit solution and have demonstrat
ed the benefits of both adenosine
and oxygen.14-16 Here we demon
strated the superiority of the UW
solution as a perfusate.
The group 1 hearts (UW per
fused) showed better recovery than
did the group 2 hearts, as demon
strated by significantly better devel
oped pressures (dP) and rates of
ventricular contraction (+dP/dt).
The rate of ventricular relaxation
( —dP/dt) was also significantly
better in the UW-perfused hearts.
This implies that the heart was
more supple, possibly due to less
ischemic contracture or less reper
fusion injury. The group 1 hearts

Discussion
The UW solution was developed
at the University of Wisconsin to
minimize hypothermia-induced cell
swelling, to prevent intracellular ac
idosis, to prevent the expansion of
the interstitial space and injury
from oxygen-free radicals (especial
ly during reperfusion) and to pro
vide substrates for regenerating
high-energy phosphate compounds
during reperfusion.8 A major differ
ence between the UW solution and
other solutions is its high potassi
um and low sodium content, which
means that the cells are bathed in
an intracellular-like solution. Dur
ing hypothermic organ preserva
tion, much of the energy expendi
ture is used to maintain cellular
membrane potential using Na-K
ATPase (Na+ pump). When the cells
are bathed in an intracellular-like
solution, there should be less need
for the Na+ pump to consume ATP

FIG. 1. Comparison of developed left ventricular pressure, + d P /d t and —d P /d t in
hearts perfused with Krebs-Henseleit solution (shaded bars) or University of
Wisconsin solution (white bars).

Table III. C o m p a riso n o f M y o c a rd ia l C re a tin e P h o s p h o k in a s e (C P K) W e ig h t G ain B e fo re and A fte r
P e rfu s io n a n d C hange in C o ro n a ry R e s is ta n c e B etw e e n th e T w o G ro u p s

Groups
1 (U n iv e rs ity o f
W is c o n s in )
2 (K re b s -H e n s e le it)

Release of
CPK/g, U/L

Weight gain, %

Change in resistance/kg,
cm H20 min/mL

1.6 7 ± 0 . 2 1
1.75 ± 0 . 2 8
^ = 0.41

3 9 ± 16
41 ± 14
p = 0 .3 3

+ 1.1 ± 3 .2
+ 0 .5 ± 3 .4
p = 0 .0 9
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also required fewer defibrillations to
maintain a stable rhythm than the
group 2 hearts. In fact, 9 of the 12
UW-perfused hearts regained a
spontaneous rhythm without any
defibrillation, and the remainder re
quired only one defibrillation. This
may imply greater electrical stability
in the UW-perfused hearts.
A potential problem with a con
tinuous perfusion model is intersti
tial edema. Both groups of hearts
gained weight after 24 hours of
perfusion because of extracellular
water, which could be seen histo
logically. This extracellular swelling
likely causes some compression of
the coronary microcirculation and
may explain the increase in coro
nary resistance in both groups.
There was no significant difference
in weight gain or in coronary resist
ance between the two groups, so
the weight gain is likely due to the
model of continuous perfusion rath
er than to the type of perfusate.
Continuous perfusion can cause in
creased cell swelling compared with
simple cold storage,17 but its advan
tages include continuous washout
of metabolic wastes and continuous
supply of nutrients. We have de
signed a prototype of a portable
perfusion apparatus that fits into a
large picnic cooler. Further refine
ment is needed before clinical
studies are initiated.
In conclusion, the UW solution
provides better preservation of func
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tion when used as a continuous
coronary perfusate than does a
modified Krebs-Henseleit solution.
There are many differences in the
composition of the two perfusates,
and it remains unclear which com
ponents contribute to the superiori
ty. The continuous perfusion model
may have advantages over simple
storage, but it has drawbacks that
limit its clinical use. Further refine
ment is needed. The UW solution is
being examined as a perfusate for
cardiac preservation, and further
study should be encouraged to im
prove on an already promising solu
tion.
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T h e Intestinoprostatic Capsule
Anastomosis: Functional and Anatomic
Results in a Canine Model
Dan Theodorescu, MD;* Allen G. Binnington, DVM;t John G. Connolly, MD, FRCS, FACS, FRCSC*
Because of its potential application to intestinal bladder reconstructions, the authors
studied the functional and anatomic results of a modification of the Carney
procedure. In this modification the enteric bladder replacement is sutured to the
periphery of the prostatic capsule after the inner two-thirds of the prostate gland
have been removed.
In eight dogs postoperative functional studies revealed that all were continent
and potent. Autopsy examination of the area of the intestinoprostatic anastomosis
revealed that the prostatic fossa was lined by a transitional epithelial layer
originating from the urethral stump and not by intestinal mucosa as might be
expected. The results indicated that this modification is simpler technically than the
original procedure, that it shortens the operating time and that it gives excellent
functional results. If used in the context of bladder cancer, however, the procedure
should be undertaken only in the presence of negative biopsies and brushings of the
urethra before surgery, because the transitional epithelium lining the prostatic fossa
represents a new area at risk for later malignant transformation. Moreover, because
of the potential importance of the area of prostatic fossa resurfaced postoperatively
by urothelium, even patients with normal preoperative urethral biopsies and
brushings who undergo such a procedure require careful follow-up with endoscopic
examination, urethral biopsy and brushings and cytologic examination of the urine.

A cause de son potentiel d’application a la recontruction intestino-vesicale, les
auteurs ont etudie les resultats fonctionnels et anatomiques d’une modification de
l’intervention de Camey. Dans cette modification, le remplacement de la vessie
enterique est suture a la peripherie de la capsule prostatique apres resection des
deux-tiers internes de la glande prostatique.
Des etudes fonctionnelles postoperatoires chez huit chiens ont montre qu’ils
etaient tous continents et avaient conserve leur puissance sexuelle. A l’autopsie,
l’examen de la region de Tanastomose intestinoprostatique a revele que la fosse
prostatique etait tapissee par une couche epitheliale transitionnelle provenant du
moignon uretral, et non pas de la muqueuse intestinale comme on aurait pu s’y
attendre. Les resultats indiquent que cette modification est techniquement plus
simple que Toperation originale, qu’elle racourcit le temps d’intervention et qu’elle
offre des resultats fontionnels excellents. Dans le contexte du cancer de la vessie,
cette intervention ne devrait toutefois etre entreprise qu’en presence de biopsies et
de brossages negatifs de Turetre, car l’epithelium transitionnel tapissant la fosse
prostatique represente une nouvelle region a risque de tranformation maligne
subsequente. En outre, a cause de l’importance potentielle de la region de fosse
prostatique retapisssee apres Toperation par l’urothelium, meme les patients ayant
des biopsies et brossages preoperatoires normaux necessiteront une surveillance
soigneuse avec examens endoscopiques, biopsies et brossages uretraux et examens
cytologiques des urines.

he Camey procedure has been
accepted as a method of recon
stituting the urinary tract following
cystectomy in men with bladder
cancer. This technique, first de
scribed by Couvelaire1 and Pyrah,2
was popularized by Camey and Leduc.3 Such procedures avoided the
use of external collecting devices,
utilizing instead the external
sphincter as a continence mecha
nism. However, there are several
undesirable technical features of the
original Camey procedure — it is
technically difficult to perform and
most of the patients were initially
impotent,4 although, with nerve
sparing techniques, this need not be
so.5'6 Also, nocturnal incontinence
has been a continuing problem.7
Although enterocystoplasty using
the prostatic capsule has been de
scribed by others,8 good experimen
tal data are lacking on the gross
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and microscopic changes that result
from this procedure, such as the
effects of surgery on potency and
continence and the nature of the
regenerated epithelium in the pros
tatic fossa. This modification of the
intestinourethral anastomosis has
two major advantages — it simpli
fies the operative technique and
assures sexual potency postoperatively. A critical, but unknown,
issue was the nature of the regener
ating epithelium in the prostatic
fossa. A new surface of urothelium
in the prostatic fossa would pose
risks that would be greater than
those associated with an epithelium
of enteric origin, especially if a
patient had positive cytologic re
sults from urethral brushings.
Hence, the nature of the new muco
sal lining of the prostatic fossa was
of interest to us. To elucidate this
issue we performed a cystectomy
with intestinoprostatic fossa recon
struction of the urinary tract in
eight dogs and carried out a de
tailed autopsy anatomic study of
the intestinoprostatic area.

The distal end of the jejunal seg
ment was closed, and the proximal
end was anastomosed to the pros
tatic capsule with interrupted 2-0
chromic catgut sutures (Fig. 2).
The prostatic capsule was tailored
so that there was no size discrepan
cy between it and the jejunal lumen.
A Penrose drain left over the anas
tomotic site was brought out
through a separate stab incision,
and a transurethral Foley catheter
was left across the prostatointestinal anastomosis.
Postoperatively pain was con
trolled with oxymorphone hydro
chloride given intramuscularly. In
travenous lines were maintained for
hydration in all dogs until they
were drinking well and a 3-day
course of antibiotics had been com
pleted. Transurethral catheters
were irrigated at regular intervals to
prevent clot retention.

Two dogs suffered severe bilateral
ureteric obstruction during the first
postoperative week requiring repeat
laparotomy. In one ureteric stents
were inserted; the second required
bilateral ureteric reimplantations.
Subsequent recovery was uncompli
cated for both. All dogs were fol
lowed up for a minimum of 2
months.
Sexual Potency and Urinary
Continence

Potency was determined by the
response of the dogs to a teaser
bitch preoperatively as well as 1 and
2 months postoperatively. One-half
of the dogs tested during the first
month were found to be impotent,
but by the second month full poten
cy was achieved in all animals.
Urinary continence was compro
mised at 1 month, but by the end of
the second month the animals had
good control of urinary function.

Results
Pathological Findings
Postoperative Period

There were no operative deaths.

Two months postoperatively, the
urinary tract was removed en bloc.

FIG. 1. Prostatic capsule remnant after
subtotal prostatectomy performed with
electrocautery.

FIG. 2. Intestinoprostatic anastomosis.
Prostatic capsule was tailored so that
there was no size discrepancy between
it and jejunal lumen.

Materials and Methods
Eight mature male beagles were
fed a standard diet before surgery.
Anesthesia was induced with intra
venous sodium thiopental and main
tained with halothane. A midline
incision was made to enter the
abdominal cavity. A suitable seg
ment of jejunum, approximately 30
cm long, was selected and isolated,
and the continuity of the bowel was
restored in a standard fashion. The
lower halves of the ureters were
mobilized and divided at the level of
the bladder. A cystectomy and a
subtotal intracapsular prostatecto
my were done, leaving a 2- to 3-mm
outer core of tissue attached to the
prostatic capsule (Fig. 1). The
ureterojejunal anastomoses were
done in an antirefluxing fashion.8
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ic sections the full depth of the
mucosal lining of the prostatic
fossa was lifted off the prostatic
tissue, which confirmed the gross
observations and delineated the tis
sue level at which the separation
had occurred. Intestinal mucosa
was present down to a few mil
limetres beyond the intestinopro
static anastomosis. The remaining
distal mucosal lining of the prostat
ic fossa was composed of normal
transitional epithelium (Fig. 4) in
continuity with the proximal ure
thra. There was no clear microscop
ic evidence of a basement mem
brane below the basal layer of the
regenerated transitional epithelial
mucosa.

gland, the urothelium regeneration
must have originated from the ure
thra.9-11 A second point of interest
was the loose, almost sleeve-like
attachment of the urothelium to the
underlying prostatic tissue and the
almost complete absence of an or
ganized and functional basement
membrane in any of the sections
analysed. This is an important find
ing, which may be due to the
“ectopic” location of the transition
al epithelium overlying the glandu
lar prostatic tissue.
The 100% preservation of poten
cy in the group is clearly due to our
resection margins being well away
from the neurovascular bundles re
sponsible for erections. Anastomo
ses at this level clearly simplified
and shortened the operative proce
dure. One of the criticisms of the
Carney procedure has always been
that all patients experience noctur
nal incontinence. The modification
described above has the advantage
of a large prostatic cavity (capsule)
lying distal to the anastomotic site.
Since our results suggest that the
continence rate is intrinsically high
after the modified procedure this
may be due to the presence of the
prostatic capsule remnant. Thus, it

Gross examination of the longitudi
nally opened intestinoprostatic
block revealed complete re-epithelialization of the prostatic fossa. The
mucosa was continuous from bowel
to urethra, and grossly (Fig. 3) it
appeared to be intestinal in origin.
It was, however, very friable and
easily lifted off the prostatic fossa
after manipulation. The intestinoprostatourethral complex was stepsectioned at 2-mm intervals perpen
dicular to the urethral axis, includ
ing tissues 1 cm above and below
the prostatic capsule. Sections were
examined under light microscopy
after routine hematoxylin-eosin
staining.
Examination of the exterior sur
face of the intestinoprostatic junc
tion showed bowel serosa continu
ous with the prostatic capsule. The
step sections revealed a rim of pros
tatic tissue left on the capsule. The
thickness of this rim varied from 2
to 4 mm. Microscopic examination
of this tissue showed that it was
normal with no evidence of transi
tional cell metaplasia. In addition,
with respect to the anastomosis
itself, there was a distinct transition
between muscular bowel wall and
prostatic tissue. In most microscop

There are several aspects to this
experimental study that merit dis
cussion. First was the observation
that the prostatic fossa was lined by
mucosa that was continuous with
and grossly resembled the enteric
epithelium, though histologically it
was urothelial in origin. Since there
were no islands of urothelium re
maining in the sections of prostate

FIG. 3. Gross appearance of intestino
prostatic fossa 2 months postoperatively. Prostatic fossa was completely
covered by what appeared to be intesti
nal epithelium.

FIG. 4. Lining of prostatic fossa showing transitional epithelium (hematoxylineosin, original magnification X 196).

Discussion
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may not be necessary to use detubularized bowel segments to elimi
nate nocturnal incontinence when
this intestinoprostatic anastomosis
is used. However, further experi
mentation and clinical studies will
be required to clarify this point.
In summary, the concept of intes
tinoprostatic anastomosis seems an
attractive one for several reasons —
its potential application with any
intestinal bladder reconstruction
makes its advantages widely appli
cable. The only serious drawback is
the suggestion that the new epithe
lium that resurfaces the prostatic
fossa is of transitional cell origin.
Thus, such procedures would clear
ly not be safe in patients with
malignant or even abnormal ureth
ral cytologic findings. The most
important result from this study is
the observation that even in pa

tients with normal preoperative
urethral study findings, there is a
clear need for regular postoperative
follow-up of the prostatic surface
mucosal lining.
We are grateful to Ms. Frances Hogue
and Ms. Sharon Mitchinson for their
secretarial assistance.
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Item 162
Intraoperative ultrasound examination may identify common bile duct stones, small pancreatic endocrine tumors,
and parathyroid adenomas. It is also useful in determining resectability of pancreatic lesions, and in providing
more precise information about the resectability of hepatic tumors in 30% of patients. However, intraoperative
ultrasound examination cannot differentiate malignant from benign nodal disease, and is not useful for staging
of carcinoma of the testicle or Hodgkin’s disease.
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Evaluation of the Operating Room
as a Surgical Teaching Venue
S.E. Scallon, BSc; D.J. Fairholm, MD, FRCSC; D.D. Cochrane, MD, FRCSC; D.C. Taylor, MD, FRCSC
Surgical educators are facing changes in residency training that have a direct impact
on the opportunity that surgeons and residents have for clinical teaching and
learning. The knowledge required of residents continues to escalate. Further, as
resident positions are reduced, the opportunity for inter-resident education is
decreased. Increased service-to-education ratios may result in resident discontent
unless surgeons take an active role in the resident’s educational experience. The
purpose of this study was to examine the educational activities that occur during the
operating-room experience.
Technical training in the procedure being done was the primary educational
activity, but there were long periods when no form of education was taking place.
The operating room provides the teacher and learner with uninterrupted time
together, and this time can and should be used for clinical teaching and learning.
Les professeurs de chirurgie ont a affronter des changements dans la formation des
residents qui ont un impact direct sur les occasions qui s’offrent aux chirurgiens et
residents d’enseigner et d’apprendre. Le savoir exige des residents continue
d’augmenter. De plus, avec la diminution des postes de residents, les occasions de
formation croisee entre residents s’estompent. Une augmentation du rapport
service / enseignement peut creer de 1’insatisfaction chez le resident, a moins que
les chirurgiens ne prennent un role actif dans l’experience pedagogique du resident.
Cette etude avait pour but d’etudier les activites pedagogiques qui ont cours durant
la formation en salle d’operation.
L’enseignement technique sur 1’intervention pratiquee etait la principale activite
pedagogique, mais il s’ecoulait de longues periodes pendant lesquelles aucune forme
d’enseignement n’etait donnee. La salle d’operation offre au professeur et a
l’etudiant une periode ensemble sans interruption. Cette periode peut et devrait
servir a l’enseignement et a l’apprentissage clinique.

urgical educators are facing
changes in residency training
that may force a revamping of the
postgraduate educational structure
and goals. Position cutbacks have
resulted in a loss of the traditional
residency training hierarchy and
have directly resulted in increased
demands for patient care being
made on resident staff. Moreover,
residents and licensing bodies are
demanding formalization and docu
mentation of the educational proc
ess. In addition to the increased
service-to-education ratio, more fac

S

tual knowledge is required of the
trainee. The increasing complexity
of some operative procedures re
quires a larger commitment of time
in the operating room and reduces
the time available for traditional
ward and bedside clinical teaching.
These factors amplify the educa
tion-service conflict that training
programs must address.
Clinical teaching is defined as the
teaching, discussion and decision
making that deals with the clinical
presentation and examination of a
patient, the differential diagnosis,
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the confirmatory investigations,
natural history, treatment options
and expectations as well as the
risks and complications of treat
ment. The end result of such an
exercise is a treatment plan for the
patient in question.
The teaching and learning of sur
gical skills1-4 and the evaluation of
the operative skills learned by sur
gical residents5-7 have been studied,
but, to date, no one has assessed
the operating room as a forum for
clinical teaching and learning. In
the light of a changing environment
for surgical training, we undertook
an assessment of opportunities for
furthering clinical teaching. Since
the operating room is now the only
place where some surgeons and
residents have uninterrupted time
together, this study was designed to
investigate, prospectively, the na
ture, frequency and perceived value
of educational interactions that oc
curred during the traditional ope
rating-room experience and to as
sess the potential of this time for
clinical teaching.

Methods
The educational activities in the
operating room were assessed from
the perspective of a trained in
dependent observer and from the
perspectives of surgeons and resi
dents. The operating-room team
was made aware of the study and
consented to the presence of an
observer during the procedure.
The frequency and nature of top
ics discussed and the teaching
methods used in the operating
room were documented by an in
dependent nonsurgeon observer
CJS, VOL. 35, NO. 2, A P R IL 1992
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(Table I). This person had been
trained to recognize subject matter
and teaching methods, their signifi
cance and the form discussions of
these topics and teaching methods
would take in the operating room.
The observer followed the patient
and staff through the pre-, intraand postoperative phases of the
procedure. The topics discussed and
the teaching methods used in each
case were recorded. No effort was
made to quantify the duration of

discussions. Results are reported as
frequency counts and averages.
After each procedure, the sur
geon and resident(s) involved in the
case completed a questionnaire to
evaluate their perceptions of the
operative experience and its educa
tional content (Table II). Their re
sponses were graded on an eightpoint scale (0 — nil to 7 — excel
lent). This format was also used to
obtain the surgeons’ and residents’
evaluations of their personal roles

Table 1. Frequency of Topics Discussed as Noted by the Independent Observer
Time period, no. of cases (%)
Topics discussed
Clinical details
This case
Similar cases
Other in house
Complications
This case
Other operations
Postop care
This case - surgical
- medical
Other cases
Operative plan
Surgical anatomy
Other medical
Nonmedical
Teaching methods
Visual
Verbal

Postop

Total

Preop

Intraop

14 (23)
2(3)
11 (18)

12 (20)
5(8)
13 (22)

0
0
0

26 (43)
7(12)
24 (40)

2(3)
0

18 (30)
2(3)

3 (5 )
0

23 (38)
2(3)

0
0
0
4(7)
0
2(3)
17 (28)

11 (18)
6(10)
1 ( 2)
9 (1 5 )
39 (65)
23 (38)
24 (40)

10(17)
0
0
0
0
0
0

21 (35)
6(10)
1 ( 2)
13 (22)
39 (65)
25 (42)
41 (68)

0
0

0
0

27 (45)
51 (85)

in the teaching and learning that
occurred during operation. These
raw data are reported as averages.
Differences in perceptions between
residents and surgeons were
analysed using Wilcoxon pairedsample tests with significant differ
ences being represented by a p
value of 0.05. Stratified contingen
cy-table analyses with p values of
0.05 were used to assess the effects
of resident experience (the assistant
number, year of residency, familiari
ty with the procedure), and resident
participation (opportunity to do the
procedure), on his or her perception
of the operating-room experience.
Individual surgeons or residents
were not evaluated.

Results
Sixty procedures were studied
during a 9-week observation period.
They included 32 pediatric general
surgical procedures, 11 neurosurgi
cal procedures and 17 adult general
surgical procedures and involved 13
surgeons and 15 residents.
A summary of the independent
observer’s observations is provided

27 (45)
51 (85)

Table II. Summary of Questionnaire Data
Mean values of responses
to questionnaire*

Topic discussed or reviewed
Discussion of case before operation
New skills taught
Routine skills used
Resident had opportunity to do procedure
Review of relevant anatomy
Review of operative steps
Discussion of operative expectations
Discussion of possible complications
Discussion of postop management
Case presentation by resident
Discussion of differential diagnosis
Discussion of management alternatives
General discussion of topic
Overall evaluation of educational experience

Overall

Surgeon

1st
asst

2nd
asst

3.8
4.0
4.5
4.1
4.4
4.5
4.6
4.4
4.5
3.8
3.4
3.6
4.0
4.7

3.8
4.6
5.3
4.1
4.8
5.0
4.8
4.3
4.5
3.4
3.3
3.5
3.8
4.9

3.7
4.5
4.3
4.7
4.0
4.3
4.5
4.6
4.4
4.3
3.6
3.8
4.3
4.7

3.9
3.2
3.4
3.0
4.1
4.1
4.5
4.5
4.5
3.6
3.1
3.7
3.8
4.3

Differences In perceptiont
between

^

Surgeon and Surgeon and
1st asst,
2nd asst,
p value
/rvalue

year of
training,);
p value

NS
NS
0.03
0.04
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS

•Responses were rated on a scale of 1 (nil) to 7 (excellent). Mean values are arithmetic averages of response ratings.
tW ilcoxon paired-sample test
JContingency-table analysis
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NS
0.03
0.007
0.005
0.02
0.02
NS
NS
NS
NS
NS
NS
NS
NS

j |

0.01
NS
NS
0.05
0.02
NS
NS
NS
NS
NS
NS
NS
NS
NS

TEACHING IN THE OPERATING ROOM

in Table I. Discussions occurred
during the pre- and intraoperative
phases of the procedure, but rarely
in the recovery room. Clinical de
tails of the case at hand and of
others “in house’’ were discussed
with equal frequency before and
during the procedure. In 10% of
cases, other similar cases were men
tioned. An operative plan was out
lined by the resident or staff sur
geon in 20% of cases. These discus
sions usually occurred intraoperatively, but on four occasions they
occurred preoperatively. Surgical
anatomy was discussed during the
procedure in 65% of cases.
The operative complications of
the procedure were discussed in
approximately 40% of the cases.
These discussions usually occurred
during the operation and related
specifically to the steps of the pro
cedure. Potential complications spe
cific to the individual patient but
not directly related to the operative
technique were discussed in 10% of
cases. The postoperative manage
ment of the patient was discussed in
33% of the cases. These interac
tions occurred almost equally in the
intraoperative and postoperative pe
riods. The postoperative care of
other cases in house was discussed
only once.
Other medical topics were dis
cussed during 25 procedures, and
in 41 cases nonmedical topics were
discussed. Twenty-four of these dis
cussions occurred intraoperatively
and 17 before the start of the
procedure.
Surgeons used two methods for
technical step-by-step instruction.
For repetitive tasks, the surgeon
performed the step initially and
then allowed the resident to do the
remaining iterations in half of the
cases (visual instruction). Verbal in
structions from the surgeon to the
resident were used to guide the
operation in 85% of cases.
The perceptual data derived from

questionnaires completed by the
surgeons and residents are summa
rized in Table II. In general, sur
geons and residents were in agree
ment for most areas evaluated, but
they did differ in their perceptions
of the types of skills used during
the procedure and who was per
ceived to do the procedure. Sur
geons scored the use of “routine
skills” higher than did the first
assistants. First assistants felt they
had a greater role in the procedure
than the surgeon thought they did.
Significant differences in the per
ceptions of surgeons and second
assistants were found in their rat
ings of the following areas: new
skills taught and learned, routine
skills used, resident opportunity to
do the procedure, review of anato
my and review of steps of the
procedure. For these topics, the
surgeons’ ratings were generally
higher than those of the second
assistant.
The resident’s experience as mea
sured by year of training, familiarity
with the operation and assistant
number affected their perception of
the operating-room learning experi
ence in three areas. As the year of
residency increased, discussion of
the case before the procedure was
less valued when it occurred. In
addition, there was less discussion
of relevant surgical anatomy. As
would be expected, there was a
greater opportunity for the resident
to do the procedure as experience
increased.
There was a significant (p =
0.05) relationship between the resi
dent’s perception of the overall
value of the learning experience and
the opportunity to do the proce
dure. Senior residents were more
likely to do the procedure and rated
their learning experience high. Al
though junior residents were not
commonly the designated surgeon,
their overall learning experiences
were also highly rated. Residents in

their middle years of training may
have had the opportunity to do
some portion of the procedure but
rated their overall learning experi
ence lower than either senior or
junior residents.
Surgeons and residents rated
clinical teaching at levels similar to
surgical skills teaching; in the opin
ion of the independent observer
clinical teaching beyond the specif
ics of the case contributed little to
the interactions that occurred in the
operating room.
Analysis of the patterns of teach
ing and learning revealed that sur
geons felt that they taught all assis
tants, although more emphasis was
placed on their interactions with the
first assistant. First assistants felt
that they never taught the surgeons
anything but that they occasionally
taught the second assistant. Second
assistants did not think that they
taught either the surgeon or the
first assistant.
Surgeons believed that they rare
ly learned anything from the first
assistant and that they never
learned from the second assistant.
First assistants usually felt they had
learned a lot from the surgeon but
nothing from the second assistants.
The second assistants felt they
could learn from both the surgeon
and the first assistant.

Discussion
Surgical training depends on
goal-directed and patient-centred in
teractions between surgeon and res
ident. Traditionally, this interplay
has occurred in the operating room,
at the bedside, in the clinic and the
conference room and has relied on
direct tutorage of trainees by their
peers and mentors. Unfortunately,
the time and personnel available for
this form of apprenticeship training
is decreasing as residency positions
are cut, as surgeons’ responsibilities
CJS, VOL. 35, NO. 2, APRIL 1992
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expand beyond patient care and
teaching and as technical training
becomes more complex. As a result,
it may be difficult to provide resi
dents in surgical training programs
with clinical teaching. Because the
time in the operating room remains
one of the few occasions that resi
dents and surgeons have together,
this study was designed to investi
gate the educational interactions
that occur in a traditional operating
room and to assess the participants’
perceptions of this activity and the
potential of this time for clinical
teaching.
Although no effort was made to
motivate the participants, the study
design required that a trained in
dependent observer was in the oper
ating room for the assessment and
that all surgeons and residents were
informed of the purpose of the
study. These features of design
could have resulted in an overesti
mate of the educational activities
occurring in the operating room, so
that the data may reflect the cur
rent best teaching practices in our
program. The time spent in educa
tion in the operating room was not
quantified because it was decided
that the value, methods and topics
of teaching would be the end points
of assessment.
The operating room was used to
teach surgical skills and to review
pertinent anatomy. The teaching of
clinical patient-related material in
the operating room occurred in less
than 50% of cases. These discus
sions covered patient history, physi
cal signs and diagnosis, and compli
cations and largely omitted discus
sion of operative planning, potential
medical complications unrelated to
the procedure and the surgeon’s
past experience with the condition.
Qualitative analysis of the time
spent in the operating room re
vealed that there were times during
the procedure, usually during clos
ing but also in the recovery room,
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when no useful surgeon-resident or
resident-resident interactions oc
curred.
In general, surgeons and resi
dents agreed on the interactions
that occurred in the operating
room. This was particularly true of
the surgeon and the first assistant.
Surgeons and second assistants
were in less agreement, suggesting
that surgeons were not as aware of
the second assistant, so the trainee
was more likely to be left out of
direct educational interactions.
This study revealed two impor
tant motivating factors active dur
ing resident education — the com
mon goal and resident responsibility
during the procedure. The largely
uniform perceptions of teaching
among the surgical team reflects
the close relationship between sur
geon (teacher) and resident (stu
dent), a relationship based on the
patient’s need and held in common
by surgeon and resident.
The powerful effect of patient
care (operative) responsibility on
perceived learning was also demon
strated in this study. For more
experienced residents, responsibility
translates into the performance of
the procedure. This interaction may
work to the disadvantage of the
“middle” residents who may not
have, or be afforded, a sense of
operative involvement. Junior mem
bers of the team are intrigued by
procedures and information that are
new to them and therefore rank
their learning experience highly.
This study suggests that the cur
rent operating-room experience
could be improved and used to
augment the clinical teaching avail
able to surgical residents. A greater
emphasis on operative plans and
relevant surgical anatomy, as well
as discussions of expectations and
nontechnical complications could
easily be incorporated within cur
rent time constraints. Broader dis
cussion of the patient’s condition

and its treatment could assist in
replacing the now-vanishing bedside
round. Without effort directed to
more junior residents, their learning
defaults to observation and indirect
assimilation. Specific planning to
engage the “middle” residents in
teaching activities and discussion
may be required. These changes in
approach would improve the teach
er’s (surgeon’s) awareness of the
student’s (resident’s) familiarity
with the case, making overestima
tion of resident skills and knowl
edge by the surgeon less likely.
The operating room affords a
unique opportunity for surgical ed
ucation and is underutilized. The
unique situation of the teacher and
learner sharing a common goal and
working together uninterrupted for
substantial periods offers an excel
lent opportunity to expand the tra
ditional role of the operating room
in surgical training. Specific plan
ning and effort to use the time
available to include “clinical teach
ing” would expand the operating
room into a laboratory of all surgi
cal education and assist in balanc
ing service-to-education ratios.
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P R E S C R IB IN G IN F O R M A T IO N
Action
In vitro studies indicate that the bacterial action ot Claforan (cefotaxime sodium) a semi-synthetic cephalosporin
antibiotic, results from inhibition of cell wall synthesis.
Indications and Clinical Uses
Treatm ent: Claforan (cefotaxime sodium) may be indicated for the treatment of infections caused by susceptible
strains of the designated micro organisms in the diseases listed below.
Lower respiratory tract infe c tio n s: pneumonia and lung abscess caused by Streptococcus pneumoniae
(formerly Diplococcus pneumoniae), other streptococci (excluding enterococci, e.g. S. taecalis), Staphylococcus
aureus (penicillinase and non-penicillinase producing), Escherichia coli, Hemophilus influenzae, (including
ampicillin resistant strains) and unspecified Klebsiella species.
Urinary tra c t in fe c tio n s: caused by Escherichia coli, unspecified Klebsiella species (including K. pneumoniae),
Proteus mirabilis, indole positive Proteus, Serratia marcescens and Staphylococcus epidermidis. Also, uncomplicated
gonorrhea caused by N. gonorrhoeae including penicillin resistant strains.
Bacteremia / S epticem ia: caused by Escherichia coli, unspecified Klebsiella strains and Serratia marcescens
Skin in fe c tio n s : caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), S. epidermidis,
Group A streptococci, Escherichia coli, Proteus mirabilis and indole positive Proteus.
Intra-abdom inal infections: caused by Escherichia coli, and unspecified Klebsiella species.
G ynecological infections: including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by
E coli, Group A streptococci and Staphylococcus epidermidis; anaerobic bacteria including unspecified Peptococcus
and Peptostreptococcus strains and some strains of Bacteroides fragilis. In several cases, although clinical cures
were achieved, bacteriological follow-up was not available.
Central nervous system in fe c tio n s: meningitis and ventriculitis caused by Haemophilus influenzae, Neisseria
meningitidis, Streptococcus pneumoniae, Klebsiella pneumoniae and Escherichia coli. Claforan is not active
against Listeria monocytogenes.
Clinical experience with Claforan in anaerobic infections is limited. Claforan has been used with some success in
wound and intra-abdominal infections against some strains of unidentified Bacteroides and anaerobic cocci
Claforan has been shown to be active against some strains of Pseudomonas
In the treatment of infections encountered in immunosuppressed and granulocytopenic patients, results of therapy
with Claforan have not been impressive.
Claforan should not be considered in the treatment of enterococcal infections, i.e. Streptococcus faecalis
Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify the causative
organisms and to determine their susceptibilities to Claforan. Therapy may be instituted before results of susceptibility
studies are known; antibiotic treatment should be re evaluated once these results become available.
P rophylactic U s e : The administration of Claforan perioperatively (preoperatively, intraoperatively and postoperatively)
may reduce the incidence of certain infections in patients undergoing elective surgical procedures (eg. abdominal
or vaginal hysterectomy, gastrointestinal and genitourinary tract surgery) that may be classified as contaminated or
potentially contaminated.
In patients undergoing caesarian section who are considered to be at increased risk of infection, intraoperative
(after clamping the umbilical cord) and postoperative use of Claforan may also reduce the incidence of certain
postoperative infections.
Effective use for elective surgery depends on the time of administration (see Dosage and Administration).
For patients undergoing gastrointestinal surgery, preoperative bowel preparation by mechanical cleansing as well as
with a non absorbable antibiotic (e.g. neomycin) is recommended.
If there are signs of infection, specimens for culture should be obtained for identification of the causative organism
so that appropriate therapy may be instituted.
Contraindications
Claforan is contraindicated in patients who have shown hypersensitivity to cefotaxime sodium, the cephalosporin
or the penicillin groups of antibiotics.
Warnings
Before therapy with Claforan is instituted, it must be carefully determined whether the patient has had previous
hypersensitivity reactions to cefotaxime, cephalosporins, penicillins or other drugs. Claforan should be given with
caution to patients with Type 1 hypersensitivity reactions to penicillin. Antibiotics, including Claforan should be
administered with caution to any patient who has demonstrated some form of allergy, particularly to drugs. If an
allergic reaction to Claforan occurs, the drug should be discontinued and the patient treated with the usual agents
(e.g. epinephrine, antihistamine, pressor-amines or corticosteroids).
Pseudom em branous colitis has been reported w ith the use of cephalosporins (and other broad spectrum
a ntib iotics); therefore, it is im portant to consider its diagnosis in patients w ho develop diarrhea during
the adm inistration of Claforan. This colitis can range from m ild to life-threatening in severity.
Treatment with broad spectrum antibiotics, such as Claforan, alters the normal flora of the colon and may permit
overgrowth of Clostridium difficile or other Clostridia. It has been established that a toxin produced by Clostridium
difficile is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to discontinuation of Claforan and replacement with a suitable specific antibiotic.
Moderate to severe cases should be managed with fluid, electrolyte and protein supplementation as indicated
When the colitis is not relieved by discontinuance of Claforan administration or when it is severe, an antibiotic
specifically effective in antibiotic-associated pseudomembranous colitis (e.g. vancomycin) or other suitable therapy
may be indicated. Other possible causes of colitis should also be considered (see Adverse Reactions).
Precautions
Claforan (cefotaxime sodium) should be prescribed with caution in individuals with a history of lower gastro
intestinal disease, particularly colitis.
The safety of Claforan in pregnancy has not been established. Consequently, use of the drug in pregnant women
requires that the likely benefit from the drug be weighed against the possible risk to the mother and fetus.
Use of Claforan in women of child bearing potential requires that the anticipated benefits be weighed against the
possible risks.
Cefotaxime is excreted in human milk in low concentrations. Caution should be exercised when the drug is
administered to nursing mothers.
Prolonged use of Claforan may result in the overgrowth of nonsusceptible organisms. Constant evaluation of the
patient’s condition is essential. If super-infection occurs, therapy should be discontinued and appropriate measures
taken.
Although Claforan rarely produces alterations in kidney function, evaluation of renal status is recommended,
especially in severely ill patients receiving high doses.
Patients with markedly impaired renal function should be placed on the special dosage schedule recommended
under Dosage and Administration, because normal dosage in these individuals is likely to produce excessive and
prolonged serum antibiotic concentrations.
Positive direct Coombs' test is known to develop in individuals during treatment with the cephalosporin group of
antibiotics, including cefotaxime sodium.
In laboratory tests a false positive reaction to glucose may occur with reducing substances but not with the use
of specific glucose oxidase methods.
As with other beta-lactam antibiotics, granulocytopenia and, more rarely, agranulocytosis may develop during
treatment with Claforan, particularly if given over long periods. For courses of treatment lasting longer than 10
days, blood counts should therefore be monitored.
Adverse Reactions
The most frequent adverse reactions with their frequency of occurrence are:
H ypersensitivity (1.8%): Rash, pruritus, fever. Local (5%): Injection site inflammation with intravenous
administration. Pain, induration and tenderness after intramuscular injection. Gastrointestinal (1.7%): Colitis,
diarrhea, nausea and vomiting. Symptoms of pseudomembranous colitis can appear during or after Claforan
treatment. Hematologic System ( < 1%): Neutropenia, transient leukopenia, eosinophilia, thrombocytopenia and
agranulocytosis have been reported. Some individuals have developed positive direct Coombs’ test during

treatment with Claforan and other cephalosporin antibiotics. Rare cases of hemolytic anemia have been reported.
G enitourinary System ( < 1%): Moniliasis, vaginitis. Liver ( < 1%): Transient elevations in SGOT, SGPT, serum
LDH and serum alkaline phosphatase levels have been reported. Kidney ( < 1%): Increased serum creatinine and
BUN have occasionally been observed. Central Nervous System (0.2%): Headache.
Symptoms and Treatment of Overdosage
Since no case of overdosage has been reported to date with Claforan, no specific information on symptoms or
treatment is available. Treatment of overdosage should be symptomatic.
Dosage and Administration
Claforan (cefotaxime sodium) may be administered intramuscularly or intravenously after reconstitution (see Table
with recommended mode of reconstitution according to route of administration).
Dosage
A dults: The dosage of Claforan should be determined by susceptibility of the causative organisms, severity of the
infection and condition of the patient.
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Guidelines for Dosage of Claforan (cefotaxime sodium)

Type of Infection

Daily Dose
(g)

*

Frequency and Route

Uncomplicated Gonorrhea

1

Uncomplicated infections

2

1 g every 12 hours IM or IV

3-6

1-2 g every 8 hours IM or IV

Moderately severe to severe infections
Very severe infections (e.g. septicemia, CNS)
Life-threatening infections

6-8
up to 12

1 g IM (single dose)

2g every 6-8 hours IV
2g every 4 hours IV

To prevent postoperative infection in contaminated or potentially contaminated surgery, recommended doses are
as follows:
(a) 1 g IM or IV administered 1/2 to 11/2 hours prior to the initial surgical incision to ensure that adequate
antibiotic levels are present in the serum and tissues at the start of surgery
(b) 1 g IM or IV administered 1-1/2 to 2 hours following the first dose; for lengthy operative procedures, additional
intraoperative doses may be administered, if necessary, at appropriate intervals (1-1/2 to 2 hours) during surgery
(c) 1 g IM or IV administered within 2 hours following completion of surgery
The total cumulative prophylactic dose should not exceed 6 g in a 12 hour period
Caesarian Section Patients
The first dose of 1 g is administered IV as soon as the umbilical cord is clamped. The second and third doses
should be given as 1 g IM or IV at 6 and 12 hours after the first dose.
Neonates, Infants, and Children
The following dosage schedule is recommended:
Neonates;
0-1 week of age
50 mg / kg IV q 12 h
1-4 weeks of age
50 mg / kg IV q 8 h
Infants and children (1 month to 12 years): For body weights less than 50 kg, the recommended daily dose is
50 to 100 mg / kg IM or IV of body weight divided into 4 to 6 equal doses, or up to 180 mg / kg / day for severe
infections (including central nervous system infections).
For body weights 50 kg or more, the usual adult dosage should be used.
The maximum daily dosage should not exceed 12 grams.
Administration of Claforan should be continued for a minimum of 48 to 72 hours after the patient defervesces or
after evidence of bacterial eradication has been obtained; a minimum of 10 days of treatment is recommended for
infections caused by Group A beta-hemolytic streptococci in order to guard against the risk of rheumatic fever or
glomerulonephritis; frequent bacteriologic and clinical appraisal is necessary during therapy of chronic urinary
tract infections and may be required for several months after therapy has been completed; persistent infections may
require prolonged treatment. Doses less than those recommended should not be employed.
Dosage for Patients with Impaired Renal Function
In patients with estimated creatinine clearance of less than 20 m L/m in / 1.73m2 the dose of Claforan should be
halved (see Precautions).
If serum creatinine values alone are available, the following formula (based on sex, weight, and age of the patient)
may be used to convert these values into creatinine clearance.
Males:

Weight (kg) x (140 - age)

Females:

0.85 x above value

72 x serum creatinine
Administration
Intra m uscular: Claforan should be injected well within the body of a relatively large muscle such as the upper
outer quadrant of the buttock (i.e. gluteus maximus); aspiration is necessary to avoid inadvertent injection into a
blood vessel.
Intravenous; The intravenous route is preferable for patients with bacteremia, bacterial septicemia, or other severe
or life-threatening infections, or for patients who may be poor risks because of lowered resistance resulting from
such debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure, or malignancy, particularly if
shock is present or impending.
For bolus administration a solution containing 1 or 2 g of Claforan can be injected over a period of 3 to 5 minutes.
Using an infusion system, it may also be given over a longer period of time through the tubing system by which
the patient may be receiving other intravenous solutions. Butterfly* or scalp vein type needles are preferred for this
type of infusion. However, during infusion of the solution containing Claforan, it is advisable to discontinue
temporarily the administration of other solutions at the same site.
Stability
Claforan reconstituted in the original vial as described under RECONSTITUTION maintains satisfactory potency for
24 hours at room temperature (25°C) and for 48 hours under refrigeration (0-5°C).
ADD-Vantage* Vial
When administering Claforan using the ADD-Vantage* Drug Delivery system, Claforan powder is added directly to a
single-dose flexible plastic ADD-Vantage* diluent container. Claforan 1 g or 2 g may be reconstituted in 50 mL or
100 mL of 5% Dextrose Injection USP or 0.9% Sodium Chloride Injection USP.
Availability
Claforan (cefotaxime sodium) is supplied as a sterile, white to pale yellow powder, in vials containing 500 mg,
1.0 and 2.0 g of cefotaxime sodium and in ADD-Vantage* vials containing 1.0 and 2.0 g of cefotaxime sodium
(expressed as acid on a dry basis).
S tora ge: Claforan in the dry state should be stored at room temperature protected from light and heat.
Product monograph available on request.
•Reg’d TM of Abbott Laboratories.
Reference
1 Bivins B.A., et a l: Antibiotics for Penetrating Abdominal Trauma: A Prospective Comparative Trial of Single
Agent Cephalosporin Therapy Versus Combination Therapy. Diagn Microbiol Infect Dis. 1989; 12:113-118.
©Trademark of Roussel UCLAF, Paris
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Bleeding Gastric and Duodenal Ulcers:
Endoscopic Therapy Versus Surgery
A. Ralph-Edwards, MD; H.S. Himal, MD, FACS, FRCSC
From a retrospective review of 156 patients with actively bleeding peptic ulcers, 61
patients had gastric ulcers and 95 patients had duodenal ulcers. Patients presented
with hematemesis or melena or a combination of the two. Forty patients with gastric
ulcers and 53 patients with duodenal ulcers were in shock. Twenty-five patients with
gastric ulcers underwent surgery. Bleeding was controlled in all patients, but in the
postoperative period five patients died of myocardial infarction, pulmonary embolism
or septic multisystem organ failure. Of 36 patients who underwent endoscopic
epinephrine sclerosis of the bleeding gastric ulcer, hemorrhage was controlled in
34. Two patients required reoperation for bleeding after surgery; both survived.
Fifty patients with duodenal ulcers had surgery. Bleeding was controlled in all
patients, but in the postoperative period 10 died of myocardial infarction and
multisystem organ failure. Of 45 patients who underwent endoscopic sclerosis,
bleeding was controlled in 40. Five patients required reoperation for bleeding after
surgery; all survived.
The authors conclude that endoscopic sclerosis should be the initial treatment for
actively bleeding gastric and duodenal ulcers. If bleeding continues or recurs then
surgery should be carried out.

L’etude retrospective de 156 patients souffrant d’ulceres gastroduodenaux hemorragiques a etabli que 61 patients avaient des ulceres gastriques et 95, des ulceres
duodenaux. Les patients presentaient de l’hematemese ou des melenas, ou une
combinaison des deux. Quarante patients souffrant d’ulceres gastriques et 53
d’ulceres duodenaux etaient en etat de choc. Vingt-cinq patients souffrant d’ulceres
gastriques furent operes. L’hemorragie fut jugulee dans tous les cas, mais cinq
patients moururent dans la periode postoperatoire, soit d’infarctus du myocarde,
d’embolie pulmonaire ou de sepsie avec defaillance plurifonctionnelle. Trente-six
patients subirent une sclerose endoscopique a l’epinephrine; l’hemorragie fut
maitrisee chez 34. Deux patients durent etre reoperes pour hemorragie apres la
chirurgie; les deux survecurent. Cinquante patients souffrant d’ulceres duodenaux
furent operes. L’hemorragie fut maitrisee dans tous les cas, mais 10 moururent
durant la periode postoperatoire d’infarctus du myocarde ou de defaillance plurifonc
tionnelle. L’hemorragie fut arretee chez 40 des 45 patients qui subirent une sclerose
endoscopique. Les cinq patients qui durent etre reoperes pour persistance de
l’hemorragie apres la chirurgie survecurent.
Les auteurs concluent que la sclerose endoscopique devrait etre le premier
recours pour les ulceres gastriques et duodenaux hemorragiques. Si les saignements
persistent ou recidivent, la chirurgie devra prendre le relais.

From the Department o f Surgery, Toronto Western Hospital and University o f Toronto,
Toronto, Ont.
Presented at the 95th annual meeting o f the Canadian Association o f Clinical Surgeons, Eastern
Division, Montreal, Que., A p ril 1991
Accepted fo r publication Sept. 18, 1991
Reprint requests to: H.S. Himal, Ste. 404A, Toronto Western Medical Building, 25 Leonard
Ave., Toronto, ON M 5T 2R2

lthough the incidence of peptic
ulcer disease in North America
is decreasing, emergency surgery
for complications such as perfora
tion or bleeding, especially in the
elderly, is on the rise.1 To decrease
the number of deaths from bleeding
gastric ulcer, early surgery has
been proposed.2 Another method
has been the establishment of a
special hospital unit to handle
bleeding peptic ulcers.3 Endoscopic
therapy, first successfully tried by
Youmans and colleagues,4 has been
used for bleeding gastric and duo
denal ulcers.56 To see whether en
doscopic therapy results in a lower
death rate than surgery, we retro
spectively reviewed a group of pa
tients with bleeding peptic ulcers.

A

Patients and Methods
We reviewed the course of 156
patients with peptic ulcers who had
signs of active bleeding; 61 had
gastric ulcers and 95 had duodenal
ulcers. Fluids and blood were used
to resuscitate all patients in shock
(blood pressure 90 mm Hg). Esophagogastroduodenoscopy was car
ried out within 12 hours of admis
sion to hospital, and the type of
active bleeding was noted as a
spurting vessel, blood clot or visible
vessel.
Before 1987 therapy was first
conservative. It consisted of the
administration of antacids and cimetidine and of blood transfusions. If
bleeding continued or recurred, sur
gery was performed. In 1987 endo
scopic therapy became available and
was carried out as soon as gastrosCJS, VOL. 35, NO. 2, APRIL 1992
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copy demonstrated a bleeding gas
tric or duodenal ulcer. This therapy
consisted of the endoscopic injec
tion of adrenaline 1:10 000, 1 to 6
mL, within and around the base of
the ulcer. Endoscopic therapy was
considered a success if the patient’s
clinical condition stabilized and
there were minimal requirements
for further blood transfusion. If
shock developed or significant
blood replacement (more than 5
units of blood) was required then
surgery was performed. Surgery
was usually performed within 24 to
36 hours of the patient’s admission
to hospital. Surgery for bleeding
gastric ulcers consisted of partial
gastrectomy and a Billroth II anas
tomosis or oversewing the ulcer,
vagotomy and pyloroplasty. Sur
gery for bleeding duodenal ulcers
consisted of vagotomy, pyloroplasty
and oversewing the bleeding ulcer.

tially and 36 had endoscopic thera
py. Of the 25 patients who under
went surgery 18 (72%) received 6 to
10 units of blood compared with
only 6 (17%) who received endo
scopic therapy. Twenty-five patients
required emergency surgery to con
trol recurrent or continuous bleed
ing. Bleeding was controlled in all
patients, but five died in the postop
erative period. One patient died of
massive pulmonary embolism, an
other of a myocardial infarction.
The other three patients who died
suffered intra-abdominal sepsis and
multisystem organ failure. Endo
scopic therapy controlled the bleed
ing in 34 of the 36 patients. Two
patients who failed endoscopic ther
apy had surgery and survived with
out complications.

Patients With Duodenal Ulcers
(Table II)

Of the 95 patients with duodenal
ulcers, 50 underwent surgery ini
tially and 40 had endoscopic thera
py. In all of the 50 patients who
underwent surgery the bleeding was
controlled, but 10 patients died in
the postoperative period. Two pa
tients died of myocardial infarction
and congestive heart failure. Eight
patients died of intra-abdominal
sepsis and multisystem organ fail
ure. Forty-five patients with actively
bleeding duodenal ulcers underwent
endoscopic therapy. Bleeding was
controlled in 40 patients. Five pa
tients had surgery for continuous
or recurrent bleeding, and all sur
vived without complications.

Table I. Clinical Features of Patients With Bleeding Gastric and Duodenal Ulcers Managed by
Endoscopic Therapy or Surgery
Gastric ulcers (n = 61)
Clinical features

The clinical features of the pa
tients in this study are illustrated in
Table I. In both ulcer groups, pa
tients who underwent surgery or
endoscopic therapy were similar
with respect to the incidence of
hematemesis, melena and hematemesis plus melena.
The frequency of shock was
higher in those with gastric ulcer
but similar in those with duodenal
ulcer who underwent surgery com
pared with endoscopic therapy. The
number of patients with major ill
nesses (cardiac disease, respiratory
insufficiency, renal failure) was si
milar in patients with gastric and
duodenal ulcers who underwent ei
ther surgery or endoscopic therapy.
Patients With Gastric Ulcer (Table
II)

Of the 61 patients with gastric
ulcers, 25 underwent surgery ini
178

(n = 25)

Endoscopic therapy
(n = 36)

Surgery
(n = 50)

Endoscopic therapy
(n = 45)

14
11
19-85

20
16
21-87

27
23
22-91

24
21
19-86

14
6
12

15
4
10

5
15
30

6
10
29

21

19

27

26

3
18
2
13

5
20
1
17

5
10

6
11

—

—

17

16

Surgery
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Male
Female
Age range, yr
Signs
Flematemesis
Melena
Hematemesis
plus melena
Shock
(blood pressure
< 90 mm Hg)
Possible contributing factors
Alcohol
NSAID*
Alcohol plus NSAID
History of major illness

Duodenal ulcers (n = 95)

‘ Nonsteroidal anti-inflammatory drugs

Table II. Outcome of Endoscopic Therapy or Surgery for Patients With Bleeding Gastric and
Duodenal Ulcers
Gastric ulcers (n = 61)
Outcome
Blood transfusion, units
1-5
6-10
> 10
Success in controlling
hemorrhage
Deaths

Duodenal ulcers (n = 95)

Surgery
(« = 25)

Endoscopic therapy
(n = 36)

Surgery
(n = 50)

Endoscopic therapy
(n = 45)

3
18
4

29
6
1

13
33
4

40
5
0

25
5

34
0

50
10

40
0
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Discussion
Our results have demonstrated
that bleeding gastric ulcers often
present with either hematemesis or
hematemesis and melena. Surgery
successfully controlled the bleeding
in all 25 patients, but 5 patients
died of complications. Endoscopic
sclerosis was successful in control
ling the bleeding in 34 of the 36
patients. The two patients who re
quired surgery both survived.
Patients with bleeding duodenal
ulcers usually presented with either
melena or melena and hematemesis.
Although surgery was successful in
controlling bleeding, 10 of the 50
patients with duodenal ulcers died
in the postoperative period. Endo
scopic sclerosis was successful in
controlling hemorrhage in 40 of the
45 patients. Five patients required
surgery, and all survived.
Elective peptic ulcer surgery has
declined dramatically in the last 30
years. This, however, has not been
translated into emergency surgery
for bleeding peptic ulcers. Gustavsson and associates1 showed that the
incidence of emergency operations
for bleeding peptic ulcers was simi
lar for the periods 1976 to 1985
and for 1956 to 1965. It was also
hoped that H2 receptor antagonists
would also play a role in reducing
the incidence of emergency as well
as elective surgery for peptic ulcer
disease. This held true for elective
but not for emergency surgery.
Christensen, Bousfield and Chris
tensen7 reported that no significant
change occurred in the rate of
surgery before or after September
1977 when cimetidine was intro
duced in Denmark. However,
McGuire and Horsley8 found a sig
nificant increase in emergency sur
gery for patients with bleeding
gastric and duodenal ulcers during
the era of H2 medication. These
were in high-risk patients who were
older and had major concurrent

illnesses. Inevitably death rates
were high in these patients.
Therapy for bleeding gastric and
duodenal ulcers has always been
controversial. More than half the
ulcers will stop bleeding and not
require surgery.9 In those patients
who are old, have concurrent medi
cal illnesses and continue to bleed
or have recurrent hemorrhage,
there is controversy about when to
operate and when to try other
forms of conservative therapy. Sev
eral authors have proposed early
surgery, especially for bleeding
gastric ulcers. Himal, Perrault and
Mzabi2 used an aggressive surgical
approach to bleeding gastric and
duodenal ulcers — early surgery for
patients with gastric ulcers and
high-risk patients with duodenal ul
cers. They were able to decrease the
death rates from 25% to 8% in
patients with gastric ulcers and
from 4% to 1% in patients with
duodenal ulcers. Another approach
has been the establishment of a
special hospital unit to manage
upper gastrointestinal bleeding.
Hunt and associates310 estab
lished such a unit at the Prince
Henry’s Hospital, Melbourne, Aus
tralia. All patients with upper gas
trointestinal hemorrhage were ad
mitted to the specialized unit. En
doscopy was carried out within 12
hours of admission. There was very
close cooperation between the gas
troenterologist, the surgeon and the
nursing staff involved in the care of
each patient. Early surgery was
carried out in patients who were in
shock, who were over 50 years of
age and who had continuing or
recurrent hemorrhage. This result
ed in a reduction in the operative
death rate from 12% to 5.8%. Thus,
the establishment of a specialized
unit and team to care for upper
gastrointestinal bleeding together
with early surgery for specific le
sions has been shown to reduce the
death rate.

In the 1970s it became possible
to treat bleeding lesions through
the endoscope. Early reports of en
doscopic control of bleeding gastric
and duodenal ulcers included those
of Papp,11 who presented four pa
tients bleeding from gastric and
duodenal ulcers. Electrocoagulation
successfully controlled the bleeding
lesions. Sugawa and colleagues12
also used electrocoagulation suc
cessfully to treat a group of pa
tients, one of whom had a bleeding
gastric ulcer. Volpicelli and col
leagues5 successfully treated two
gastric ulcers and one duodenal
ulcer with electrocoagulation.
Papp13 updated his experience by
reporting on the successful endo
scopic electrocoagulation of bleed
ing peptic ulcers in 44 patients.
Gaisford6 also reported excellent re
sults with endoscopic elec
trocoagulation of patients with
bleeding gastric and duodenal ul
cers. Twenty-nine bleeding gastric
and 13 bleeding duodenal ulcers
were successfully treated this way.
Electrocoagulation has given way
to three current methods of endo
scopic control of bleeding gastric
and duodenal ulcers — laser photo
coagulation, heater-probe coagula
tion and sclerosis.
Endoscopic laser therapy was
first successfully carried out clini
cally by Kiefhaber, Nath and Mo
ritz.14 Laser coagulation was suc
cessful in 75 patients with bleeding
gastric and duodenal ulcers. Fruhmorgen and associates15 successful
ly treated 10 bleeding peptic ulcers
with argon laser coagulation.
Several controlled trials were
then carried out to study the effica
cy of laser coagulation. Swain and
colleagues16 reported that bleeding
ulcers with a visible vessel were
successfully treated by argon laser.
Rutgeerts, Vantrappen and Broeckaert17 showed that the yttriumaluminum-garnet (YAG) laser suc
cessfully controlled actively bleed
ers',
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ing gastric and duodenal ulcers.
Macleod and colleagues18 reported
that YAG laser significantly de
creased the rebleeding rate and the
requirement for emergency surgery
in patients with bleeding peptic ul
cers. Swain19 also reported excellent
results with the YAG laser in the
treatment of actively bleeding gastr
ic and duodenal ulcers.
Another method of endoscopic
control of bleeding peptic ulcers is
heater-probe thermocoagulation. In
1977 Protell and associates20 re
ported on the development of a
heater probe used endoscopically to
stop upper gastrointestinal he
morrhage. Since then there have
been many reports on its use. Lin
and colleagues21 treated 35 patients
with bleeding peptic ulcers who
were in shock. Thirty-three (94%) of
the ulcers stopped bleeding after
use of the heater probe. These same
authors updated their study22 and
reported that in 147 (96%) of 153
cases massive peptic ulcer hemorrh
age was controlled with the heater
probe. Fullarton and associates23
reported on a controlled trial in
which the heater probe was suc
cessful in stopping hemorrhage
from actively bleeding peptic ulcers.
The third method is endoscopic
sclerosis. Panes and colleagues,24 in
a controlled trial, reported that en
doscopic sclerosis with adrenalinepolidocanol led to significant reduc
tion in the requirements for emer
gency surgery and for transfusion
in bleeding peptic ulcers.
In another study, Panes and col
leagues25 reported on endoscopic
sclerosis for bleeding peptic ulcers
with a visible bleeding vessel. Per
manent endoscopic hemostasis was
obtained in 45 (90%) of 50 patients.
Chung, Leung and Steele26 pub
lished a randomized trial in which
adrenaline was injected endoscopi
cally into actively bleeding peptic
ulcers. Endoscopic sclerosis result
ed in a substantially decreased
180
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need for emergency surgery and
for blood transfusions. Nakagawa,
Asaki and Sato27 reported on endo
scopic sclerosis of bleeding peptic
ulcers with absolute alcohol. Of
134 bleeding peptic ulcers 129 were
well controlled by this method.
Reports in the literature have
also been published comparing dif
ferent methods of endoscopic con
trol of bleeding gastric and duode
nal ulcers. Matthewson and col
leagues28 compared neodymium
(Nd):YAG laser and heater probe
with no endoscopic therapy. Al
though laser and heat-probe thera
py substantially reduced the rate of
recurrent bleeding compared with
controls, there was no difference
between the two methods. Lin and
colleagues29 compared heat-probe
thermocoagulation with pure alco
hol injection and found that, al
though both were effective, heatprobe therapy was more successful
than alcohol sclerosis. Chung and
associates,30 in a randomized trial,
compared endoscopic adrenaline
sclerosis with heat-probe thermoco
agulation. Both were effective in
stopping bleeding from actively
bleeding peptic ulcers, but adrena
line injection was easier to carry out
and had a higher initial success
rate. Laine31 compared multipolar
electrocoagulation with endoscopic
sclerosis for bleeding peptic ulcers.
Both were effective in controlling
bleeding.
The conclusions that can be
drawn from all these papers are that
endoscopic therapy is successful in
stopping bleeding gastric and duo
denal ulcers. The different methods
appear to be equally effective, but
endoscopic sclerosis with adrenaline
is simple and cost effective.
Our 20% operative mortality for
bleeding gastric and duodenal ul
cers is high. Eighty percent of the
patients with gastric and duodenal
ulcers who underwent surgery were
over 60 years of age. Sixty-six

percent of the patients with gastric
ulcers and 56% of the patients with
duodenal ulcers were in shock.
Eighty-eight percent of the patients
with gastric ulcers and 74% of the
patients with duodenal ulcers re
ceived more than 5 units of blood
before surgery. Many of these pa
tients had associated medical ill
nesses such as severe congestive
heart failure, respiratory insufficien
cy and renal failure. These patients
were considered serious surgical
risks by their physicians.
Reports in the literature have
also reported significant mortality
in older patients with associated
medical illnesses. Morris and col
leagues32 reported death rates of
24% and 9% from gastric and duo
denal ulcers, respectively. Hunt3
also reported a high death rate in
patients with peptic ulcers, who had
major associated illnesses and who
were over 60 years of age.
Although this is not a controlled
trial, it does conclusively demon
strate the efficiency of endoscopic
therapy. Our results compare favou
rably with those reported in the
literature. Endoscopy therapy suc
cessfully controlled hemorrhage in
74 (91%) of 81 actively bleeding
peptic ulcers. Chung, Leung and
Steele26 reported that adrenaline in
jection controlled bleeding in all 34
patients with actively bleeding ul
cers. However, 2 of the 34 patients
later underwent surgery because of
rebleeding. Panes and colleagues24
reported that endoscopic sclerosis
controlled the bleeding in 52 (95%)
of 55 patients. Lin and colleagues29
reported that endoscopic sclerosis
ultimately stopped the bleeding in
24 (71%) of 34 patients. Nakagawa,
Asaki and Sato27 reported that en
doscopic sclerosis stopped the
bleeding in 130 (97%) of 134 pa
tients.
We, therefore, conclude that en
doscopic therapy should be the ini
tial treatment for bleeding gastric

BLEEDING GASTRIC AND DUODENAL ULCERS

and duodenal ulcers. If patients
continue to bleed or bleed after
surgery, then surgery or repeat sur
gery should be performed.
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will provide information on the possible emergence of bacterial resistance. If anerobic organisms are suspected to be contibuting
to the infection, appropriate therapy should be administered.
CONTRAINDICATIONS
CIPRO® (ciprofloxacin hydrochloride tablets) and CIPRO® I.V. (ciprofloxacin injection) are contraindicated in patients who have
shown hypersensitivity to ciprofloxacin or other quinolone antibacterial agents.
WARNINGS
Children The safety of CIPRO® and CIPRO® I.V. (ciprofloxacin hydrochloride tablets and ciprofloxacin injection) in children has not
yet been established. Damage to juvenile weight-bearing joints and lameness were observed both in rat and dog studies but not
in weaned piglets (see TOXICOLOGY). Histopathological examination of the weight-bearing joints in immature dogs revealed
permanent lesions of the cartilage. Consequently, CIPRO® and CIPRO® I.V. should not be used in prepubertal patients.27
Experience in pubertal patients below 18 years of age is limited.
Pregnancy The safety of CIPRO® and CIPRO® I.V. in the treatment of infections in pregnant women has not yet been established
(see PRECAUTIONS).
PRECAUTIONS
General Anaphylactic reactions including cardiovascular collapse have occurred rarely in patients receiving therapy with CIPRO®
and CIPRO® I.V. (ciprofloxacin hydrochloride tablets and ciprofloxacin injection). These reactions may occur within the first 30
minutes following the first dose and may require epinephrine and other emergency measures.
CIPRO® and CIPRO® I.V. may cause central nervous system (CNS) stimulation which may lead to tremor, restlessness, light
headedness, confusion, and very rarely to hallucinations or convulsive seizures. Therefore, CIPRO® and CIPRO® I.V. should be
used with caution in patients with CNS disorders, such as severe cerebral arteriosclerosis o r epilepsy. Patients with known
convulsive seizure disorders should only be treated with CIPRO® and CIPRO® I.V. if anticonvulsant therapy has been initiated.
SERIOUS AND FATAL REACTIONS HAVE BEEN REPORTED IN PATIENTS RECEIVING CONCURRENT ADMINISTRATION OF
CIPRO® I.V. AND THEOPHYLLINE. These reactions include cardiac arrest, seizure, status epilepticus and respiratory failure.
Similar serious adverse events have been noted with administration of theophylline alone, however, the possibility that
ciprofloxacin may potentiate these reactions cannot be eliminated. If concomitant use cannot be avoided, the plasma levels of
theophylline should be monitored and appropriate dosage adjustments should be made.
Severe hypersensitivity reactions characterized by rash, fever, eosinophilia. jaundice, and hepatic necrosis with fatal outcome
have also been reported to occur very rarely in patients receiving ciprofloxacin in combination with other drugs. The possibility
that these reactions were related to ciprofloxacin cannot be excluded. Ciprofloxacin should be withdrawn at the first appearance
of a skin rash or other signs of hypersensitivity.
Crystalluria related to ciprofloxacin has been reported only rarely in man because human urine is usually acidic. Crystals have

Ciprofloxacin has been shown to interfere with the metabolism and pharmacokinetics of caffeine. Excessive caffeine intake should
be avoided.
Some quinolones, including ciprofloxacin, have been associated with transient increases in serum creatinine levels in patients who
are concomitantly receiving cyclosporine.
Quinolones have been reported to increase the effects of the oral anticoagulant warfarin and its derivatives. During concomitant
administration of these drugs, the prothrombin time or other appropriate coagulation tests should be closely monitored.
Probenecid blocks renal tubular secretion of ciprofloxacin and has been shown to produce an increase in the level of ciprofloxacin
in the serum.
Concomitant administration of a nonsteroidal anti-inflammatory drug (fenbufen) with a quinolone (enoxacin) has been reported to
increase the risk of CNS stimulation and convulsive seizures.
Antacids containing aluminum or magnesium hydroxide have been shown to reduce the absorption of ciprofloxacin. Concurrent
administration with these agents should be avoided.
Administration of sucralfate prior to CIPRO® resulted in a 30% reduction in absorption of Ciprofloxacin. Concurrent
administration with ciprofloxacin should be avoided.
Oral ferrous sulfate at therapeutic doses decreases the bioavailability of oral ciprofloxacin, therefore concomitant therapy is not
advised.
Renal Impairment Since ciprofloxacin is eliminated primarily by the kidney, CIPRO® and CIPRO® I.V. should be used with caution
and at a reduced dosage in patients with impaired renal function. (See DOSAGE AND ADMINISTRATION).
Hepatic Impairment In preliminary studies in patients with stable chronic liver cirrhosis, no significant changes in ciprofloxacin
pharmacokinetics were observed. The kinetics of ciprofloxacin in patients with acute hepatic insufficiency, however, have not been
fully elucidated. An increased incidence of nausea, vomiting, headache and diarrhea were observed in this patient population.
ADVERSE REACTIONS
CIPRO® (ciprofloxacin hydrochloride tablets) and CIPRO® I.V. (ciprofloxacin injection) are generally well tolerated. During
worldwide clinical investigation, 16,580 courses of ciprofloxacin treatment were evaluated for drug safety.
Adverse events, possibly, probably or highly probably related to ciprofloxacin occurred in 1395 (8.8%) of patients. The adverse
reactions according to treatment (oral, iv, and sequential therapy) show that the incidence of adverse reactions was 8.0% for the
group treated orally, 17% for the group treated with CIPRO® I.V. and 15.3% for the group treated sequentially. The difference
between the oral and iv group relates to adverse vascular reactions which are known to be associated with iv administration.
In orally treated patients enroled in clinical trials, the most frequently reported events, possibly,probably drug-related were:
nausea (1.3%) and diarrhea (1.0%).
In patients treated with CIPRO® I.V., the most frequently reported events, possibly, probably drug-related were: rash (1.8%),
diarrhea (1.0%), and injection site pain (1.0%).
Events possibly, probably drug-related occurring at a frequency of less than 1% with ciprofloxacin oral and i.v. treatment during
clinical trials and subsequent post-marketing surveillance are as follows:
6astro-lntesti*al: vomiting, dyspepsia, abdominal pain, flatulence, dysphagia, enlarged abdomen, dry mouth, stomatitis,
gastrointestinal moniliasis, anorexia, jaundice. The following have been reported very rarely: constipation, tooth discoloration,
ulcerative stomatitis, pseudomembranous colitis, intestinal perforation, esophagitis, increased appetite, gastro-intestinal
hemorrhage, melena, liver damage, tenesmus, ileus, toxic megacolon, hepatomegaly, glossitis.
Cardiovascular system: palpitation, tachycardia, phlebitis. The following have been reported very rarely: hypertension, hot flashes,
cerebrovascular disorder, syncope, kidney vasculitis, vasodilation, atrial fibrillation, cardiac arrest, angina pectoris,
electrocardiogram abnormality, myocardial infarct, substemal chest pain, pulmonary embolus, pericarditis, hypotension.
Nervous System: increased sweating, dizziness, agitation, tremor, somnolence, insomnia, confusion, hallucinations, convulsion,
headache. The following have been reported very rarely: anxiety, depression, nervousness, apathy, depersonalization, abnormal
dreams, hemiplegia, sleep disorder, neuritis, paresthesia, polyneuritis, diplopia, meningism, migraine. In some instances these
reactions occurred after the first administration of CIPRO®. In these instances, CIPRO® has to be discontinued and the doctor
should be informed immediately.
Respiratory System: dyspnea. The following have been reported very rarely: hiccup, increased cough, stridor, larynx edema, voice
alteration, lung edema, pharyngitis, hyperventilation, lung hemorrhage.
Skin and Appendages: rash, pruritus. The following have been reported very rarely: urticaria, photosensitive dermatitis,
angioedema, alopecia.
Special Senses: tinnitus, abnormal vision, taste perversion. The following have been reported very rarely: conjunctivitis, comeal
opacity, eye pain, colour blindness, chromatopsia, diplopia, ear pain.
Urogenital System: albuminuria, hematuria. The following have been reported rarely: leukorrhea, dysuria, urinary retention, acute
kidney failure, abnormal kidney function, nephritis, vaginitis.
Hypersensitivity: rash. The following have been reported rarely: pruritus, drug fever, anaphylactic/ anaphylactoid reactions
including facial, vascular and laryngeal edema, serum sickness, petechiae, haemorrhagic bullae and small nodules (papules) with
crust formation showing vascular involvement (vasculitis), Stevens-Johnson-syndrome, interstitial nephritis, hepatitis; very rarely,
major liver disorders including hepatic necrosis, joint pain.

Blood and Blood constituents: eosinophilia, leukocytopenia, leukocytosis, anaemia. Very rarely: haemolytic anaemia,
thrombocytopenia, thrombocytosis, altered prothrombin levels.
Laboratory values: increased alkaline phosphatase, Gamma - GT, transaminases, cholestatic parameters, lactic dehydrogenase,
BUN, NPN, AST, ALT, decreased creatinine clearance, hypercholesteremia, albuminuria, bilirubinemia, hyperuricemia, increased
sedimentation rate. The following have been reported rarely: electrolyte abnormality, hypercalcemia, hypocalcemia, acidosis,
crystalluria and haematuria.

Other thrombophlebitis. Very rarely, asthenia, death.
Most of the adverse events reported were described as only mild or moderate in severity .There have been 54 reports of
arthropathies with CIPRO®. Ten of these reports involved children'. Arthralgia was usually the first symptom which led to rapid
assessment and withdrawal of the drug. No irreversible arthropathies have been observed.
SYMPTOMS AND TREATMENT OF OVERDOSE
Overdose has not yet been reported with CIPRO® and CIPRO® I.V. (ciprofloxacin hydrochloride tablets and ciprofloxacin injection).
In the event of acute overdosage, the stomach should be emptied by inducing vomiting or by gastric lavage. The patient should be
carefully observed and given supportive treatment.

The duration of treatment depends upon the severity of infection. Generally ciprofloxacin should be continued for at least 3 days
after the signs and symptoms of infection have disappeared. The usual duration is 7 to 14 days. However, for severe and
complicated infections more prolonged therapy may be required. Bone and joint infections may require treatment for 4 to 6
weeks or longer.
Sequential IV/PO Therapy
In patients receiving intravenous ciprofloxacin, oral ciprofloxacin may be substituted when clinically indicated at the discretion of
the physician. Clinical studies evaluating the use of sequential IV/PO therapy in septicemia have not yet been completed.
Impaired Renal Function
Ciprofloxacin is eliminated primarily by renal excretion. However, the drug is also metabolized and partially cleared through the
biliary system of the liver and through the intestine. This alternate pathway of drug elimination appears to compensate for the
reduced renal excretion of patients with renal impairment. Nonetheless, some modification of dosage is recommended,
particularly for patients with severe renal dysfunction. The following table provides a guideline for dosage adjustment. However,
monitoring of serum drug levels provides the most reliable basis for dosage adjustments. Only a small amount of ciprofloxacin
(<10%) is removed from the body after haemodialysis or peritoneal dialysis._____________________________________________
Creatinine Clearance
mL/s (mL/min)

D0SA6E AND ADMINISTRATION
The determination of dosage for any particular patient must take into consideration the severity and nature of the infection, the
susceptibility of the causative organism, the integrity of the patient's host-defense mechanisms, and the status of renal function.
Oral Administration
CIPRO® (Ciprofloxacin hydrochloride tablets) may be taken before or after meals. Absorption is faster on an empty stomach.
Patients should be advised to drink fluids liberally and not take antacids containing magnesium or aluminum.
Adult The recommended dosages of oral CIPRO® are:______________________________
Location of Infection

Type/Severity

Unit Dose

Frequency

Daily Dose

Urinary Tract

Mild/Moderate
Severe/Complicated

250 mg
500 mg

q 12h
q 12h

500 mg
1000 mg

Lower Respiratory Tract
Bone & Joint
Skin & Soft Tissue

Mild/Moderate
Severe/Complicated5

500 mg
750 mg

q 12h
q 12h

Infectious Diarrhea

Mild/Moderate/Severe 500 mg

q 12h

Dose

> 0 .5 (30)

No Dose adjustment

< 0 .5 (30)
and patients on haemodialysis or
peritoneal dialysis

Use recommended dose once daily or
half usual dose twice daily

When only the serum creatinine concentration is available, the following formula (based on sex, weight and age of the patient)
may be used to convert this value into creatinine clearance. The serum creatinine should represent a steady state of renal
function:
Creatinine Clearance mL/sec

In traditional units mL/min

Males:

Males:

1000 mg
1500 mg

Weight (kg) x (140 - age)
49 x serum creatinine (pmol/L)

Weight (kg) x (140 - age)
72 x serum creatinine m g/100 mL

Females:

0.85 x the above value

Females:

0 .85 x the above value

1000 mg

Children
The safety and efficacy of CIPRO® and CIPRO® I.V. in children have not been established.

* e.g. hospital-acquired pneumonia, osteomyelitis
Depending on the severity of the infections, as well as the clinical and bacteriological responses, the average treatment period
should be approximately 7 to 14 days. Generally, treatment should last 3 days beyond the disappearance of clinical symptoms or
until cultures are sterile. Patients with osteomyelitis may require treatment for a minimum of 6 to 8 weeks and up to 3 months.
With acute cystitis, a five-day treatment may be sufficient.

CIPRO® and CIPRO® I.V. should not be used in prepubertal patients (see WARNINGS).

Product Monograph available upon request.

Intravenous Administration
Adult The recommended adult dosages of CIPRO® I.V. (ciprofloxacin injection] are:
Location of Infection

Type/Severity

Unit Dose

Frequency

Daily Dose

Urinary Tract

Moderate/Severe/
Complicated

200 mg to
400 mg

q 12h

400 mg to
800 mg

Lower Respiratory Tract
Skin or Skin Structure
Blood
Bone

Moderate

400 mg

q 12h

800 mg

© MILES CANADA INC., 1992
® Registered Trademark. MILES CANADA INC., is the Registered User of the Trademark CIPRO®, the original brand of
ciprofloxacin hydrochloride.
™ The trademark of the CIPRO tablet, consisting of its colour, shape and size, is a trademark of MILES CANADA INC.

Definitive clinical studies have not been completed in severe respiratory tract and other infections.

References: 1. Cipro / Cipro I.V. Canadian Product Monograph, MILES CANADA INC., September 1991. 2. Current manufacturers' prices as of July, 1991.
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Cardiopulmonary Bypass
for Resuscitation of Patients
With Accidental Hypothermia
and Cardiac Arrest
Fritz J. Baumgartner, MD;* Michael T. Janusz, MD, FRCSC, FACS;*
W.R. Eric Jamieson, MD, FACC, FACS, FRCSC;* Thomas Winkler, MD;*
Lawrence H. Burr, MD, FRCSC;* Judith A. Vestrup, MD, FRCSC;t

Hypothermic patients have been successfully rewarmed by a number of methods.
However, when cardiac arrest occurs, as it frequently does at core temperatures of
less than 27°C, prolonged cardiopulmonary resuscitation (CPR) is required, because
defibrillation can rarely be achieved until the patient has been rewarmed to 30° to
34°C. Five cases of accidental hypothermia with cardiac arrest treated with
cardiopulmonary bypass are discussed.
The first patient died as a result of inadequate low-flow cardiopulmonary bypass
by the femorofemoral route. The second patient had prolonged CPR by closed-chest
cardiac massage and warm peritoneal lavage followed by transthoracic
cardiopulmonary bypass. This patient regained consciousness but was found to be
paraplegic and died from bowel infarction related to peritoneal rewarming without
adequate perfusion. In the last three patients, high-flow cardiopulmonary bypass
was rapidly achieved using a no. 28 French chest tube for femoral venous
cannulation, and they recovered completely.
In cases of accidental hypothermia with cardiac arrest, rapid institution of full
cardiopulmonary bypass provides excellent circulatory support and rapid
rewarming. This avoids the complications of prolonged inadequate circulation that
occur when closed-chest cardiac massage and external rewarming are used.
Le rechauffement des patients hypothermiques peut etre obtenu par plusieurs
methodes. Toutefois, quand survient un arret cardiaque comme cela se produit
souvent quant la temperature centrale descend sous les 27°C, une reanimation
cardiopulmonaire (RCP) de longue duree est necessaire puisqu’une defibrillation
peut rarement etre obtenue, a moins que la temperature du malade ne soit ramenee
entre 30° et 34°C. On commente ici, cinq cas d’hypothermie accidentelle avec arret
cardiaque, qui ont ete traites par circulation extracorporelle.
Le premier patient est decede apres une circulation extracorporelle a bas debit,
insuffisante, par voie femorofemorale. Le second malade eut une RCP prolongee par
massage cardiaque externe et lavage peritoneal tiede, suivis d’une circulation
extracorporelle transthoracique. Ce patient reprit conscience, mais on decouvrit qu’il
etait paraplegique et il deceda d’un infarctus intestinal relie au rechauffement
peritoneal alors que la perfusion etait insuffisante. Chez les trois derniers patients,
une circulation extracorporelle a grand debit fut rapidement institute a l’aide d’un
catheter thoracique French de calibre 28 pour canulation femorale, et ils se
retablirent completement.
Dans les cas d’hypothermie accidentelle avec arret cardiaque, la mise en route
immediate d’une circulation extracorporelle complete assure un excellent soutien
circulatoire et un rechauffement rapide. Elle evite les complications d’une circulation
insuffisante prolongee qui survient quand on utilise un massage cardiaque externe
avec rechauffement externe.
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hypothermia remains
A ccidental
a challenging, if infrequent,

clinical problem. It may afflict vic
tims of outdoor sporting accidents
who suffer prolonged exposure to a
winter environment or immersion in
cold water. In an urban environ
ment, it commonly involves drug or
alcohol intoxication followed by
cold exposure, or it may occur in
debilitated persons confined to inad
equately heated domiciles. As body
temperature decreases the respira
tory rate slows to as little as 1 to
2/m in .1 Neurologic reflexes may
disappear at body core temperatures
less than 27°C, and cardiac ar
rhythmias, including sinus or nodal
bradycardia, ventricular fibrillation
or asystole, may ensue.1-8
Despite the appearance of clinical
death presented by such patients,
successful resuscitation with com
plete recovery has been reported by
use of cardiopulmonary bypass78
and by closed-chest cardiac mas
sage,9 with rewarming by heating
blankets,2 warmed humidified ventiFrom the *Division o f Cardiovascular and
Thoracic Surgery and the fD ivision o f Gen
eral Surgery, Department o f Surgery, Univer
sity o f British Columbia, Vancouver, B C
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CARDIOPULMONARY BYPASS

lation,2 and warmed irrigations3 and
peritoneal dialysis.4 The role of car
diopulmonary bypass in such pa
tients, versus nonoperative meth
ods, remains incompletely defined.
In an attempt to clarify this role we
present our experience with resusci
tation of victims of accidental hypo
thermia using cardiopulmonary by
pass.

Case Reports
Between 1978 and 1990, five
patients suffering from accidental
hypothermia with severe circulatory
depression or cardiac arrest were
referred to the surgical service of
the Vancouver General Hospital. A
summary of these cases follows.

Case 1
A 70-year-old woman who was a
long-term alcoholic was found after
lying unconscious for possibly 2
days by an open balcony door. Her
pulse rate was 20 beats/min, blood
pressure 3 5 /0 mm Hg and rectal
temperature 22°C.
The patient was transferred to
the operating room, where ventricu
lar fibrillation occurred. She was
promptly defibrillated successfully.
Femorofemoral cardiopulmonary
bypass was commenced, but venous
return was very poor (only 300
mL/min). Using this flow, the pa
tient was rewarmed to 30°C over
3.5 hours, with an increase in blood
pressure to 70/40 mm Hg. Bypass
was discontinued and she was
transferred to the intensive care
unit where external warming was
continued. The patient remained co
matose with some response to pain
only, and she died 40 hours after
admission as a result of progressive
hemodynamic deterioration.
The poor flow rates obtained se
verely limited the usefulness of by
pass in this case.

Case 2
A 27-year-old woman was
brought to the emergency room
after having been found outside
during a cold (3°C) rainy night. She
had a history of possible drug in
gestion. She was noted to be asystolic, neurologic signs were absent
and her body temperature was
20°C, rectally. Closed-chest mas
sage and ventilation were begun
with rewarming by warm bladder
irrigations and warm peritoneal di
alysis. After 3 hours the core tem
perature had risen to 26°C, but she
remained asystolic. The cardiovas
cular surgical service was consult
ed, and she was transferred to the
operating room. Cardiopulmonary
bypass was started with femoral
artery cannulation and thoracotomy
and atrial cannulation for venous
return. Closed-chest massage was
interrupted only for the thoracoto
my. After 85 minutes on bypass her
body temperature was 37 °C. Dopa
mine was necessary to wean her
from cardiopulmonary bypass. Postoperatively her mentation improved,
and 48 hours postoperatively she
was talking to hospital personnel
with only mild impairment of cere
bration. It was apparent on awaken
ing, however, that she was paraple
gic, and no recovery of this was
observed. After 48 hours she be
came septic, and a laparotomy 4
days postoperatively disclosed in
farction of the gallbladder, smallbowel segments and rectum. She
remained severely septic and died of
septic shock the following day.

Case 3
A 22-year-old woman who was
suspected of having taken a seda
tive overdose and who had not been
seen for 3 days was found by pa
ramedics in a cold (15°C) room. Her
respiratory rate was 2/min, pulse
20 beats/min and she had no de

tectable blood pressure. On intuba
tion ventricular fibrillation devel
oped. Closed-chest cardiac massage
was begun immediately. On admis
sion to the emergency room her
temperature was 22°C. She was
transferred to the operating room
and placed on cardiopulmonary by
pass, with cannulation of the left
femoral vein using a no. 28 French
chest tube, which was advanced its
full length into the inferior vena
cava, and cannulation of the left
femoral artery. She was placed on
full cardiopulmonary bypass with a
pump flow of 3500 mL/min, after a
total of 87 minutes of closed-chest
massage. Spontaneous defibrillation
occurred, and after 1 hour on by
pass her core temperature was
37.2°C. She was weaned from by
pass without the use of inotropic
agents.
Postoperatively, her neurologic
status improved to normal at 48
hours postoperatively. She was dis
charged after an uncomplicated re
covery.

Case 4
A 35-year-old man was intoxicat
ed and attempted to walk home
from a party on a cold (2°C) rainy
night. He was found early the fol
lowing morning, lying by a foot
path. He was noted to have occa
sional gasping respirations and was
taken to the emergency room where
he was found to be asystolic, with
absent neurologic signs and a rectal
temperature of 26°C. Known apneic
time without resuscitation was 15
minutes. Intubation and ventilation
and closed-chest cardiac massage
were started and continued for 120
minutes while an operating room
was prepared. His rectal tempera
ture fell to 23°C during this time.
He was placed on femorofemoral
bypass in the same manner as the
patient in case 3. Pump flow was
4000 mL/min. He was defibrillated
CJS, VOL. 35. NO. 2, APRIL 1992
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on bypass, and after 62 minutes, he
was weaned from bypass at a body
temperature of 36°C without diffi
culty and without the use inotropic
drugs.
He was neurologically responsive
at that time and continued to make
a smooth recovery except for some
memory loss that resolved over the
following month.

Case 5
A 60-year-old alcoholic was
found unconscious at a local beach
on a cold night. A pulse was palpa
ble, and he was transported immedi
ately to the emergency room where
a systolic pressure of 60 to 70
mm Hg, a pulse rate of 20 beats/m in and a body temperature of
21°C were recorded. His heart was
in sinus rhythm. Intubation and
fluid resuscitation were performed.
An attempted percutaneous perito
neal lavage with 2 L of warm saline
brought his temperature close to
23°C before he was taken to the
operating room; however, enteric
contents were noted in the perfu
sate return. Right femorofemoral
bypass was established with a flow
of 2300 mL/min. A no. 28 French
chest tube was used for venous
return. He was slowly rewarmed
over 3 hours with a slow rise in
body temperature, blood pressure
and pulse rate. There were no pre
mature ventricular contractions or
other dysrhythmias during the re
warming period. On laparotomy an
enterotomy from the lavage cathe
ter was found. This was repaired
and the patient did well subsequent
ly. He returned to his baseline sta
tus and was discharged soon there
after.

Discussion
Our experience illustrates several
important points in the manage
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ment of patients with accidental
hypothermia. First it is important to
recognize that complete recovery is
possible in patients with severe hy
pothermia and cardiac arrest, even
though such patients may present
with asystole and absent neurologic
signs. Our fourth case demon
strates that complete recovery is
possible even if the cardiac arrest
was unwitnessed and of unknown
duration.
Presumed cardiac arrest in hypo
thermic patients is often witnessed
by paramedics because these pa
tients tend to suffer cardiac arrest
when they are moved.3 However,
chest compressions may convert a
nonpalpable but perfusing sinus
bradycardia into ventricular fibrilla
tion. None the less, cardiopulmo
nary resuscitation (CPR) is indicat
ed in truly pulseless victims of
hypothermia, and this has led to
disagreement regarding appropriate
prehospital management of such
patients.9’10 Several predictors in
creasing the likelihood of a poor
outcome in a victim of hypothermia
have been identified.9"12 These in
clude prehospital cardiac arrest, low
or absent presenting blood pres
sure, elevated serum urea nitrogen
levels, need for endotracheal intuba
tion, major trauma and systemic
infection or other serious illness.
Patients with severe accidental
hypothermia have been successfully
resuscitated by closed-chest or open
cardiac massage and a variety of
warming methods, including warm
irrigations or peritoneal dialysis and
warmed, humidified ventilation.1
These methods, however, are slow,
and prolonged cardiac massage may
be needed. We believe that our
second case illustrates the difficul
ties of such an approach. CPR time
was prolonged (3.5 hours), with a
rise in core temperature from 22°C
to 26°C and no recovery of sinus
rhythm. Following resuscitation
with cardiopulmonary bypass, the

patient awoke and displayed mini
mal impairment of cerebral func
tion. We suspect that her paraple
gia was related to the prolonged
attempt at re-warming with inade
quate perfusion by closed-chest
massage, and the fatal complication
of bowel infarction was likely due to
warm peritoneal dialysis with inade
quate visceral circulation.
It is crucial to remember that
rewarming must occur simulta
neous with resuscitation (i.e., main
tenance of adequate cardiovascular
support, acid-base balance, oxygen
ation and intravascular volume). If
rewarming occurs independently of
such resuscitation, cardiac function
and oxygen delivery will be unable
to keep pace with increased meta
bolic demands, leading to organ
infarction.
A number of studies imply that
passive external rewarming, perito
neal lavage and partial cardiopulmo
nary bypass give generally good
results. This is true provided that
cardiac arrest in the hypothermic
victim is adequately managed by
CPR or other cardiac support and
that physiologic intravascular vol
ume, oxygenation and pH are main
tained.13’14 Nevertheless, we believe
that cardiopulmonary bypass, when
available, is the most reliable way to
maintain such adequate physiologic
parameters. Multiple reports have
documented the efficacy of cardi
opulmonary bypass1’5"815"18 in the
hypothermic patient. These have
included successful recovery of a
patient who was in ventricular fi
brillation for 1.5 hours and had a
pH value of 6.4115 and recovery of a
child who was submersed in cold
water for 66 minutes.16 CPR is
unlikely to be as effective as partial
cardiopulmonary bypass, and Althaus and associates3 observed that
the hearts of hypothermic patients
were in a state of rigid contracture,
impairing the efficacy of closedchest cardiac massage.

CARDIOPULMONARY BYPASS

Cannulation of one or both femo
ral veins and femoral artery can be
performed quickly, while closedchest cardiac massage continues.
Flow rates of 3 to 4 L/m in can
usually be obtained,5,6 and these
flows are in the acceptable range
for full cardiopulmonary bypass (50
to 60 m L /k g • min*1) and hence
provide satisfactory tissue perfu
sion. Although thoracotomy may
occasionally be necessary to obtain
adequate venous return to the
heart-lung machine, the need for
this is minimized by use of a long
venous catheter with multiple side
holes, such as the no. 28 French
chest tube that we used in cases 3,
4 and 5. Should flow still be inade
quate, thoracotomy can be per
formed in the presence of partial
bypass rather than total cardiac
arrest.

pass, when available, is the quickest
and safest method of resuscitation,
as it provides both efficient rewarm
ing and adequate perfusion.
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Conclusions
Complete recovery from acciden
tal hypothermia with cardiac arrest
can be achieved, even after pro
longed periods of cardiac arrest. We
believe that cardiopulmonary by

Some ped|

10.

References

4.

7.

8.

9.

et al: Management of profound acciden
tal hypothermia with cardiorespiratory
arrest. Ann Surg 1982; 195: 492-495
Davis M, J udson JA: Warm peritoneal
dialysis in the management of accidental
hypothermia: report of five cases. NZ
M edJ 1981; 94: 207-209
K ucelberc J, S chiller H, Berg B et al:
Treatment of accidental hypothermia.
Scand J Thorac Cardiovasc Surg 1967;
1:142-146
Fell RH, Gunning AJ, Bardhan KD et
al: Severe hypothermia as a result of
barbituate overdose complicated by car
diac arrest. Lancet 1968; 1: 392-394
T owne WD, Geiss WP, Yanes HO et al:
Intractable ventricular fibrillation associ
ated with profound accidental hypo
thermia — successful treatment with
partial cardiopulmonary bypass. N Engl
J Med 1972; 287: 1135-1136
W ickstrom P, Ruiz E, Lilia GP et al:

11.

12.

13.
14.

15.

16.

17.

18.

Accidental hypothermia core re-warming
with partial bypass. Am J Surg 1976;
131: 622-625
S teinman AM: Cardiopulmonary resusci
tation and hypothermia. Circulation
1986; 74 (4): 29-32
D anzl DF, Pozos RS, Auerbach PS et
al: Multicenter hypothermia survey. Ann
Emerg Med 1987; 16: 1042-1055
Danzl DF, H edges JR, Pozos RS: Hypo
thermia outcome score: development
and implications. Crit Care Med 1989;
17: 227-231
H auty MG, E srig BC, H ill JG et al:
Prognostic factors in severe accidental
hypothermia: experience from the Mt.
Hood tragedy. J Trauma 1987; 27:
1107-1112
Moss J: Accidental severe hypothermia.
Surg Gynecol Obstet 1986; 162: 501513
Moss JF, Haklin M, S outhwick HW et
al: A model for the treatment of acciden
tal severe hypothermia. J Trauma 1986;
26: 68-74
C ohen DJ, C line JR, L epinski SM et al:
Resuscitation of the hypothermic pa
tient. Am J Emerg Med 1988; 6: 475478
B olte RG, B lack PG, Bowers RS et al:
The use of extracorporeal rewarming in
a child submerged for 66 minutes.
JAMA 1988; 260: 377-379
Maresca L, Vasko JS: Treatment of
hypothermia by extracorporeal circula
tion and internal rewarming. J Trauma
1987; 27: 89-90
S plittcerber FH, T albert JG, S weezer
WP et al: Partial cardiopulmonary by
pass for core rewarming in profound
accidental hypothermia. Am Surg 1986;
52: 407-412

rather...

w a tc h th e ir
s to c k s g o d o

...th a n s u ffe r h e m o r r h o id a l
p a in .
But w o u ld n 't m o st of y o u r patients prefer
the effective pain relief of Proctosedyl?

First subm itted by
Dr. Florentine F. Rasario
Chateauguay, Quebec

A

C o n ta in s a n a n e s th e tic .
ROUSSEL

ADPR-01/01/92
l PAAB |

| PMAC |

!j

O intm ent: 15 g an d 3 0 g tu b e s w ith can n u la .
S u p p o sito rie s: b o x e s o f 12 and 24.
P re scrib in g in fo rm a tio n a v a ila b le on request.

CJS, VOL. 35, NO. 2, APRIL 1992

187

ORIGINAL ARTICLES

A g e as a Risk Factor in Major
Genitourinary Surgery
Kevin R. Baker, MD, FRCSC, FSOGC; Harold P. Drutz, MD, FRCSC, FSOGC, FACOG, FACS, FICS
Surgery for urinary incontinence is often not considered in elderly persons (older
than 65 years) because of their age. In this paper the authors examine the effect of
age on the success rate and complications of abdominal correction (modified
retropubic colpourethropexy with or without other major gynecologic surgery) for
genuine stress incontinence. Other than age, length of hospital stay and some
urodynamic values there were no statistically significant differences in success and
complication rates between the elderly and younger patients. The authors conclude
that in properly selected elderly patients with genuine stress incontinence,
retropubic colpourethropexy is as safe and effective as in younger patients.

A cause de leur age, souvent on n’envisage pas la chirurgie pour les personnes de
plus de 65 ans souffrant d’incontinence urinaire. Dans cet article, les auteurs
examinent les effets de l’age sur le taux de succes et les complications de la
correction abdominale (colpo-uretropexie retropubienne modifiee, avec ou sans autre
chirurgie gynecologique importante) pour incontinence urinaire a Teffort reelle.
Outre l’age, la duree d’hospitalisation et certains resultats urodynamiques, il n’y a
pas eu de differences significatives entre les taux de succes et de complications des
patients ages et ceux des plus jeunes. Les auteurs conduent que chez des patients
bien choisis souffrant d’incontinence urinaire a Teffort reelle, la colpo-uretropexie
retropubienne est aussi sure et efficace que chez les patients plus jeunes.
rinary incontinence is a clinical
syndrome whose incidence in
creases with age. In community
dw elling (n o n in stitu tio n alized )
women, genuine stress incontinence
(GSI) is the most common condition
leading to involuntary loss of
urine.1 Approximately 12% of the
North American population is 65
years of age or older, and twothirds of them are women.2 With
aging, urinary incontinence be
comes increasingly widespread,
being reported in 10% to 20% of
community-dwelling people, 35% of

U

acute care patients and more than
50% of institutionalized patients.2
The problem of urinary inconti
nence is often viewed by lay and
medical people as an inevitable ac
companiment of aging, and conse
quently the condition is often ig
nored. This attitude brings emotion
al, psychologic, social and physical
hardship to those suffering from
urinary incontinence. Choosing not
to operate on those patients amena
ble to surgery because of their age
is a form of discrimination that
should not be tolerated.

From the Gynecological Urology and Urodynamic Investigative Unit, Mount Sinai Hospital, and
the Section o f Urogynecology, Department o f Obstetrics and Gynecology, University o f Toronto.
Toronto, Ont.
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In this paper we reviewed the
experience of the Mount Sinai Hos
pital, Section of Urogynecology,
with 289 patients who underwent a
retropubic colpourethropexy to cor
rect stress urinary incontinence.
The diagnosis of stress incontinence
was made by clinical and urodynam
ic testing. The standard procedure
was modified by the senior author
(H.P.D.) in that nonabsorbable su
ture material was used. The success
rate, complications and preoperative
urodynamic findings by age group
are discussed.

Patients and Methods
Between August 1976 and De
cember 1988, 289 women under
went a retropubic colpoure
thropexy. All procedures were per
formed by the senior author
(H.P.D.) together with the fellows
and residents on the urogynecology
service at the Mount Sinai Hospital
in Toronto. The average age of the
patients at the time of surgery was
51.4 years (range from 25 to 86
years). The average gravidity was
3.2 (range from 0 to 12) and the
average parity was 2.6 (range from
0 to 9); 96% of the deliveries were
vaginal and 4% were by cesarian
section.
Urine loss on stress (i.e., cough
ing, jumping) was demonstrated in
all patients either lying or standing.
All patients underwent urody
namic examination before surgery,
consisting of uroflowmetry and si
multaneous surface perianal sphinc-
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ter electromyography (EMG) with
the Dantec 2100 Urosystem (Dantec
Elektronik A/S, Skovlunde, Den
mark) followed by catheter mea
surement of residual urine. Cystometrography (CMG) was per
formed and a static supine urethral
pressure profile (SSUPP) was ob
tained with double-lumen, no. 10
French silicone catheters and pull
er, with carbon dioxide at a flow
rate of 120 mL/min. The data were
recorded on a Browne two-channel
recorder (Browne Medical, Carpinteria, Calif.). Dynamic cystourethroscopy was performed with a no. 15
French zero-degree Storz-Hopkins
female cystourethroscope (Laborie
Surgical Ltd., Rexdale, Ont.). This
procedure demonstrated funnelling
into the upper part of the urethra in
all patients. With updating of our
equipment, the last 90 women in
the study underwent level III multi
channel urodynamic examination
before surgery. These tests, all per
formed on the Dantec 2100 Urosys
tem, included the following: repeat
uroflowmetry with simultaneous pe
rianal surface EMG; medium-fill
electronically subtracted water cys
tometry in the supine and sitting
positions; and static and dynamic
urethral pressure profiles in the
supine and standing positions, with
double-lumen no. 8 French microtip
catheters in the urethra and an
additional microtip catheter in ei
ther the vagina or rectum to mea
sure intra-abdominal pressure. All
patients had a trial of conservative
therapy consisting of attempts at
voiding, perineal strengthening ex
ercises, hormonal replacement ther
apy and a-adrenergic drugs or pes
sary when indicated. All patients
over 65 years of age had preopera
tive medical assessment as did any
younger patient who had a preoper
ative medical condition requiring
medical evaluation.
Methods, definitions and units
conformed to the standards recom

mended by the International Conti
nence Society,3 except where specif
ically noted. Statistical analysis con
sisted of the Student’s f-test (twotailed) or the x2 test (with Yates
correction for continuity) where ap
plicable. For the purposes of this
paper failure of the retropubic colpourethropexy was defined as de
monstrable loss of urine on vigor
ous stress in either the supine or
standing positions at subjectively
full bladder capacity or demonstra
ble stress urinary incontinence at
the time of follow-up multichannel
urodynamic testing.
Operative Technique

Once into the space of Retzius,
under direct vision, the surgeon
placed two sutures in a helical fash
ion at the level of the urethrovagi
nal junction (approximately 1 cm
and 3 cm lateral to the urethrovagi
nal junction) and a third suture as
far along the anterolateral aspect of
the vault of the vagina as possible.
Each end of the suture was passed
through Cooper’s ligament, so that
for the three bites of the vagina
there were six sutures placed
through Cooper’s ligament (the an
terolateral aspect of the ileopectineal line). In the first 229 (79%)
cases 0 Tevdek suture was used for
the retropubic colpourethropexy.
Thereafter, in the other 60 (21%)
cases we used 0 or 2-0 Prolene
suture because the monofilament
suture is less likely to tear through
the vagina. Sutures were placed
into the vagina carefully avoiding
the vaginal mucosa.

Results
Of the 289 women who under
went a retropubic colpourethropexy
50 (17%) were 65 years of age or
older at the time of surgery. Ninetyseven (34%) of the 289 women had

previously undergone surgery for
incontinence, and 29 (30%) of them
had had two or more procedures.
No significant differences were
noted in the gravidity, parity or the
weight of the women.
With respect to preoperative
medical problems (Table I), there
were no significant differences be
tween the age groups in regard to
the number of patients in each
category, other than cancer, which
was higher in the older age group.
This does not reflect the severity of
the disease process, which could
not be retrieved from the clinic
charts.
The urodynamic findings in the
two age groups at two levels of
testing are shown in Tables II and
III. The maximal urethral closure
pressure (MUCP) was significantly
lower (p < 0.001) in the older
group on both level II and level III
testing. Also the functional length
(FL) was significantly less and the
number of patients with low closure
pressures was significantly more in
the older group (Table III). Bladder
capacity ranged from 150 mL to
800 mL on urodynamic testing.
Patients whose urinary bladder ca
pacity was less than 300 mL re
ceived appropriate pharmacologic
therapy (hormonal replacement,
oxybutinin etc.) before surgery. The
proportion of patients with urinary
Table I. Number (%) of Medical Problems
Present at the Time of Surgery or
Previously by Age Group
Age group, yr
Problem

>65
<65
(n = 50) (n = 239) p value

Chronic chest 1 ( 2)
Smoking
13(26)
Cerebrovascular
2 ( 4)
Diabetic
1 ( 2)
Cardiac
5 (1 0 )
Hypertensive
9 (1 8 )
Respiratory
4 ( 8)
Thyroid
3 (6 )
Renal
1 ( 2)
Cancer
3 ( 6)

18 ( 8)
83 (35)

NS
NS

4 ( 2)
12 ( 5)
10 ( 4)
31 (13)
22 ( 9)
8 ( 3)
4 ( 2)
3 ( 1)

NS
NS
NS
NS
NS
NS
NS
0.025 <
p < 0.05
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transfusions than the older women,
and the older women stayed in
hospital an average of 1.9 days
longer than the younger women.
The operative time, estimated blood
loss, febrile morbidity (body temper
ature more than 38°C on two sepa
rate readings taken more than 4
hours apart, excluding the first 24
hours after operation) and wound
infection rates were similar.
Postoperative follow-up ranged
from 6 weeks to 12 years (median 1
year, mean 2.1 years). There were
only 13 failures of colpoure

bladder capacity less than 300 mL
was the same in both groups.
There were no significant differ
ences in the number of associated
surgical procedures performed at
the time of colpourethropexy (Table
IV). The incidence of multiple surgi
cal procedures was equal in both
age groups.
In regard to the operative statis
tics for both groups (Table V) the
only significant differences were in
the number of patients transfused
and the duration of hospitalization
— the younger women had more

Table II. Preoperative Urodynamic Testing Results for Total Group. Level II Testing With Carbon
Dioxide*
Age group, yr

(n = 239)

/rvalue

82.33 (20-200)
341.73 (150-700)

87.26 (25-380)
364.33 (150-800)

NS
NS

2.49 (0.7-4.7)

2.49 (0.5-5.4)

NS

53.93 (10-130)

< 0.001

Test
Cystometrography
First desire to void, mL
Maximal bladder capacity, mL
Static supine urethral pressure profile
Functional length, cm
Maximal urethral closure pressure,
cm H20

< 65

> 65
(n = 50)

41.46 (12-84)

'Values are means (and range).

Table III. Preoperative Urodynamic Testing Results for Total Group. Level III Multichannel Testing
With Saline*
Age group, yr
Measurement
First desire to void, mL
Maximal bladder capacity, mL
Urethral pressure profile
Functional length, cm
Maximal urethral closure
pressure, cm H20
Low pressure,! no. (%)

< 65
(/» = 67)

> 65
(n = 23)

p value

202.70 (44-365)
443.35 (246-666)

213.52 (41-752)
510.88 (220-999)

NS
NS

2.15 (0.5-4.2)

2.60 (1.5-3.8)

0.005 < p < 0.01

37.88 (12-114)
14 (20)

< 0.001
0.001 < p < 0.05

20.91 (4-40)
13 (54)

'Values are means (and range).
tM axim al urethral closure pressure < 20 cm H20
Table IV. Number (%) of Associated Surgical Procedures Performed by Age Group
Age group, yr
Procedure

> 65
(n = 50)

Total abdominal hysterectomy
Posterior repair
Retropubic colpourethropexy
Bilateral salpingo-oophorectomy
Internal anterior repair
Internal posterior repair
Colposacropexy

27
1
50
34
10
14
10
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( 54)
( 2)
(100)
( 68)
( 20)
( 28)
( 20)

< 65
(n = 239)

148
3
239
140
53
45
27

( 62)
( 1)
(100)
( 59)
( 22)
( 19)
( 11)

/rvalue
NS
NS
NS
NS
NS
NS
NS

thropexy, giving a 96% success rate
for the procedure. The median time
to failure was 1 year (mean 1.4
years). Of the 13 women with a
failed procedure, 10 (77%) had pre
viously undergone incontinence sur
gery. Five of the 13 failures were in
women 65 years of age or older
(0.05 < p < 0.10).

Discussion
When performing the preopera
tive urodynamic testing we noted
that elderly patients had significant
ly lower MUCPs and FLs. To elimi
nate artifactually low closure pres
sures secondary to previous inconti
nence surgery the same urodynamic
parameters were examined in 30 (of
50) women of the older age group
and in 162 (of 239) women of the
younger age group who underwent
primary surgery for stress urinary
incontinence. Once again the MUCP
on level II testing and the FL and
MUCP on level III testing were
significantly less in the older age
group (Tables VI and VII). Similar
findings were reported by Rud,4 in a
study of 169 women, who showed
that the MUCP and FL increased
from infancy to the age of 20 to 25
years, thereafter decreasing with in
creasing age. These results also
support the findings of Sand and
colleagues5 that MUCP was not
independent of age as a risk factor
for the failure of surgery. Despite
this finding both Rud and Sand and
colleagues had similar success
rates.
A literature search of the last 10
years was undertaken to seek simi
lar reports. There were few papers
specifically looking at age as a risk
factor for surgical correction of
GSI. Most papers dealt with general
surgical problems in the elderly —
specifically, cholecystectomy and
colectomy as emergency proce
dures. Our results corroborate the
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Table V. Operative Statistics
Age group, yr
Measurement
Operating time, min (range)
Estimated blood loss,
mL (range)
Transfusion, no. (%)
of patients
Duration of hospitalization,
d (range)
Fever, no. (%) of patients
Wound complications, no. (%)
of patients
Deep venous thrombosis, no.
(%) of patients
Pulmonary embolism, no. (%)
of patients

> 65

< 65

(n = 50)

(n = 239)

/rvalue

167.62 (89-240)

179.42 (80-360)

NS

521.17 (75-4000)

624.18 (50-5000)

NS

12 (24)

84 (35)

< 0.001

12.74 (8-26)
2(4)

10.89 (6-30)
16 ( 7)

0.01 < p < 0.02
NS

2(4)

6(3)

NS

0

3 ( 1)

NS

0

1 (0.5)

NS

Table VI. Preoperative Urodynamic Testing Results for Women Who Underwent Colpourethropexy
as the Primary Procedure. Level II Testing With Carbon Dioxide*

findings o f Gillon and Stanton,6
who had excellent long-term results
in 35 patients between the ages o f
65 and 82 years who underwent
surgery for GSI with minimal post
operative morbidity.
We conclude that elective, cor
rective, abdominal surgery in prop
erly selected elderly patients with
GSI (as diagnosed by urodynamic
testing) should not be withheld be
cause o f age. The majority o f these
patients will be cured o f GSI with
success and morbidity rates similar
to their younger counterparts. It is
the patients requiring emergency
surgery who have higher morbidity
and mortality.7

Age group, yr
Measurement
First desire to void, mL
Maximal bladder capacity, mL
Urethral pressure profile
Functional length, cm
Maximal urethral pressure closure,
cm H20

> 65

< 65

(n = 30)

( n = 162)

84.83 (50-200)
346.38 (150-700)

85.90 (10-380)
356.99 (170-800)

2.57 (0.7-4.7)
41.36 (15-84)

References
p value

NS
NS

2.55 (0.7-4.7)

NS

56.63 (10-130)

< 0.001

'Values are means (and range).

Table VII. Preoperative Urodynamic Testing Results for Women Who Underwent
Colpourethropexy as the Primary Procedure. Level III Multichannel Testing With Saline*
Age group, yr
Measurement
First desire to void, mL
Maximal bladder capacity,
mL
Urethral pressure profile
Functional length, cm
Maximal urethral pressure
closure, cm H20
'Values are means (and range).

> 65
(/? = 11)

< 65
(rr= 4 3 )

/rvalue

175.188 (74-319)

225.30 (41-752)

NS

430.09 (316-632)

482.50 (220-999)

NS

2.08 (0.5-4.2)

2.80 (1.5-3.8)

0.002 < p < 0.005

20.64 (4-34)

37.95 (13-80)

0.002 < p < 0.005
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T h e Accuracy of the Cartier Tibial Guide
in Knee Arthroplasty
Patrick Kinnard, MD, FRCSC; Clement Asselin, MD
The authors reviewed, radiologically, the postoperative position of the tibial
component in 51 knee arthroplasties performed between 1987 and 1989 with
Cartier’s extramedullary tibial guide.
The results compared favourably with those of other studies. A variation of 1.9°
on anteroposterior roentgenograms and 2.4° on lateral roentgenograms was
obtained by five orthopedic surgeons, suggesting that, for knee arthroplasties, the
guide of Cartier is a useful tool and produces reliable results.

here are two types of guide
that have been designed for
accurate resection of the proximal
tibia — extramedullary and in
tramedullary.1
Philippe Cartier from Paris de
signed an extramedullary guide. It
uses the tibial crest as a reference
point to perform the proximal tibial
resection at 90° in the anteropost
erior and lateral planes (personal
communication, 1990).
This guide (Fig. 1) consists of a
black V-shaped block that fits
against the tibial crest below the
tibial tuberosity. The telescoping T
bar is positioned at the level of bone
destruction or at a level determined
preoperatively.

The horizontal tibial cut is made
by placing the blade of the oscillat
ing saw on top of the T bar or
through the slot.

Patients and Methods

Discussion

Forty-one patients (27 women,
14 men) underwent 51 knee re
placements at the Centre Hospitalier de l’Universite Laval between
January 1987 and January 1989.
The diagnosis was osteoarthritis
in 34 knees, rheumatoid arthritis in
13 knees and other conditions in 4
knees. The accuracy of tibial com
ponent placement was assessed
from weight-bearing anteroposter

The goals of knee arthroplasty
are freedom from pain, stability,
good range of motion for daily
living activities and durability.
The durability of a knee arthro
plasty includes, among other fac
tors, accurate alignment of the
prosthetic component. The primary
complication in early knee arthro
plasty has been tibial loosening, and
there is a need to define the con
cepts of proper alignment.
Many authors1-6 recommend the
placement of the tibial component
at 90° ± 5° to the long axis of the
tibial shaft as seen on both the
anteroposterior and lateral roent-

From the Division o f Orthopedic Surgery, Centre Hospitalier de I ’Universite Laval, Ste-Foy, Que.
Accepted fo r publication June 12, 1991
Reprint requests to: Dr. Patrick Kinnard, Division o f Orthopedic Surgery, Centre Hospitalier de
I ’Universite Laval, 2705 bout. Laurier, Ste-Foy, PQ G1V4C2
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Findings
On the anteroposterior roentgen
ogram, the results demonstrated a
variation of 1.9°. Thirty-six knees
had a mean tibial component tilt in
varus of 2° (p < 0.05), and 9 knees
had a mean tibial component tilt in
valgus of 0.8° (p < 0.05) (Fig. 3).
On the lateral roentgenogram, a
variation of 2.4° was obtained.
Eighteen knees had a mean anterior
tilt of 2.4° (p > 0.05) and 27 knees
had a mean posterior tilt of 2.9° (p
> 0.05) (Fig. 4).

Les auteurs ont evalue la position radiologique postoperatoire de la composante
tibiale de 51 arthroplasties du genou faites entre 1987 et 1989 avec l’aide du guide
tibial de Cartier.
Les resultats sont comparables a d’autres etudes. Une variation de 1,9° sur les
radiographies anteroposterieures et de 2,4° sur les radiographies laterales fut
obtenue par cinq chirurgiens orthopediques, demontrant la fiabilite du guide de
Cartier lors du placement de la composante tibiale dans les protheses totales du
genou.

T

ior and lateral roentgenographic
views obtained after surgery (Fig.
2). Results were analysed by Stu
dent’s f-test.

CARTIER TIBIAL GUIDE

FIG. 1. Tibial guide of Cartier.

FIG. 3. Postoperative alignment as
determined from weight-bearing an
teroposterior roentgenogram.

genograms. There is a presumptive
association between com ponent
malposition and late failure due to
loosening. Therefore a satisfactory
replacement cannot be achieved un
less the prosthesis is correctly
aligned.67 Varus and anterior posi
tions may place an excessive load
on the tibial component during gait
and must be avoided.1’6’7
With the tibial crest as a primary
reference, the tibial guide of Cartier
is easy to handle and can be recom
mended because it compares favou

FIG. 4. Postoperative alignment as determined from weight-bearing lateral
roentgenogram.

rably with other intramedullary and
extramedullary guides.1'3"7

4. Insall
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Clinical Presentations of Gastrointestinal
Inflammatory Fibroid Polyps
J. Ali, MD, FACS, FRCSC;* W. Qi, MSc;* S.S. Hanna, MB, BCh, FACS, FRCSC;*
S-N. Huang, MD, FRCPCf
Two cases of inflammatory fibroid polyps are described. They involved the
uncommon sites of the terminal ileum and ileocecal region respectively. Both
lesions, although benign, presented as possible malignant tumours. One was
associated with anemia and the other with obstructive symptoms.
From a review of the literature and the two case reports the authors believe that
the diagnosis of such inflammatory fibroid polyps, on clinical and gross
appearances, can be difficult, and they emphasize the importance of awaiting
histologic assessment before proceeding with extensive definitive surgery.

On decrit deux cas de polypes fibroi'des inflammatoires. Ils affectaient deux foyers
anatomiques peu frequemment touches, soit l’ileon terminal et la region ileocaecale.
Bien que benignes, les lesions presentaient les apparences de tumeurs possiblement
malignes. Une etait reliee a de l’anemie alors que la seconde causait des symptomes
d’obstruction.
Apres etude de la litterature et des deux cas, les auteurs croient que le diagnostic
des polypes fibroi'des inflammatoires, a partir du tableau clinique et de l’aspect
macroscopique, peut etre difficile; ils soulignent l’importance d'attendre les resultats
de l’examen histologique avant de proceder a une chirurgie definitive etendue.

nflammatory fibroid polyps of the
gastrointestinal tract were first
described in detail by Vanek in
1949,1 and the term was first
coined by Helwig and Ranier.23 Al
though the lesion is relatively rare
clinically, it is most frequently diag
nosed as a gastric lesion with ob
structive symptoms45 and is com
monly considered as a possible ma
lignant mass. Characteristically an
inflammatory fibroid polyp is a soli
tary tumour-like mass in the stom
ach and is rarely found elsewhere.
It consists of loosely organized,

I

vascular, fibrous tissue with a vari
able number of eosinophils.5 The
lesion is usually seen in the muco
sal and submucosal layers and can
involve the muscle layer. The fol
lowing two patients presented clini
cally with possible malignant le
sions, which were uncommon be
cause they involved the terminal
ileum and ileocecal region respec
tively and because one patient pre
sented with anemia from gastroin
testinal hemorrhage. In both cases
the correct diagnosis was not con
sidered from the clinical findings
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and was made only after histologic
assessment.

Case Reports
Case 1

A 66-year-old blind and deaf
woman was seen at Sunnybrook
Health Science Centre because of
anemia (hemoglobin level 76 g/L).
Three months previously she had
been found to be anemic (hemoglo
bin level 55 g/L), and a smallbowel enema at that time had
shown a defect in the distal ileum.
Her anemia was investigated by
colonoscopy and upper gastrointes
tinal endoscopy. The endoscopic
findings were negative, but colono
scopic and biopsy findings were
inconclusive, suggesting neurofi
broma of the terminal ileum. She
had a known history of neurofi
bromatosis. However, the gross en
doscopic appearance of the lesion
suggested adenocarcinoma of the
ileocecal region. At laparotomy
there was extensive mesenteric ade
nopathy with a tumour involving
the terminal ileum and ileocecal
region. This gave the impression of
a malignant lesion, and a right
hemicolectomy with primary anas
tomosis was performed. Her postop
erative course was uncomplicated,
and she was discharged from hospi
tal 10 days after operation.
Pathological findings. On open
ing the small bowel, a spherical

GASTROINTESTINAL INFLAMMATORY FIBROID POLYPS

pedunculated polyp, 1 cm in diame
ter, was seen on the ileocecal valve,
which also had a thickened wall of
up to 1 cm. Many smaller mucosal
polyps were noted in the terminal
ileum (Fig. 1). These varied from
sessile, umbilicated, pale protru
sions with maroon central coloura
tion to pedunculated polyps, the
largest of which was 2 cm long
with a 0.8-cm long stalk. The cecal
mucosa was pale and smooth. A
single diverticulum was identified.
The cut surface of the polyps re
vealed a pale firm surface with a
fine vascular core. In the attached
mesenteric fat, many pale firm
lymph nodes were present, the larg
est one measuring 1.5 cm in diame
ter.
Microscopic examination of the
mucosal polyps showed that some
had surface ulceration and that they
were largely composed of active
proliferative fibrocytic inflammatory
granulation tissue with many eosin
ophilic leukocytes, lymphocytes and
plasma cells (Fig. 2). The small
lesions appeared to arise from the
lamina propria and showed heavy
infiltration of pleocytic cells without
demarcation (Fig. 3). The mucosal
lymphoid aggregates were displaced
downward but were not effaced
(Fig. 2). No neurofibromatous le
sion was noted. Immunocytochemical staining for S-100 protein dem
onstrated increased dendritic reticu
lar cells scattered in the infiltration,
which shared positive staining cha
racteristics with normal nerve
fibres.
Electron microscopic examina
tion confirmed fibrocytic, histiocyt
ic, dendritic and leukocytic cellular
infiltrations. The mesenteric nodes
showed reactive lymphoid hyperpla
sia.
Case 2
This 51-year-old man presented
with a 5-day history of crampy

periumbilical pain and nausea but
no vomiting. Three radiologic views
of the abdomen suggested a partial
small-bowel obstruction. A contrast
barium enema refluxed approxi
mately 1 m of the terminal ileum
and delineated a smooth 5-cm
small-bowel tumour, which almost

completely obstructed the bowel
(Fig. 4).
At laparotomy a tum our of the
small bowel was found almost com
pletely obstructing the lumen of the
bowel approximately 30 cm from
the ileocecal valve. The tum our ap
peared to be intrinsic to the bowel

FIG. 1. Case 1. Portion of small bowel shows multiple areas of thick mucosal folds
and nodular lesions, some of which appeared umbilicated.

FIG. 2. Case 1. Portion of inflammatory fibroid polyp of ileocecal valve, showing
surface ulceration, high vascularity and inflammatory infiltration of mucosa
resulting in downward displacement of ileocecal lymphoid aggregates (hematoxylin-eosin, original magnification X 20).
CJS, VOL. 35. NO. 2, APRIL 1992
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wall with transmural spread. Mesen
teric lymphadenopathy was also
identified. Approximately 40 cm of
small bowel was resected with pri
mary anastomosis. A perfectly
smooth tum our was found arising
from the bowel wall and completely
obstructing the lumen.

The patient was discharged after
an uncomplicated postoperative
course.
Pathological findings. The re
sected small bowel contained a
globular mass measuring 2.8 X 4 X
4 cm. The mass was firm and
smooth. It had a sessile base and

was firmly attached to the bowel
wall (Fig. 5). The cut surface
showed that it was homogeneous,
pale tan and without necrosis or
calcification (Fig. 6). Except for
focal mucosal ulceration on the
small-bowel wall opposing the
mass, the remaining portion of
small bowel was normal.
Microscopic examination revealed
a uniform composition of loosely
arranged, vascularized, fibrillar con
nective tissue rich in stellate fibrocytes and myxoid stroma. Scat
tered inflammatory cells and large
numbers of eosinophils were pres
ent (Fig. 7). The surface of the
mass was ulcerated. The entire
mass was not encapsulated, and the
inner muscular coat of the small
bowel was split by the infiltration,
which did not reach the serosa. The
regional nodes were normal.

Discussion
FIG. 3. Case 1. Broad-based mucosal infiltration of fibroinflammatory components
in terminal ileum correlating with thickened mucosal fold without ulceration. This
appears to be early lesion (hematoxylin-eosin, original magnification X 70).

FIG. 4. Case 2. Reflux of contrast into terminal ileum from postevacuation barium
enema demonstrates dilated small bowel with partially obstructing small-bowel
tumour (arrows).
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Many cases of inflammatory fi
broid polyps of the gastrointestinal
tract have been reported since the
lesion was first described by Vanek.
Although inflammatory fibroids
may occur anywhere in the alimen
tary tract, they are most frequently
seen in the stomach.45 However, as
demonstrated by our two cases, the
lesions may occur in the terminal
ileum and ileocecal areas and cause
anemia or obstructive symptoms.
This type of clinical presentation is
difficult to distinguish from that of
a malignant lesion. When extensive
curative resection is contemplated
for a presumed malignant tumour
involving these uncommon sites it
is therefore important to await the
findings of pathological assessment
instead of relying entirely on clini
cal findings, since the inflammatory
fibroid polyp is a completely benign
entity.
The pathological findings of our
two cases were the same as those

GASTROINTESTINAL INFLAMMATORY FIBROID POLYPS

previously described.4-8 Microscopi
cally the inflammatory fibroid pol
yps are characterized by vascular
and fibrocytic proliferation and a
polymorphic inflammatory re
sponse, usually dominated by eosi
nophils.4-6"9 Using immunocytochemistry for the first time for this
type of lesion, Johnstone and Morson9 pointed out that inflammatory
fibroid polyps are localized, tumour
like but self-limiting proliferations
of a histiocytic nature. Because of
the distinct histologic entity of in
flammatory fibroid polyps, the le
sions should be distinguished from
other inflammatory polyps and from
other benign soft-tissue tumours
such as Von Recklinghausen’s dis
ease and neurofibromatosis. The
multiplicity of inflammatory fibroid
polyps as illustrated in our case 1,
and the unusual involvement of the
small bowel as seen in our cases has
been recognized previously.6 The
ulcerated nature of some of the
lesions in our patient 1 probably
explains the clinical presentation of
anemia from gastrointestinal he
morrhage. The lesion is considered
benign, even in those polyps report
ed to demonstrate hypercellularity,
necrosis and features of focal sarco
matoid changes. Such patients have
survived from 6 to 17 years postoperatively without evidence of persis
tent or recurrent disease.7 The
cause and histogenesis of the lesion
have remained obscure since the
original description. The immunocytochemical and electron mi
croscopic findings reported by
Shimer and Helwig8 concur with
ours and do not support a neural
origin for these tumours.
Our two cases, therefore, demon
strate that inflammatory fibroid pol
yps may present in unusual loca
tions in the gastrointestinal tract,
and the clinical features may be
indistinguishable from those of a
malignant lesion. Histologic assess
ment is therefore required to con

firm the benign nature of this le
sion.

1949; 25: 397-411
2. Helwic EB, R anier B: Inflammatory fi

broid polyps of stomach. Am J Pathol
1952; 28: 535-536
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Osteoblastoma: Experience
With 23 Patients
C.P. Beauchamp, MD, FRCSC;* C.P. Duncan, MD, ChB, FRCSC;t
A.K. Dzus, MD, FRCSC;$ K.S. Morton, MD, CM, FRCSC§
A retrospective review of 23 patients with osteoblastoma was undertaken in an
attempt to answer questions concerning the aggressiveness and potential
malignancy of this tumour. Demographic information confirmed that recorded in the
literature. There was no suggestion of malignant potential, but, significantly, one
tumour persisted, with local recurrence after 11 operations over a period of 27
years. A second tumour, a spinal lesion, occurred (still in a benign form) after a
symptom-free period of 17 years. Recognition of aggressive features clinically,
radiologically and histologically suggests the need for more aggressive surgical
treatment, and late recurrence indicates the need for a more guarded prognosis and
longer follow-up.

Une etude retrospective de 23 patients souffrant d’osteoblastome a ete entreprise
afin de repondre a certaines questions concernant l’agressivite et le potentiel malin
de cette tumeur. Les renseignements demographiques ont confirme l’information
retrouvee dans la litterature. On n’a constate aucun potentiel malin mais, fait
important, une tumeur a persiste avec recidive locale apres 11 operations pratiquees
sur une periode de 27 ans. Une seconde tumeur, une lesion spinale, est apparue
(toujours sous forme benigne) apres une periode exempte de symptomes de 17 ans.
La reconnaissance ciinique, radiologique et histologique de caracteristiques d'agressivite suggere la necessite d’un traitement chirurgical plus agressif et les recidives
tardives indiquent la necessite d'un pronostic plus prudent et d’une surveillance
plus prolongee.

rom its beginning in 19321 and
its naming in 19562-3 osteoblas
toma has remained a controversial
entity. Its relationship to osteoid
osteoma is still debated.4-11 The
existence of a malignant form of
this tumour has been reported12 and

F

denied,1344 and transformation of
benign lesions into malignant osteo
blastoma has been discussed at
length.1015'17 Sung and Liu, in
1979,9 asked “Can osteoid osteoma
become osteoblastoma?”, a question
possibly answered in the negative
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by Pieterse and colleagues18 in
1983 and by Morton, Quenville and
Beauchamp19 in 1989. Aggressive
osteoblastomas were described as
early as 1979,20 and later by Tonai
and colleagues14 and, more thor
oughly, by Dorfman and Weiss.10
The senior author (K.S.M.) has
recognized this spectrum in earlier
publications,8'19'21 concluding that
the entity osteoblastoma can indeed
be distinguished from osteoid osteo
ma on the one hand and low-grade
osteogenic sarcoma on the other,
that malignant osteoblastic lesions
are best described as osteogenic
sarcoma (low or high grade) and
that so-called transformations (from
osteoid osteoma to osteoblastoma
or osteoblastoma to osteogenic sar
coma) more likely represent initial
misinterpretation of the clinical, im
aging and histopathological data.
With this background, we exam
ined 23 cases registered in the
University of British Columbia Bone
Tumour Registry from 1957 to
1990 and present the results of this
review. We recognize that the small
number of cases managed over a
relatively long period by a large
number of surgeons treating lesions
widely distributed in the skeleton
cannot produce meaningful statis
tics. Our purpose was only to exam
ine each case in the hope of detect
ing any outstanding feature of the
lesion that might provide answers
to the questions posed previously,
assist in the diagnosis and manage
ment of the tumour and possibly
add to our knowledge of its progno
sis.
CJS, VOL. 35, NO. 2, A P R IL 1992
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Patients and Methods
For inclusion in this series all
nonmalignant osteoid or woven
bone-forming (as opposed to lamel
lar bone) tumours arising in bone
and of a size greater than 1.4 cm
were considered.22 Thus, osteomas
and the related lesion osteoid osteo
ma were arbitrarily excluded. We
adhered to strict histologic criteria
and proof of metastasis to exclude
truly malignant lesions but accepted
those lesions exhibiting aggressive
ness and local recurrence. Twentythree patient records were available
for review in the form of bone
tumour registry or hospital files,
original or photographed radio
graphs and histologic slides.

Findings and Discussion
Demography

Demographic information was si
milar to that of larger reported
series,22'23 with the age of patients
ranging from 15 months to 52
years at the time of diagnosis.
Twenty-one of the 23 patients were
30 years of age or younger, and 14
were in their second decade; 14
were male and 9 female. The site of
origin was widely distributed, sug
gesting that the lesion could be
expected to occur in any bone.
Notably, six were in the spine and
four in the skull. Other bones in
volved included the os calcis, patel
la, metacarpal, talus, scapula and
long bones.
Symptoms and Signs

Symptoms and signs were not
acute, and the history tended to be
long. Pain was the usual presenting
complaint, occasionally mimicking
that expected of osteoid osteoma.
In spinal lesions, scoliosis and neu
rologic abnormalities were encoun
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tered, and in two orbital lesions
proptosis was noted.
Radiologic Appearance

The radiologic appearances could
not be described as characteristic,
an observation possibly explained
by the fact that the tumour is not
common (less than 1% of primary
bone tumours24), that it occurs in
widely varying sites and is frequent
ly quite small (1.5 to 5.0 cm in
dimension). However, as long ago
as 1960, Pochaczevsky, Yen and
Sherman25 concluded that its ap
pearance might be “fairly character
istic” and recorded their radiologic
differential diagnosis, which ap
pears valid today and is consistent
with observations in our 23 pa
tients. We agree, further, that, in a
patient under 30 years of age with a
lytic lesion in bone, perhaps with
reactive sclerosis, suggesting some
degree of aggressiveness and occur
ring in the vertebral posterior ele
ments, osteoblastoma should be
considered a diagnostic possibility.
Osteoblastoma by definition is larg
er than osteoid osteoma. This tu
mour can destroy overlying cortex
and protrude into the soft tissues,
usually with a delicate shell of reac
tive bone that mimics the blown-out
expanded appearance of aneurysmal
bone cyst (Fig. 1).
We did not obtain sufficient in
formation to comment on radionu
clide or special imaging studies, but
one recent patient illustrates the
expected appearance on technetium
bone scanning (Fig. 2) and comput
ed tomography (Fig. 3). Pathologic
fracture was not encountered in this
series, nor has it been reported as a
notable feature in others.23'24'26'27

which the predominant cell has be
nign characteristics and is produc
ing an osteoid or woven bone ma
trix with or without calcification.
Clinically and histologically aggres
sive tumours were not excluded.
One of these has already been re
ported in detail;19 a second is noted
in Figs. 1 to 3. These two patients
also illustrated, radiologically and
pathologically, an aneurysmal ap
pearance, a feature noted by oth-

FIG. 1. Shoulder of 16-year-old boy
with osteoblastoma in neck of scapula.
Initial radiographs demonstrated deli
cate “blown-out” shell of reactive
bone, possibly indicating more aggres
sive behaviour.

Diagnosis

Inevitably the final diagnosis ac
cepted was histopathologically
based — a primary bone tumour in

FIG. 2. Technetium bone scan of le
sion shown in Fig. 1. Note intense
uptake in and around glenoid lesion.

OSTEOBLASTOMA

ers.14'27 Overlap in the microscopic
appearance of osteoid osteoma was
acknowledged so that occasionally
the arbitrary size differentiation was
used.
Treatment

In the 34 years encompassed by
this review, treatment has evolved
slowly but significantly. As a benign
lesion, the tumour tissue has been
removed as completely as possible
(e.g., by intralesional curettage or
partial excision) without unduly
damaging structures (neural, vascu
lar), and the resulting defect has
been encouraged to heal by the
addition of autologous bone. How
ever, over the years a philosophy of
wider, more thorough, local exci
sion has been applied and made
possible by improved surgical tech
niques. We have not used chemo
therapy, but we resorted to radio
therapy for one unusually persistent

lesion,19 and in one recent patient
with late recurrence, radiotherapy
was offered but declined. This girl
presented at the age of 17 years
with mid-back pain and mild neuro
logic abnormalities consistent with
the lytic lesion noted radiologically
in her ninth thoracic vertebra.
Treatment by intralesional excision
of the extradural mass established
the diagnosis as osteoblastoma and
reversed the neurologic abnormali
ties. No further treatment was car
ried out and she functioned fully
free of symptoms for 17 years until
May 1989, when she returned with
the same symptoms and signs, and
a recurrence of the histologically
benign osteoblastoma involving the
ninth thoracic vertebra. Again in
tralesional excision confirmed the
local recurrence and relieved her
symptoms. On this occasion postsurgical radiotherapy was offered
(though perhaps unenthusiastically)
but was declined.

FIG. 3. Computed tomography of osteoblastoma illustrated in Figs. 1 and 2.
Destructive expansion extends into coracoid process, mimicking appearance of
aneurysmal bone cyst.

In a series such as this, with only
23 patients treated over a period of
34 years by 17 different surgeons
of at least two disciplines, no mean
ingful statistical information can be
expected, even with “adequate” fol
low-up. The benign nature of the
disease is suggested by the appar
ently successful treatment by in
tralesional curettage, with or with
out added autologous bone, in 21
patients. However, of far greater
significance is the 30-year persis
tence in the patient reported ear
lier19 and the recurrence after 17
years in the patient referred to
above. The first patient, with an
aggressive osteoblastoma arising in
a metacarpal, had persistent disease
with local recurrence and extension
after 11 operative procedures in 27
years. The second patient, with a
vertebral lesion, had a quiescent
period following intralesional exci
sion and local recurrence of benign
disease 17 years afterward. Experi
ence with these two patients has led
us to respect this benign tumour,
particularly in its histologically
identifiable aggressive form and in
difficult anatomical sites, such as
the spine. We now recommend,
when possible, a surgical approach
similar to that carried out with
giant cell tumours of bone — thor
ough curettage using a high-speed
burr with attempted chemical or
thermal “sterilization” of the cu
retted bed and autologous bone
grafting when appropriate. Meticu
lous excision of spinal lesions, spar
ing neural structures is recommend
ed as primary treatment. We have
not recommended additional radio
therapy for these generally young
patients but have used it in the one
older patient who had numerous
local recurrences.

Discussion and Conclusions
We are satisfied that osteoblasCJS, VOL. 35, NO. 2, APRIL 1992

201

BEAUCHAMP ET AL

toma exists as a definable entity,
though it is sometimes necessary to
resort to the arbitrary size limits to
separate it from the closely related
osteoid osteoma. Osteoblastoma can
mimic aneurysmal bone cyst, radiologically, grossly at operation and
histologically, but careful identifica
tion of the tumour cell and its
ability to produce osteoid will avoid
this diagnostic error.
In our series we documented at
least one19 and possibly two cases
(Figs. 1 to 3) of aggressive behavi
our of an osteoblastoma. Such be
haviour was recognized in 1979 by
Revell and Sholtz20 and fully de
scribed in 1984 by Dorfman and
Weiss.10
On the question of malignancy or
malignant transformation, we tend
to side with Bertoni and associ
ates,13 Tonai and colleagues14 and
Dorfman and Weiss.10 If malignancy
is identified histologically and the
tumour cells can produce osteoid,
and, particularly, if metastases can
be demonstrated, then we prefer to
call that tumour an osteogenic sar
coma. We also prefer the view that
so-called malignant transformation
of an osteoblastoma, implied by
Mayer15 and Merryweather and col
leagues,17 represents underdiagno
sis in the first instance (i.e., the
tumour was malignant from the
beginning).
To evaluate the incidence of local
recurrence, our follow-up informa
tion is insufficient for statistical
analysis. However, our experience
in the patient who had a recurrence
after 17 years is, in our opinion, of
considerable significance. When the
histologic appearance of the lesion
at first presentation was compared
with its appearance 17 years later
no change in appearance or inter
pretation could be found; in neither
instance could the tumour be de
scribed as malignant or even ag
gressive. Therefore we must con
clude that, even with a fully benign
202
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appearance, osteoblastoma treated
by intralesional excision can lie clin
ically dormant only to recur many
years later. Of interest is a similar
case with recurrence after 9 years,
referred to by a number of au
thors.28' 30 Clearly this information
has significance in our approach to
treatment, consideration of ade
quate follow-up and in evaluation of
follow-up reports.

13. B ertoni F, Unni KK, McL eod RA et al:
Osteosarcom a resem bling osteoblas
tom a. Cancer 1985; 55: 4 1 6 -4 2 6
14. T onai M, Campbell CJ, Ahn GH et al:

15.
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17.

References
1. J affe HL, Mayer L: An osteoblastic
osteoid tissue-forming tumor of a meta
carpal bone. AMA Arch Surg 1932; 24:
550-564
2. J affe HL: Benign osteoblastoma. B u ll
Hosp Joint Dis 1956; 17: 141-151
3. L ichtenstein L: Benign osteoblastoma.
A category of osteoid and bone forming
tumor other than classical osteoid osteo
ma which may be mistaken for giant cell
tumor or osteogenic sarcoma. Cancer
1956; 9: 1044-1052
4. Dahlin DC, J ohnson EW: Giant osteoid
osteoma. J Bone Joint Surg [Am] 1954;
36: 559-572
5. L ichtenstein L, S awyer WR: Benign
osteoblastoma. Further observations
and report of twenty additional cases. J
Bone Joint Surg [Am] 1964; 46: 755765
6. S chajowicz F, Lemos C: Osteoid osteo
ma. Closely related entities of osteoblas
tic derivation. Acta Orthop Scand 1970;
41: 272-291
7. D e S ouza Dias L, F rost HM: Osteoid
osteoma-osteoblastoma. Cancer 1974;
33: 1075-1081
8. Morton KS, Vassar PS, K nickerbocker
WJ: Osteoid osteoma and osteoblas
toma: reclassification of 43 cases using
Schajowicz’s classification. Can J Surg
1975; 18: 148-152
9. S unc HW, L iu C: Can osteoid osteoma
become osteoblastoma? A case report.
Arch Orthop Trauma Surg 1979; 95:
217-219
10. Dorfman HD, W eiss SW: Borderline
osteoblastic tumors: problems in the
differential diagnosis of aggressive os
teoblastoma and low-grade osteosar
coma. Semin Diagn Pathol 1984; 1:
215-234
11. H ealey JHN, Ghelman B: Osteoid osteo
ma and osteoblastoma: current concepts
and recent advances. Clin Orthop 1986;
204: 76-85
12. S chajowicz F, L emos C: Malignant os
teoblastoma. J Bone Joint Surg [Br]
1976; 58: 202-211

18.

19.

20.

21.

22.

23.

Osteoblastoma: classification and report
of 16 patients. Clin Orthop 1982; 167:
1441-1445
M ayer L: Malignant degeneration of
so-called benign osteoblastoma. Bull
Hosp Joint Dis 1967; 28: 4-13
Seki T, F ukuda P, Issii Y et al: Malig
nant transformation of benign osteoblas
toma. J Bone Joint Surg [Am] 1975; 57:
424-426
Merryweather R, Middlemis JH, S anerkin NG et al: Malignant transformation
of osteoblastoma. J Bone Joint Surg [Br]
1980; 62: 381-384
P ieterse AS, Vernon-Roberts B, P ater
son DC et al: Osteoid osteoma trans
forming to aggressive (low-grade malig
nant) osteoblastoma: a case report and
literature review. Histopathology 1983;
7: 789-800
Morton KS, Quenville NF, Beauchamp
CP: Aggressive osteoblastoma. A case
previously reported as a recurrent oste
oid osteoma. J Bone Joint Surg [Br]
1989; 71: 428-431
Revell PA, S choltz CL: Aggressive
osteoblastoma. J Pathol 1979; 127:
195-198
Morton KS, Bartlett LH: Benign os
teoblastic change resembling osteoid os
teoma. Three cases with unusual radio
logical features. J Bone Joint Surg [Br]
1966; 48: 478-484
McL eod RA, Dahlin DC, B eabout JW:
The spectrum of osteoblastoma. Am J
Roentgenol 1976; 126: 321-335
M irra JM, R icci P, Gold RN: Bone
Tumours: Clinical Radiologic and Patho
logic Correlations, Lea & Febiger, Phila

delphia, 1989:389-430
24. Dahlin DC: Bone Tumors: General As
pects and Data on 6,221 Cases, 3rd ed,

CC Thomas, Springfield, 111, 1978: 8698
25. P ochaczevsky R, Y en YM, S herman RS:
The roentgen appearance of benign os
teoblastoma. Radiology 1960; 75: 429437
26. S chajowicz F: Tumours and Tumour
like Lesions o f Bone and Joints, Springer-Verlag, New York, 1981: 47-62
27. E nnekinc WF: Musculoskeletal Tumour
Surgery, Churchill Livingstone, New

York, 1983: 1043-1053
28. Marsh BW, Bonficlio M, B rady LP et
al: Benign osteoblastoma: range of man
ifestations. J Bone Joint Surg [Am]
1975; 57: 1-9
29. J ackson JR, Bell MEA: Spurious “ be
nign osteoblastom a.” A case report. J
Bone Joint Surg [Am] 1977; 59: 3 9 7 -

400
30.

Jackson RP: Recurrent osteoblastoma: a
review. Clin Orthop 1978; 131: 229232

ORIGINAL ARTICLES

Intramuscular Triceps Rupture
Shawn W. O’Driscoll, MD, PhD, FRCSC
A 25-year-old man who had a complete intramuscular rupture of the long head of
the triceps was treated nonoperatively and followed up prospectively for 10 years.
The injury occurred after 4 days of white-water kayaking without any direct blow.
Strengthening was performed by doing push-ups. Nine years of isokinetic testing
revealed that isometric strength was normal, but endurance testing was reduced by
5% to 10%.
Ruptures of the muscle belly can occur due to direct trauma or by forced elbow
flexion during triceps contraction. From this and the few case reports available it
appears that nonoperative treatment is effective and recommended for patients who
do not require significant endurance strength in elbow extension. Whether or not
the results can be improved by surgical repair is uncertain.

Un homme de 25 ans qui avait subi une rupture intramusculaire complete de la tete
longue du triceps fut traite sans operation, et reevalue de facon prospective pendant
10 ans. La blessure survint apres 4 jours de kayak en eau vive, sans coup direct. Le
renforcement musculaire fut obtenu par exercices de traction. Neuf annees
d’epeuves isocinetiques ont revele une force isometrique normale mais le test
d’endurance etait diminue de 5 %a 10 %.
Une rupture des muscles du ventre peut survenir a la suite d’un traumatisme ou
par flexion forcee du coude durant la contraction du triceps. De ce cas et des
quelques autres rapports de cas disponibles, il semble qu’un traitement non
chirurgical est effficace et peut etre recommande pour les patients qui n’ont pas
besoin d’une force d’endurance importante pour l’extension du coude. Ce n’est pas
sur que les resultats puissent etre ameliores par reparation chirurgicale.

upture of the triceps tendon is
rare, and rupture of the triceps
muscle belly is even rarer.1' 10 An
extensive review of the literature
revealed only four reported cases of
intramuscular triceps rupture.19"11
Objective and long-term data re
garding treatment and prognosis
are unavailable. The purpose of this
report is to supplement the paucity

R

of literature on this topic. A patient
who suffered a complete rupture of
the muscle belly of the long head of
the triceps was treated nonopera
tively and followed up prospectively
for 10 years. The unique circum
stance that permitted this period of
close observation is that the patient,
an orthopedic surgeon, is the au
thor of the report.

From the Upper Extremity Reconstructive Service, Division o f Orthopedic Surgery, St. Michael’s
Hospital, University o f Toronto, Toronto, Ont.
Accepted for publication Oct. 23, 1990
Reprint requests to: Dr. Shawn W. O'Driscoll, Ste. 800, 55 Queen St. E. Toronto, ON M 5C 1R6

Case Report
At the age of 25 years, the
patient, who was otherwise healthy
and had no previous musculoskele
tal injuries, ruptured the triceps
muscle belly while white-water
kayaking. The rupture occurred
while the patient was performing
maximal effort forward strokes
through heavy rapids at a very high
water level. No unusual paddling
conditions were encountered, and
there was no direct blow to the arm.
In other words, there were no sud
den or forceful passive movements
of the limb, nor did the patient
experience anything that might be
considered a “true injury.” Due to
the level of concentration required,
the patient was not aware of the
rupture as it occurred but became
aware of it upon emerging from the
rapids. He experienced severe pain
in the right (dominant arm) triceps
muscle as well as a defect in the
muscle belly.
Physical examination revealed an
obvious complete rupture of the
long head of the triceps in its
midsubstance. There was a visible
and palpable gap of 2 to 3 cm in the
muscle belly, which was quite deep
(Fig. 1). There was profound weak
ness of extension, partly due to
painful inhibition, such that the
patient could not change the gears
in an automobile with a manual
transmission using the injured ex
tremity.
CIS, VOL. 35, NO. 2, A P R I L 1992
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Management was nonsurgical,
and no specific therapy was recom
mended. The pain resolved during
the first couple of months, and use
of the arm was increased according
to pain tolerance. Once the pain had
disappeared it was evident there
was weakness of extension. This
became less noticeable over the en
suing 6 months. The arm was

strengthened by doing as many con
secutive push-ups as possible, once
daily.
During the next 12 months the
arm felt as strong as the other arm
when doing push-ups, but endur
ance requirements could not be met
when cross-country skiing or
kayaking. Weakness was not obvi
ous in the first few minutes of

exercise, but fatigue quickly set in,
resulting in what was perceived as
significant weakness. This gradual
ly improved over the next 2 years.
An interesting observation was
that during periods of more regular
exercise the endurance seemed to
be much improved and after periods
of no exercise, or less exercise, the
endurance limitation was once
again apparent. The endurance
weakness was associated also with
pain in the lateral and medial heads
of the triceps, which presumably
were being overworked because of
the less functional long head. Dur
ing the next 7 years there was no
subjective impression of isometric
weakness. However, early fatigue
and endurance weakness were no
ticed occasionally following periods
of relative inactivity despite full re
sumption of sports and regular
daily exercise involving 60 push
ups.
Nine years later extension
strength was tested isokinetically.
Isometric strength was equal to
that of the other side, but endur
ance testing revealed a 5% to 10%
decrease compared with that of the
contralateral nondominant extremi
ty, rather than a slight increase as
would be expected in a normal
dominant limb.12
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Discussion
Mechanism o f Injury

FIG. 1. (Top) Posterior view of normal (left) triceps. (Bottom) Posterior view of
affected (right) triceps 10 years after rupture of long head of triceps muscle belly.
Defect has filled in with scar tissue and its contour has rounded off.
204

JCC, VOL. 35, N ° 2, A VRIL 1992

Up until 6 years before this inju
ry occurred the patient had been
paddling at a competitive level, but
he had not kayaked for 3 years.
Consequently there was a marked
disparity between the patient’s
physical condition and technical
skills at this sport, which relies
largely on technique and less on
strength. This is particularly true
for slalom racing for which the
patient was training for 5 days 5
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hours a day during that week. Lack
of appropriate technical skill results
in extreme increases in the require
ment for strength to execute the
involved manoeuvres. This ex
plained the patient’s muscle pain
and ultimately what was interpreted
to be a fatigue failure of the triceps
muscle. Surprisingly the injury
seemed to have occurred during
what would be considered normal
active use of the arm in this sport.
Ruptures of the triceps have been
reported to occur in several anatom
ic regions — tendon (avulsion or
rupture),3' 6-8-13-14 musculotendinous
junction,2-5-13 muscle belly,1-7-911-13
and muscle origin (avulsion).1-13-15
Ruptures of the muscle belly can
occur from direct traum a11 or by
forced elbow flexion during triceps
contraction.1-7-9-13 McMaster13 dem
onstrated that in healthy tissues
subjected to indirect trauma it is
usually not the tendon that rup
tures.
The clinical findings of intramus
cular rupture of the triceps include
severe pain, a tender palpable mass
in the triceps that becomes more
evident during attempted extension,
and sometimes a palpable gap in the
muscle.1-7-9-11
This case represents the first
known example of what was likely a
fatigue rupture of the triceps mus
cle belly. However, it is difficult to
be certain that the mode of failure
was fatigue rather than sudden
flexion during triceps contraction.
The intensity of concentration re
quired for the activity during which
the rupture occurred was so great
that a sudden excessive force might
have been experienced and not ap
preciated. The technique used for
white-water kayak paddling in
volves primarily elbow extension
rather than elbow flexion. This is
accomplished by placing one blade
of the paddle in the water and, with
the elbow on that side remaining
extended, forcefully extending the

contralateral elbow and rotating the
torso fully forward so that the con
tralateral limb is pushing forward
on the end of the paddle out of the
water (Fig. 2). Thus the hand on
the end of the paddle that is in the
water acts as a fulcrum. At the end
of the stroke the blade in the water
is pulled back only to the level of
the body and not beyond. This
explains why injuries in this sport
result in damage to the extensor
muscles of the elbow rather than to
the flexor muscles.
This case report contributes to
our understanding of the possible
causes, treatment and prognosis of
intramuscular rupture of the tri
ceps. As there have been so few
reported cases it is impossible to be
certain of these aspects. There were
no direct blows, and the mode of
failure was definitely through ten
sile failure of the muscle. It was due
to repeated concentrated use and
overuse superimposed on a premorbid state of relative inactivity.
Little is known regarding the
prognosis for treated or untreated
triceps muscle ruptures. Penhallow11 repaired the triceps in a

35-year-old longshoreman but pro
vided only 1 month of follow-up.
Montgomery7 reported the case of a
20-year-old man whose triceps rup
ture was treated by surgical repair,
but follow-up was limited to 2
months. Post9 described a 48-yearold woman who was asymptomatic
except for slight loss of extension
power 2 years after nonsurgical
treatment. Aso and Torisu1 reported
a 36-year-old woman who had a
satisfactory result 19 months after
nonoperative treatment. The patient
in this report noticed no loss of
isometric strength in the affected
arm 10 years after injury without
treatment, but did notice slight loss
of endurance following periods of
relative inactivity. This was con
firmed by isokinetic strength test
ing. This finding is compatible with
that of a recent report16 that indi
cated greater sensitivity of endur
ance testing by isokinetic tech
niques than by isometric techniques
for elbow strength.
These collective data suggest
that nonoperative treatment can be
recommended for patients who do
not require significant endurance

FIG. 2. Paddling stroke in kayaking requires primarily elbow extension strength
rather than flexion.
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DIFLUCAN
(fluconazole/pfizer)

AN OPPORTUNISTIC WAY
TO TREAT FUNGAL INFECTION
PRODUCT INFORMATION
NAME OF DRUG
DIFLUCAN TABLETS
DIFLUCAN INTRAVENOUS INFUSION 2 mg/mL in 0.9% SODIUM CHLORIDE
(fluconazole)
THERAPEUTIC CLASSIFICATION Antifungal
ACTIONS: Fluconazole is a highly selective inhibitor of fungal cytochrome P-450 sterol C-14alpha-demethylation. Mammalian cell demethylation is much less sensitive to fluconazole
inhibition. The subsequent loss of normal sterols correlates with the accumulation of 14-alphamethyl sterols in fungi and may be responsible for the fungistatic activity of fluconazole.
INDICATIONS AND CLINICAL USE: DIFLUCAN (fluconazole) is indicated for the treatment of:
1. Oropharyngeal and esophageal candidiasis. DIFLUCAN is also effective for the treatment of
serious systemic candidal infections, including urinary tract infection, peritonitis, and
pneumonia. 2. Cryptococcal meningitis. 3. Prevention of the recurrence of cryptococcal
meningitis in patients with acquired immunodeficiency syndrome (AIDS).
Specimens for fungal culture and other relevant laboratory studies (serology, histopathology)
should be obtained prior to therapy to isolate and identify causative organisms. Therapy may
be instituted before the results of the cultures and other laboratory studies are known; however,
once these results become available, anti-infective therapy should be adjusted accordingly.
CONTRAINDICATIONS: DIFLUCAN (fluconazole) is contraindicated in patients who have shown
hypersensitivity to fluconazole, to any of its excipients, or other azole related compounds.
WARNINGS: Patients with baseline abnormal liver function tests and those who develop
abnormal liver function tests during DIFLUCAN (fluconazole) therapy should be monitored for
the development of more severe hepatic injury. Although serious hepatic reactions have been
rare and the causal association with DIFLUCAN uncertain, if clinical signs and symptoms
consistent with liver disease develop that may be attributable to fluconazole, DIFLUCAN
should be discontinued, (see ADVERSE REACTIONS).
Immunocompromised patients, especially those with AIDS, who develop rashes during
treatment with DIFLUCAN should be monitored closely and the drug discontinued if lesions
progress, (see ADVERSE REACTIONS).
In rare cases, as with other azoles, anaphylaxis has been reported.
PRECAUTIONS
Use in Pregnancy: There are no adequate and well-controlled studies in pregnant women.
DIFLUCAN (fluconazole) is not recommended in pregnant women unless the potential benefit
outweighs the potential risk to mother and fetus.
Use in Nursing Mothers: Fluconazole is secreted in human breast milk at concentrations
similar to plasma, hence its use in nursing mothers is not recommended.
Use in Children: The clinical use of DIFLUCAN in children below 13 years of age has not been
established.
Use in Elderly: DIFLUCAN was well tolerated by patients aged 65 years and over.
Drug Interactions
Cimetidine and Antacids Absorption of orally administered DIFLUCAN does not appear to be
affected by gastric pH. Cimetidine did not affect oral bioavailability of fluconazole to a
clinically m eaningful extent; reduction of about 13% in AIJC (area under the plasma
concentration-time curve) and 21% in peak plasma concentration (Cmax) was observed.
Administration of magnesium/aluminum hydroxide formulation, just prior to DIFLUCAN
administration had no clinically relevant effects on the absorption or elimination of fluconazole
in normal volunteers.
Cyclosporine DIFLUCAN administered at 100 mg daily dose does not affect cyclosporine
pharmacokinetic levels in patients with bone marrow transplants. There have been several
reports in the literature associating concomitant administration of high doses of DIFLUCAN with
an increase in cyclosporine plasma concentrations in renal transplant patients with or without
impaired renal function. Therefore, when DIFLUCAN and cyclosporine are coadministered,
cyclosporine levels should be monitored and cyclosporine dose accordingly adjusted.
Warfarin DIFLUCAN increased the prothrombin time after warfarin administration in healthy
males. Though the magnitude of change was small (12%), careful monitoring of prothrombin
time in patients receiving coumarin-type anticoagulants is recommended.
Hydrochlorothiazide Concomitant administration of multiple doses of DIFLUCAN and
hydrochlorothiazide was associated with increases in fluconazole plasma levels which were
not considered to be clinically significant.
Sulfonylurea-Oral Hypoglycemics The potential for hypoglycemia due to decreased elimination
and increased blood levels of sulfonylurea oral hypoglycemics (glibenclamide, glipizide and
tolbutamide) has been demonstrated with concomitant administration of DIFLUCAN. Blood
glucose levels should be monitored closely and the dose of the hypoglycemic agent should be
adjusted as necessary.
Phenytoin Concomitant administration of DIFLUCAN at steady state and phenytoin at steady
state resulted in an increase of up to 75% in AUC of phenytoin. Since phenytoin has a low
therapeutic ratio, phenytoin plasma levels should be closely monitored when DIFLUCAN is
coadministered. The dose of phenytoin should be adjusted to maintain therapeutic levels.
Rifampin Concomitant administration of DIFLUCAN and rifampin resulted in a 25% decrease
in the AUC and a 20% shorter half-life of fluconazole. The dosage of fluconazole should be
increased by 25% when fluconazole is administered with rifampin.
Zidovudine (AZT) and/or Pentamidine Isethionate Though no formal interaction studies have
been completed for DIFLUCAN and concomitant zidovudine and/or pentamidine isethionate,
these drugs have been used together in patients with AIDS with no clinically important
difference in the pattern of adverse events.
Theophylline Concomitant administration of DIFLUCAN and theophylline resulted in an 18%
decrease in the mean plasma clearance of theophylline. Patients who are receiving high doses
of theophylline or who are otherwise at increased risk for theophylline toxicity should be
observed for signs of theophylline toxicity while receiving fluconazole, and therapy modified
appropriately if signs of toxicity develop.
Oral Contraceptives In pharmacodynamic studies, single and multiple 50 mg oral doses of
DIFLUCAN had no clinically significant effects on ethinyl estradiol or levonorgestrel
pharmacokinetics in healthy women taking oral contraceptives. However, at 200 mg daily, the
AUCs of ethinyl estradiol and levonorgestrel were increased, 40% and 24%, respectively.

Drug/Drug Interaction Interaction studies with other medications have not been conducted, but
such interactions may occur.
Drug/Laboratory Test Interactions: None known.
ADVERSE REACTIONS: Sixteen percent of over 4000 patients treated with DIFLUCAN
(fluconazole) in clinical trials of 7 days or more experienced adverse events.
Treatment was discontinued in 1.5% of patients due to adverse clinical events and in 1.3% of
patients due to laboratory test abnormalities.
Adverse clinical events were reported more frequently in HIV infected patients (21%) than in
non-HIV infected patients (13%). However, the patterns of adverse events in HIV infected and
non-HIV infected patients were similar. The proportions of patients discontinuing therapy due
to clinical adverse events were similar in the two groups (1.5%). The two most serious
adverse clinical events noted during clinical trials with DIFLUCAN were: 1. Exfoliative skin
disorders 2. Hepatic necrosis Because most of these patients had serious underlying disease
(predominantly AIDS or malignancy) and were receiving multiple concomitant medications,
including many known to be hepatotoxic or associated with exfoliative skin disorders, the causal
association of these reactions with fluconazole is uncertain. Two cases of hepatic necrosis
and one exfoliative skin disorder (Stevens-Johnson syndrome) were associated with a fatal
outcome.
The following treatment-related clinical adverse events occurred at an incidence of 1% or
greater in 4,048 patients receiving fluconazole for 7 or more days in clinical trials: Nausea 3.7%
Headache 1.9% Skin Rash 1.8% Vomiting 1.7% Abdominal Pain 1.7% Diarrhea 1.5% Other
treatment-related clinical adverse events which occurred less commonly (0.2 to <1%) are
presented by organ system below:
Skin and Appendages: pruritus.
Musculoskeletal: myalgia.
Central and Peripheral Nervous System: convulsions, dizziness, paresthesia, tremor, vertigo.
Autonomic Nervous System: dry mouth, increased sweating.
Psychiatric: insomnia, somnolence.
Gastrointestinal: anorexia, constipation, dyspepsia, flatulence.
Liver and Biliary System: cholestasis, hepatocellular damage.
Special Senses: taste perversion.
Hematopoietic: anemia.
General: fatigue, malaise, asthenia, fever.
In rare cases, anaphylaxis has been reported.
LABORATORY TEST ABNORMALITIES
Liver Function: Clinically significant increases were observed in the following proportions of
patients: AST (SGOT) 1%, ALT (SGPT) 1.2%, Alkaline Phosphatase 1.2%, Total bilirubin
0.3%. The incidence of elevated serum transaminases was independent of age or route (p.o.
or i.v.) of administration but was greater in patients taking DIFLUCAN concomitantly with one
or more of the following medications: rifampin, phenytoin, isoniazid, valproic acid, or oral
hypoglycemic agents. Clinically significant increases also were more frequent in patients
who: 1) had SGOT or SGPT elevations greater than three times the upper limit of normal
(>3xULN) at the time of entering the study (baseline), 2) had a diagnosis of hepatitis at any
time during the study and, 3) were identified as alcohol abusers. The overall rate of serum
transaminase elevations of more than 8 times the upper limit of normal was approximately
1% in patients treated with DIFLUCAN during clinical trials. (See table below)
Percent
Percent
Number
Number*
of
Percent
Drugof
Percent
DrugLab
Abnormal
Related
Parameter
Patients
Patients
Abnormal
Related
Baseline <3xULN
Baseline > 3xULN
9.4
3.8
3007
4.2
0.8
SGOT
53
2874
4.8
1.0
SGPT
3.1
0.0
65
Non-Hepatitis Patients
Hepatitis Patients
2900
3.9
0.8
SGOT
160
10.6
1.9
11.4
2.1
2799
4.4
1.0
SGPT
140
Non-Alcohol Abuse
Alcohol Abuse
3018
4.2
0.9
SGOT
42
9.5
2.4
4.7
1.0
2899
SGPT
40
10.0
2.5
Never Received
Received
I.V. Fluconazole
I.V. Fluconazole
4.2
0.9
144
5.6
1.4
2916
SGOT
2800
4.7
1.0
SGPT
139
5.0
0.7
< 65 Years Old
2.65 Years Old
2783
4.3
0.9
SGOT
277
4.3
1.1
4.8
1.0
2681
SGPT
258
3.9
1.2
'Note: Only patients who had measurements at baseline and during therapy were included.
Renal Function: Clinically significant increases were observed in the following proportions of
patients: blood urea nitrogen (0.4%) and creatinine (0.3%).
Hematological Function: Clinically meaningful deviations from baseline in hematologic
values which were possibly related to DIFLUCAN were observed in the following proportions
of patients: hemoglobin (0.5%), white blood cell count (0.5%), and total platelet count
( 0 . 6% ) .
SYMPTOMS AND TREATMENT OF OVERDOSAGE
Symptoms: There has been one reported case of overdosage with DIFLUCAN. A 42-year-old
patient infected with human immunodeficiency virus developed hallucinations and exhibited
paranoid behavior after reportedly ingesting 8200 mg of DIFLUCAN. The patient was admitted
to the hospital, and his condition resolved within 48 hours.
Treatment: In the event of overdosage, symptomatic treatment (with supportive measures
and gastric lavage if necessary) may be adequate. Fluconazole is largely excreted in urine. A
three hour hemodialysis session decreases plasma levels by approximately 50%.
Mice and rats receiving very high doses of fluconazole, whether orally or intravenously,
displayed a variety of nonspecific, agonal signs such as decreased activity, ataxia, shallow
respiration, ptosis, lacrimation, salivation, urinary incontinence and cyanosis. Death was
sometimes preceded by clonic convulsions.
DOSAGE AND ADMINISTRATION
Oral and Intravenous Treatment: Fluconazole is well absorbed and excreted predominantly
unchanged in urine following oral administration in man. The oral bioavailability is essentially
complete (greater than 90%). and is independent of dose. Peak plasma concentrations after
oral administration are attained rapidly, usually within 2 hours of dosing. Since oral absorption
is rapid and almost complete, the daily dose of DIFLUCAN (fluconazole) is the same lor
oral and intravenous administration. The term inal plasma elimination half-life is
approximately 30 hours (range 20-50 hours).
The daily dose of DIFLUCAN and the route of administration should be based on the infecting
organism, the patient's condition and the response to therapy. Treatment should be
continued until clinical parameters and laboratory tests indicate that an active fungal infection
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strength in elbow extension.
Whether or not the results can be
improved by surgical repair is un
certain.
I thank Mr. T.D. Cahalan, RPT, of the
Biomechanics Laboratory, Mayo Clinic,
Rochester, Minn., for performing the
Cybex testing.
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DIFLUCAN I.V. for infusion is a sterile solution of fluconazole in saline at a concentration of
2 mg/mL which is made iso-osmotic with sodium chloride 9 mg/mL.
Directions tor Use: Inspect visually for particulate matter or discoloration prior to
administration. Do not use if cloudiness or precipitation is evident.
Reject the contents as unsterile if the metal seal is broken. NOT INTENDED FOR MULTIDOSE
USE: discard any portion not used when the seal is first broken.
Connect an intravenous giving set to the bottle of DIFLUCAN (fluconazole) intravenous
solution and also insert a venting set through the bung. Infuse DIFLUCAN intravenous
solution at a maximum rate of 200 mg/hour. Flush DIFLUCAN intravenous solution remaining
in the giving set with sterile normal saline.
Because fluconazole is available as a dilute saline solution, in patients requiring sodium or
fluid restriction, consideration should be given to the rate of fluid administration.
Incompatibility: It is recommended that DIFLUCAN I.V. be infused separately.
Compatibility: Administration sets (“giving" sets).
DIFLUCAN I.V. infusion is compatible with (i.e. not susceptible to absorption) sets constructed
of a delivery tube (PVC) luer lock (modified phenylene oxide), flash ball (latex) drip chamber
(polypropylene) and piercing spike (polypropylene).
DOSAGE FORMS
Availability: DIFLUCAN TABLETS are available as pink tablets containing 50 mg, 100 mg.
and 200 mg of fluconazole.
Supplied in bottles (opaque polyethylene) of 50 or 100 tablets.
DIFLUCAN I.V. is available as a sterile aqueous solution for direct infusion. Each mL contains
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Laparoscopic Inguinal Herniorrhaphy
Y-M. Dion, MD, MSc, FACS, FRCSC; J. Morin, MD, FRCSC
Between Mar. 13 and Sept. 16, 1991, the authors performed 10 inguinal
herniorrhaphies laparoscopically. Two patients with a type II hernia (indirect with
dilated internal ring but intact posterior inguinal wall) had laparoscopic
preperitoneal closure of the internal ring with interrupted O-Prolene. Seven patients
had a type IIIA hernia (direct), and one patient had a large type IIIB hernia (indirect
with dilated internal ring and medial encroachment or destruction of transversalis
fascia of Hesselbach triangle). They all underwent laparoscopic preperitoneal
placement of Prolene mesh, which was fixed in place with interrupted 0-Prolene
sutures. All patients recovered promptly, with less pain and minimal limping,
resulting in high patient acceptance of the procedure. There were no complications.
Although no recurrence was noted and the technique appears sound, it is too early
to predict its long-term success. At present, the preperitoneal approach is difficult to
perform because of lack of appropriate instrumentation. The surgeon who plans to
perform such a procedure must be familiar with the anatomy. We suggest that every
potential candidate for laparoscopic inguinal hernia repair should be apprised of the
advantages and disadvantages of this approach. A research consent form should be
read and signed by every patient.

Entre le 13 mars et le 16 septembre 1991, les auteurs ont pratique 10
herniorraphies par voie laparoscopique. Deux patients ayant une hernie de type II
(indirecte, avec dilatation de l’anneau profond mais integrity de la paroi posterieure)
ont eu une fermeture preperitoneale laparoscopique de Tanneau profond, par suture
a points separes de 0-Prolene. Sept patients avaient une hernie de type IIIA (directe)
et un patient, une grosse hernie de type IIIB (indirecte, avec dilatation de Tanneau
profond et empietement interne ou destruction du fascia transverse du triangle de
Hesselbach). Ils subirent tous la pose preperitoneale, par voie laparoscopique, d’une
meche de Prolene maintenue en place par des sutures a points separes de 0-Prolene.
Tous les patients se sont retablis rapidement, eprouvant moins de douleur et une
claudication minimale. II en resulta un haut niveau de satisfaction pour cette
intervention. II n'y eut aucune complication. Bien qu’aucune recidive n’ait ete
observee et que la technique paraisse fiable, il est trop tot pour predire sa reussite a
long terme. A present, l’abord preperitoneal est difficile a realiser a cause d’un
manque d’instrumentation appropriee. Le chirurgien qui prevoit pratiquer une telle
intervention doit etre familier avec l’anatomie. Nous conseillons que tout candidat a
une herniorraphie inguinale laparoscopique soit informe des avantages et
inconvenients de cette approche. Un formulaire de consentement eclaire devrait etre
lu au patient et etre signe par lui.

From the Department o f Surgery, Hopital St-Fran(ois d ’A ssise and Universite Laval, Quebec,
Que.
Accepted for publication Nov. 19, 1991
Reprint requests to: Dr. Y-M. Dion, Department o f Surgery, H op ital St-Franqois dAssise, 10 de
1’Espinay, Quebec, P Q C 1L 3 L 5

ver the past 18 months, inter
est has increased in laparo
scopic inguinal hernia repair. Four
pioneers in this field have described
their techniques.1-4 The results ap
pear gratifying for the patients.
However, long-term follow-up is
lacking, and the value of each of
these techniques will only be known
in 5 to 10 years. Because we have
good experience with the preperito
neal approach to inguinal and femo
ral hernias described by Nyhus and
colleagues56 and because we have
found laparoscopy useful for the
treatment of cholelithiasis,78 choledocholithiasis,9 duodenal ulcer re
sistant to medical therapy and ap
pendicitis, we established a program
to evaluate the value of a laparo
scopic preperitoneal approach to in
guinal hernias. To date, 10 patients
have been treated using this tech
nique.

O

Patients and Methods
Between Mar. 13 and Sept. 16,
1991, 10 patients aged 31 to 61
years (average 44 years) with symp
tomatic inguinal hernias were of
fered laparoscopic inguinal herni
orrhaphy based on the Nyhus pre
peritoneal approach.5610 A research
consent form informed patients
about our technique and about the
conventional methods. Important
points about the technique, such as
uncertain recurrence rate, necessity
to insert a Foley catheter in the
bladder, possibility of mesh repair
C JS, V O L. 35, N O . 2, A P R I L 1992
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and entry into the abdominal cavity,
were stressed. Patients are fol
lowed up every 3 months for 2
years, then every 6 months for
another 8 years.
The technique was individualized
according to the type of hernia. We
adopted the Nyhus classification of
groin hernias:5 type I — pediatric
hernia with a normal internal ring,
type II — indirect hernia with a
dilated internal ring but with an
intact posterior wall of the inguinal
canal (inferior epigastric vessels not
displaced), type III — hernia with
weakness of posterior wall of the
inguinal canal and type IV — recur
rent hernia. Type III hernias were
further divided into three catego
ries: IIIA — direct hernia, IIIB —
indirect hernia with internal ring
dilated, medially encroaching on or
destroying transversalis fascia of
Hesselbach triangle (e.g., massive
scrotal, sliding or pantaloon hernia)
and IIIC — femoral hernia.
Treatment was offered only to
adults. Laparoscopic repairs, ac
cording to the previous classifica
tion, are given in Table I.
Patients with type II hernia were
offered laparoscopic intra-abdomi
nal invagination of the sac and
preperitoneal closure of the dilated
internal ring lateral to the cord.
Patients with type IIIA and IIIB
defects were offered laparoscopic
preperitoneal mesh repair after in
tra-abdominal invagination of the
sac. Type IIIC patients were offered
closure of the defect by reapprox
imation of the structures (iliopubic

.

Table 1 P ro p o s e d L a p a ro s c o p ic T re a tm e n t
o f G roin H e rn ia s

H ernia type
II
IIIA
IIIB
IIIC
IV
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tract to Cooper’s ligament). Type IV
patients were offered a mesh repair.
Technique
After creation of a pneumoperito
neum and insertion of a Foley cath
eter with the patient in the Tren
delenburg position, two 1-cm tro
cars (Karl Storz Gmbh & Co., Tuttlingen, Germany) were inserted, one
at the level of the umbilicus and the
second slightly inferior to the first
and lateral to the midline on the
side opposite the hernia. A third
5-mm subumbilical trocar was intro
duced just lateral to the epigastric
vessels on the side of the hernia and
approximately 2 cm below the um
bilicus.
The peritoneum was incised with
scissors (Karl Storz Gmbh & Co.),
starting medially at the umbilical
ligament, arching over the inguinal
defect and continuing laterally to
the internal inguinal ring. The pre
peritoneal fat was then peeled away
from the transversalis fascia and
conjoined tendon above, and from
Cooper’s ligament and the iliopubic
tract below. The cord was separated
from the surrounding structures,
and the hernial sac was invaginated.
In the case of a type II hernia,
the upper edge of the internal in
guinal ring (transversus abdominis
arch) was approximated using two
or three interrupted stitches of
O-Prolene (Ethicon, Peterborough,
Ont.) on its lower edge (iliopubic
tract), and the peritoneum was
closed with clips.
When mesh was needed, the
same dissection was performed and
a 7-cm X 5-cm piece of Prolene
mesh was used. An incision was
made in the lateral portion of the
mesh to allow inclusion of the cord.
Sutures of O-Prolene were applied
lateral to the cord to unite the
upper and lower edges of the inter
nal ring and the incised portions of

the mesh to recreate a normal inter
nal ring. Interrupted sutures were
applied between the mesh and Coo
per’s ligament below, and the con
joined tendon (and arch of the
transversus abdominis muscle)
above. To complete the repair, a
larger mesh was applied, unsutured,
to the first mesh in a manner
similar to that used by Schultz.3
The peritoneum was closed with
clips.

Results
Two patients with type II indirect
hernias had simple closure of the
internal ring. Seven others with
type IIIA direct hernias had mesh
closure. One patient had a large
indirect hernia (type IIIB) with weak
fascia around the internal ring ori
fice and had a mesh closure (Table
II).

No complications were noted. We
keep patients hospitalized for 2
days after the operation. One pa
tient stayed 3 days in hospital for
personal reasons and another left
earlier with no pain.
All patients were walking with
little pain in their groin and no
limping the morning after the oper
ation. Palpation of the site of the
operation produced almost no dis
comfort for the patient. This is a
considerable difference compared
with the conventional open ap
proach. Patients, on average, took
enteral analgesia 1.5 times and par
enteral analgesics 1.4 times (Table
II). Three patients had had a con
ventional Bassini procedure on the
other side and confirmed that the
laparoscopic procedure was less
painful.
We have had no recurrences, but
as previously mentioned, our fol
low-up period is only 0 to 6 months
and this is obviously too short to
permit any meaningful conclusion
to be drawn.

LAPAROSCOPIC INGUINAL HERNIORRHAPHY

type IIIB) or direct inguinal hernias
(type IIIA). The inlay prosthetic
buttress applied to the posterior
inguinal wall by the preperitoneal
approach will become the standard
method of repair of recurrent groin
hernias.”
It is of particular interest that
although six of our patients were
younger than 42 years old, four of
them had direct hernias. This con
firms that accurate preoperative di
agnosis of the type of inguinal
hernia is not possible. The surgeon
must be prepared to insert and fix a
mesh.
We agree with Lichtenstein15 that
simple invagination of the hernial
sac is as effective as high ligation,
provided the muscle layer is secure
ly closed.
With respect to recurrence rate,
the Nyhus approach stands out be
cause it has a recurrence rate of
1.7%.5 Although Schultz3 reports
excellent short-term results, we are
concerned that he does not apply
stitches to the mesh, which seems
rather small compared with that
suggested by Stoppa.1617 Popp2 fa
vours a technique similar to the one
described by Schultz.3
To date, Gerr’s technique1 can be
used only in patients with small
type II hernias, because he closes
the peritoneal margins with a spe
cial stapling device. Fitzgibbons4
uses the novel approach of placing
a Prolene mesh over the hernial

Discussion
Recent articles by Schultz3 and
Popp2 have focused on the advan
tages of the laparoscopic approach:
pain less severe and of shorter
duration; no muscle incision; ana
tomical and tension-free repair; and
a quick return to work. Patient
acceptance of this procedure is also
high. All of our patients would
choose it again if a hernia devel
oped on the contralateral side.
Disadvantages include entrance
into the abdominal cavity (the sur
geon should be an accomplished
laparoscopist) and use of a mesh.
An infection rate of 2% to 10% has
been reported when mesh is used in
different abdominal locations.11"13
Lichtenstein, Shulman and Amid14
reported an infection rate of 0.03%
when they used a tension-free repair
with Marlex (Bard Canada Inc., Mis
sissauga, Ont.) patches on 7133
patients in nine different institu
tions. This demonstrates that ap
propriate intraoperative care is im
portant to reduce mesh infection.
When the mesh is placed in the
preperitoneal space, bowel obstruc
tion due to adhesion to the mesh is
unlikely. Nyhus, Klein and Rogers6
stated, and we agree, that “the only
setting in which a prosthetic mesh
may be used in the primary repair
of groin hernias is large indirect (in
reality a combined indirect and di
rect) (later classified by Nyhus as

Table II. Patient Data

Age, yr

Hernia
type

Postoperative
stay, d

31
35
41
42
56
46
61
34
41
52

II
IIIA
IIIA
II
IIIA
IIIA
IIIB
IIIA
IIIA
IIIA

1
2
2
2
2
3
2
2
2
2

’ Number of times taken

Analgesia*
Parenteral
1
2
4
1
1
2
1
1
1

0

Enteral

defect and stapling it to the perito
neum around the defect. To avoid
bowel adhesion to the mesh and
possible obstruction or fistula for
mation, he applies Interceed (Ethicon, Peterborough, Ont.) to the
mesh. The follow-up of patients
who underwent these procedures is
not sufficiently long to permit any
valid conclusion.
When performing the preperito
neal procedure, the most important
limiting factors are the technical
difficulties of (a) adhering to the
principles of adequate dissection
and (b) suturing the mesh in place.
We need better instrumentation and
some innovation to complete this
procedure in a time similar to that
for conventional interventions.
Because the inguinal ring is close
to the anterior abdominal wall, this
operation is more difficult than any
other we have performed in the
abdominal cavity by laparoscopy.
We are presently evaluating exter
nal lifting of the abdominal cavity
to visualize the inguinal region bet
ter.
New clip appliers may allow easi
er mesh fixation in the future, but
patients with type II and type IIIC
hernias will still benefit from a few
appropriately placed sutures.
At the present stage of develop
ment of laparoscopic herniorrha
phy, we do not suggest that any of
the techniques be used routinely
unless the patient is informed that
the operation is in the developmen
tal phase and that the long-term
recurrence rate is unknown. A re
search consent form should be read
and signed by all patients.

0
2

0
2
1
4
1
2
2
1
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NEUROSCIENCE CRITICAL CARE:
PATHOPHYSIOLOGY AND PA 
TIENT MANAGEMENT. Sharon Bow
ers Marshall, Lawrence F. Marshall,
Helen R. Vos et al. 459 pp. Illust.
W.B. Saunders Company,
London/
Harcourt Brace Jovanovich, Inc.,
Philadelphia; HBJ-Holt-Saunders Dis
tribution Services, Toronto. 1990.
Price not stated. ISBN 0 -7 2 1 6 2 7 9 0 -0
The evolution of neuroscience critical
care into more specialized and techni
cally sophisticated units has resulted in
a demand for more in-depth knowledge
by those who staff these units. Good
observation and assessment skills are
necessary, and they require a sound
background in neuroanatomy, physiolo
gy and neuropathology.
This volume provides a framework
for the development of this knowledge
and the formation of these skills. The
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book begins with a standard practical
review of neuroanatomy followed by a
well-written unencumbered presentation
of the neurologic assessment. The de
tails of neurophysiology, cerebral me
tabolism, intracranial pressure and the
effects of systemic, metabolic and elec
trolyte disturbances on the nervous sys
tem are detailed in later chapters. Ap
propriately distributed throughout
these chapters are case histories that
illustrate in a more practical fashion the
basic concepts.
A section on neurodiagnostic proce
dures offers an understanding and ap
preciation of the logic behind the vari
ous tests, and their indications, limita
tions and potential for morbidity.
In the chapter on neurologic, neuro
surgical intensive care, the authors ac
quaint the reader with the various phys
iological monitoring systems and the
rational for their use. Included are
illustrations of the equipment and set

up and some comments on trouble
shooting. This is followed by a practical
chapter on complications in the critical
ly ill “ neuro” patient, in which the
more commonly encountered problems
are reviewed. Each item is followed by a
table illustrating the nursing diagnosis
and recommended intervention. At the
end of each chapter is a brief reference
list to assist the reader who wishes
more information or detail.
Directed mainly at nursing staff, this
book should also prove worthwhile to
student and resident physicians rotating
through critical care areas. It is an
excellent ready source of information
for use in neurologic wards and neuro
science critical care areas.
Michael T. Richard, MD, FRCSC
Head
Division of Neurosurgery
Ottawa General Hospital
Ottawa, ON
K1H8L6
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CARDIOTHORACIC SURGERY
St. Paul’s Hospital, Vancouver
The Department of Surgery at St. Paul’s Hospital is
currently seeking a cardiac surgeon to head the Division of
Cardiothoracic Surgery. St. Paul’s Hospital is a 581-bed
UBC affiliated acute care teaching hospital located in
downtown Vancouver. The Cardiac Sciences Program at
St. Paul’s Hospital serves the province of British Colum
bia. Clinical care programs are being enhanced with ex
panded diagnostic capabilities and an increase in open heart
surgery cases to over 700 per annum. Clinical programs
are supported by active research programs at both a basic
and clinical level.
The department is currently seeking an energetic, aca
demically-oriented cardiac surgeon to strengthen the Car
diac Surgery Program and to lead the division’s participa
tion in academic affairs, particularly research. Individuals
will receive the appropriate academic appointment at
the University of British Columbia.
In accordance with Canadian immigration requirements,
priority will be given to qualified Canadian citizens and
permanent residents of Canada.
Please submit a curriculum vitae and the names of three
referees by Apr. 30, 1992, to:
Dr. John MacFarlane
Chairman
Department of Surgery
St. Paul’s Hospital
1081 Burrard Street
Vancouver, BC
V6Z 1Y6

—S92-105

Chairman, Division of Vascular Surgery
Department of Surgery
University of Toronto
A search committee has been struck for the position of
University Chairman of the Division of Vascular Surgery.
This is in accordance with departmental guidelines which
call for a mandatory search at the end of a 10-year term,
in which the incumbent may be a candidate for an addi
tional 5-year term.
The Division of Vascular Surgery plays a major role in the
clinical and academic programs of the Department of Sur
gery and includes 11 faculty members. It participates ful
ly in undergraduate and postgraduate teaching programs
at the University of Toronto. The Chairman is expected to
provide leadership and set a high standard in the areas of
clinical care, teaching and research.
In accordance with Canadian immigration requirements,
this advertisement is directed to Canadian citizens and
permanent residents.
Individuals interested in being considered for this position
should communicate with:
Chairman of the Search Committee
Professor B. Langer
Department of Surgery
University of Toronto
The Banting Institute
100 College Street, Room 311
Toronto, Ontario
M5G 1L5

—S92-104
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CJS is the only Canadian publication exclusively for surgeons. No other Canadian surgical publication reaches over 9000
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Average issue readership of CJS (81%) is among the highest of any medical journal in Canada, the latest readership studies confirm the best and most cost efficient way to reach Canadian surgeons is through the pages of CJS.
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PLASTIC SURGEON/
MEDICAL DIRECTOR
C raniofacial P rogram m e
The Hospital for Sick Children (University of
Toronto), a 520-bed acute care teaching
hospital, is seeking a Plastic Surgeon/Medical
Director for the Craniofacial Programme. The
Division of Plastic Surgery has a long
tradition of excellence in clinical care and
innovative research. The characteristics which
will be considered in applicants include
excellence in patient care, leadership in
teaching, administrative capabilities and
demonstrated achievements which would
foster research within the Division.
The applicant must be certified or eligible for
certification by the Royal College of
Physicians and Surgeons. In accordance with
the immigration requirements, priority will be
given to Canadian citizens and permanent
residents of Canada.
Please reply with curriculum vitae by

May 3 1 ,1 9 9 2 to: Dr. Robert Filler,
Surgeon-in-Chief, Department of Surgery,
The Hospital for Sick Children,
555 University Ave., Toronto, Ontario,
Canada M5G 1X8

Il k p I

the hospital

FOR SICKCHILDREN
—S92-108

SCOTT & WHITE
The Division of Neurological Surgery of
White Clinic and Texas A&M University
of Medicine is seeking a Neurosurgeon
clinicai/faculty position as Director
Division of Neurological Surgery.

Scott &
College
to fill a
of the

Scott & White is located in Temple, Texas,
approximately 60 miles north of Austin and 120
miles south of Dallas/Ft. Worth. Temple is a
family oriented city of 5 0,000 with numerous
nearby lakes and outdoor activities.
Scott & White provides an exceptionally
attractive salary and benefits package to include
4 weeks vacation and 3 weeks C.M.E.
For more information, please call Barry Harper
at 1-800-725-3627 or send curriculum vitae to:
Dennis J. Lynch, M.D.
Chairman, Department of Surgery
Scott & White Clinic, Texas A&M
University College of Medicine
2401 South 31st Street
Temple, TX 76508
—S91-83

University of Alberta
Edmonton

Professor and Chair
Department of Surgery
University of Alberta and
University of Alberta Hospitals
Applications are invited for the position of Professor and Chair,
Department of Surgery, of the Faculty of Medicine at the University of
Alberta and the University of Alberta Hospitals. We are searching for an
outstanding academic surgeon with proven administrative experience'who,
as Chair, will foster excellence in teaching and patient care, while strongly
supporting the development of research in the Department. The University
of Alberta Hospitals is a leader in the introduction of continuous quality
improvement into medical and operational processes and is committed to
related health services research.

Western Memorial is a fully accredited, 359-bed, general hospital
which serves the west coast of Newfoundland. Corner Brook is
a scenic community of 30 000 people and has excellent summer
and winter recreational facilities.

The Department of Surgery has 20 full-time and a large number of parttime staff representing a wide range of subspecialties. Major departmental
strength is located at the University of Alberta Hospitals and the Royal
Alexandra Hospital, Misericordia - Edmonton General (Grey Nuns)
Hospital, Charles Camsell Hospital and Cross Cancer Institute are actively
involved in various programs. The Department conducts surgical teaching
for a medical school of 480 students and has 54 postgraduate surgical
residents in approved training programs. There is significant potential for
further enhancement of academic programs.

Remuneration per current medical association arrangements.
Assistance with travel and accommodation is available.

This appointment will at the rank of full Professor with salary
commensurate with qualifications and experience. Applicants should reply
by April 30, 1992, enclosing curriculum vitae and the names of three
referees to:
Douglas R. Wilson, M.D.
Dean, Faculty of Medicine
University of Alberta
2)2.00 Mackenzie Health Sciences Centre
Edmonton, Alberta T6G 2R7
T he University of A lberta is committed to the principle of equity in employmnet. The
University encourages applications from aboriginal persons, disabled persons, members of
visible minorities and women.
—S92-109
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Western Memorial presently requires the services of a surgeon
to replace the services of a retiring surgeon. The sucessful appli
cant would be required to work with three other general sur
geons to provide services for 98 surgical beds.

Interested applicants must be eligible for registration in Newfound
land.
have sucessfully completed the evaluating examinations of
the Medical Council of Canada, with the exception of graduates of
medical schools in the United Kingdom, Ireland, New Zealand,
Australia, South Africa, the United States and Canada.

(

Interested applicants are invited to telephone collect or to write to
the following address:

H. R. Watts, MD
Executive Director
Western Memorial Regional Hospital
PO Box 2005
Corner Brook, Newfoundland A2H 6J7
CANADA
Tel: (709) 637-5635
(Collect calls accepted.)

* 1
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Redacteur Adjoint

The Canadian Medical Association is seeking
a coeditor for the Canadian Journal of
Surgery (CJS).

L ’Association des medecins du Canada est a
la recherche d ’un redacteur adjoint pour le
Journal canadien de chirurgie (JCC).

This is a part-time, unpaid position, but the
successful candidate will be able to work out
o f his/her present office and will receive an
honorarium to cover office expenses.

II s’agit d ’un poste a temps partiel non
remunere, mais le candidat choisi pourra
travailler d son bureau actuel, et Ton
remboursera les depenses administratives.

The successful candidate will work with a
coeditor in the following areas: to select
material fo r publication in the CJS; to solicit
high-quality original and review articles,
including those presented at surgical meetings;
to solicit and write editorials; to participate
with the publisher, the editorial board and
sponsoring societies in formulating editorial
policy fo r CJS; to approve issue content; to
select cover pictures and highlights; to
maintain a database o f reviewers and records
o f circulating manuscripts; to prepare an
annual report o f journal activities; to chair the
annual editorial board meeting; and to select
new editorial board members from candidates
nominated by sponsoring societies.

Candidates should have a fellowship in surgery
and a broad knowledge o f clinical medicine.
They should have excellent skills in oral and
written communication, preferably in both
English and French. They should have highly
developed critical reading skills, particularly in
the literature o f clinical scientific medicine. A
knowledge o f clinical epidemiology is
desirable. Experience in editing a scientific
journal is desirable but not essential.
Please submit a letter o f application and your
curriculum vitae, by May 15, 1992, to Mrs.
Susan Stockwell, Director o f Publications.

Le candidat choisi travaillera avec un
deuxieme redacteur adjoint dans les domaines
suivants : choix des textes a publier dans le
JCC; sollicitation d ’articles originaux et de
comptes rendus critiques de grande qualite,
notamment ceux presentes aux reunions de
chirurgiens; dem ande et redaction
d ’editoriaux; participation avec I ’editeur, le
conseil de redaction et les societes
commanditaires a la formulation de la
politique de redaction du JCC; approbation du
contenu des numeros; choix des illustrations
de couverture et des fa its saillants; maintien
d ’une base de donnees des reviseurs et des
dossiers de manuscrits en circulation;
preparation d ’un rapport annuel des activites
du JCC; presidence de la reunion annuelle du
conseil de redaction; choix de nouveaux
membres du bureau de redaction a partir des
candidats nommes par les societes
commanditaires.
Les candidats devraient detenir le titre
d ’Associe en chirurgie et avoir de nombreuses
connaissances dans le domaine de la medecine
clinique. Ils devraient posseder d ’excellentes
aptitudes pour les communications orales et
ecrites, de preference en anglais et en frangais.
Ils devraient posseder des aptitudes
exceptionnelles pour la lecture critique, en
particulier de la litterature en medecine
clinique et scientifique. Des connaissances en
epidemiologie clinique sont a souhaiter.
L'experience de la redaction d ’une revue
scientifique est a souhaiter mais non
essen tie He.
Veuillez faire parvenir une lettre de demande
et votre curriculum vitae d ’ici le 15 m ai 1992,
a Tattention de M m e Susan Stockwell,
Directrice des publications.
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CARDIAC SURGICAL FELLOWSHIP: ON The Division of Cardiovascular Surgery at
Sunnybrook Health Centre of the University of
Toronto is currently seeking a fellow in adult
cardiac surgery. The position will be for 1
year initially beginning July 1992, and is
available to persons eligible for or possessing
FRCSC, ABS or ABTS. The fellow will be
involved in the clinical activities of a busy
adult open heart program (600 cases per
year). Clinical research encouraged and sup
ported. Salary commensurate with experi
ence. Canadian citizens with eligibility for
Ontario licence preferred. Please respond with
a CV to: Dr. Bernard S. Goldman. Head,
Cardiovascular Surgery, Sunnybrook
Health Science Centre. 2 0 7 5 Bayview
Ave., Ste. H410, Toronto, ON M 4N 3 M 5
Canada.
-S91-95

RESIDENCY IN GENERAL THORACIC
SURGERY: ON - An opening is available for
a 1-year senior residency in general thoracic
surgery at Victoria Hospital, University of
Western Ontario, London, Ontario commenc
ing July 1, 1993. The 1-year residency con
sists of extensive experience in all aspects of
general thoracic surgery. Opportunities exist
for active participation in ongoing research.
Applications must be eligible, or possess
FRCSC or ABS, and have completed 6
months of general thoracic surgery training
and 6 months of cardiac surgery in an accred
ited program prior to commencing. Interested
applications should submit CVs to: Dr. Rich
ard Inculet, Program Director. General
Thoracic Surgery, Victoria Hospital. 375
South St., London. ON, Canada N6A 4G5.
-S92-102
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TRANSPLANT
SURGEON

DIRECTOR OF SURGICAL ONCOLOGY:
SK - The Department of Surgery at the
University of Saskatchewan seeks applica
tions for an appointment as Director of the
Surgical Oncology Service. The successful
candidate would hold a full-time tenure track
faculty appointment in the Department of
Surgery; a full-time appointment at the Royal
University Hospital in Saskatoon, and an As
sistant Director position with the Saskatoon
Cancer Centre. Salary and professorial rank
would be commensurate with previous aca
demic experience. The canadidate must be
certified by the Royal College of Physicians
and Surgeons of Canada in general surgery
and have at least 2 years of accredited post
certification training in oncology. Experience
in academic oncology practice would be valu
able. Recent research activity would be ex
pected. The appointee will be actively in
volved in undergraduate and postgraduate
education. Interested candidates should sub
mit applications with curriculum vitae and
names of three referees to: Dr. Roger G.
Keith, Professor and Chairman, Depart
ment of Surgery, University of Saskatche
wan, Royal University Hospital, Saska
toon, SK, Canada S7N 0X0. Deadline for
applications will be Mar. 31, 1992. The Uni
versity of Saskatchewan is an equal opportu
nity employment institution. Preference for
this appointment will be given to Canadian
applicants in accordance with Canadian immi
gration policies.
-S92-103

T h e U n iv e r sity of C algary
D e p a r t m e n t o f S urgery and
F o o th ills H o sp ita l in v it e
a p p l i c a t i o n s fo r a c lin ic a l
a c a d e m ic a p p o i n t m e n t as a
transplant surgeon. Academic
interest and ability, as well as
specialty credentials in general
surgery or urology, are essential
qualifica tio n s. T he s e le c te d
c a n d i d a t e w ill b e p a r t o f a
m u lti-d iscip lin a ry
renal
transplant team. Starting date is
negotiable.
P lea se su b m it a c u r r ic u l u m
vitae and the names of three
references by June 1, 1992, to:

Dr. R.Y. McMurtry
Professor and Head
Department of Surgery
The University of Calgary
1403 - 29 Street N.W.
Calgary, Alberta T2N 2T9

Syntex Inc.
Toradol

—S92-106

136,137, 158

PHYSICIAN ASSISTANT
IN NEUROSURGERY
Applications are invited for the position of physician assistant in neuro
surgery. The post becomes vacant July 1, 1992 and is for a period
of 1 year (renewable). The Provincial Neurosurgery Unit is based at the
Health Sciences Centre and you will be expected to assist at the
Janeway Children's Hospital. Previous experience in surgery and the
Medical Council of Canada Evaluating Examination is required. Salary
- $67 471.
In accordance with Canadian immigration requirements, priority will be
given to Canadian citizens and permanent residents. Closing date for this
advertisement is Apr. 30, 1992.
For further information contact:
Dr. F. B. Maroun, Acting Chairman
Department of Surgery
The General Hospital
Health Sciences Centre
St. John’s, NF
A1B 3V6
—S92-111
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The University of Calgary
CHIEF, GENERAL SURGERY
The University o f Calgary D epartm ent o f Surgery and Foothills Hospital
invite app licatio n s for an academ ic position as C hief of the Division
o f General Surgery .
T h e s e le c te d ca n d id a te w ill be re sp o n sib le for th e d ev e lo p m en t
and p ro m o tio n o f research initiatives w ithin th e Division, as w ell as
th e prom otion o f quality p atien t care and adm inistrative duties related
to the functions of an academ ic division.
Please subm it a curriculum vitae and the names o f three references by
April 30, 1992, to:

Dr. R.Y. McMurtry
Professor and Head
Department o f Surgery
The University o f Calgary
1403 - 29 Street N.W.
Calgary, Alberta T2N 2T9

For prescribing information see page 206
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A BREAKTHROUGH SYSTEMIC ANTIFUNGAL
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POWERFUL
ENOUGH FOR
ADVANCED
INFECTION...
SAFE ENOUGH
FOR EARLY
USE

lipN

DIFLUCAN* (fluconazole/pfizer) offers potent antifungal
therapy with unprecedented safety and tolerability.1

High clinical cure rates1were seen in oropharyngeal
and systemic candidiasis in HIV+ and cancer patients,
with efficacy comparable to amphotericin B in
cryptococcal meningitis.
Unique pharmacokinetics2 provide rapid, extensive
distribution of DIFLUCAN* to target tissues and fluids
including the CSF, saliva, sputum and urinary tract.
Favourable safety profile2; serious adverse effects
are rare. Only 1.5% of patients were withdrawn from
therapy due to side effects, while mild Gl side effects
were reported in only 8.6% of patients.
Convenient once-daily dosing in oral tablets and
intravenous formulation.

oral/i.v.

w*

DIFLUCAN *
(fluconazole/pfizer)

AN OPPORTUNISTIC WAY
TO TREAT FUNGAL INFECTION
©Pfizer Canada Inc. 1992
Kirkland, Quebec H9J 2M5

Product Monograph available on request. | PAASI
'Prepared by Pfizer Canada Inc. (R.U.) ■—
Pfizer Inc. TM Owner l CWIACl

Taking suture technology
to new heights
NEW

D

r*
(BRAIDED SYNTHETIC ABSORBABLE SUTURE)

d e x o n ®n
3.5 Metric
_

B I-C O LO R ™ Braided Polyolycolic
Acid Suture with Polycaprolate™
. _
.
Coatlno System

T-12
37 mm
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DAVIS+GECK
C yanam id Canada Inc.
M arkham
®/~Registered User: Cyanamid Canada Inc.

DEXONII, the newest generation
in the evolution of synthetic
absorbable sutures, offers markedly
different performance in handling,
tying and knot snug-in.
The unique new Polycaprolate™
Coating System...
•Allows the sutures to pass through
tissue smoothly with little or no
chatter or drag
• Provides superior suppleness and
silk-like feel
• Ensures minimal out-of-package
memory
In addition, DEXON II offers un
equalled out-of-package tensile
strength*andexcellentknotsecurity. ^

There is a difference. , j
See it.. .feel it.. .try it!
•DEXON compared to Vicryl.t Data on file.
tTrade m ark of Ethicon.

